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Abstract 
 
All DNA transactions involving overtwisting or undertwisting of the double helix 
alter the topological state of DNA, yielding distortions known as DNA supercoiling 
or DNA torsional stress. Under conditions of negative supercoiling susceptible 
sequences within B-form DNA may be transformed to stable, non-B-DNA structures 
such as G-quadruplex. G-quadruplex DNA has the potential to create or destroy 
transcription factor binding sites or influence nucleosome positioning and so may 
contribute to gene regulation, making it an attractive therapeutic target. Although in 
vitro and in silico studies support the notion that G-quadruplex is regulatory, a 
compelling in vivo demonstration of G-quadruplex function is lacking.  
 
Using computational and experimental approaches previously developed to identify 
DNA segments that actually adopt non-B DNA conformations in vivo, I have 
identified sequences with a high probability of secondary structure formation. 
Identified sequences are located in the promoters of three genes central to cancer 
biology where much of the work in G-Quadruplex has been focused. I have 
expanded this focus into the field of neuroscience by identifying a further three 
sequences in the promoters of genes implicated in a range of neurological disorders. 
Preliminary biochemical analysis of these regions assessed methylation status and 
transcription factor binding profiles corresponding to a dynamic model of G-
quadruplex formation at the well characterised CT element in the c-MYC promoter.  
 
In order to provide definitive structure function analysis of G-quadruplex I designed 
a gene editing strategy to reengineer the well characterized CT element of c-MYC.  
The initial strategy used AAV- targeting vectors to introduce strategic mutations that 
destabilize G-quadruplex DNA conformations in the CT element of c-MYC in the 
HCT-116 cell line via homologous recombination. In parallel to these structure-
destabilizing mutations, neutral base changes were targeted to the 5´-UTRs of the 
targeted alleles, distinguishing them from their respective unmodified homologous 
partners. qPCR and ChIP analysis of the relative expression and factor binding 
profiles of targeted and wild-type alleles  will enable a definitive structure function 
analysis of basal or induced expression; determining whether these secondary 
structures have a functional role in regulating gene expression and the factors 
involved. 
 
Low targeting efficiencies of the AAV gene editing strategy prompted me combine 
the recent technology of the CRISPR-Cas system with traditional AAV targeting to 
produce a highly efficient, high fidelity and streamlined approach to gene editing. 
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Chapter 1 
General Introduction
21 
 
1.1 Gene regulation 
1.1.1 Transcription  
  Transcription is the key step in regulation of gene expression; a 
fundamentally stochastic process with randomness in transcription and 
translation leading to cell-cell variations in mRNA and protein levels (Raj and 
van Oudenaarden, 2008).  
Eukaryotic gene expression is driven by a series of complex and dynamic 
events. The process is initiated by the assembly of a set of protein complexes 
TFIIA, TFIIB, TFIID, TFIIE, TFIIF and TFIIH generally referred to as the 
general transcription factors (GTFs) (Orphanides et al., 1996). These complexes 
assemble into a ~2 MDa complex which is then anchored to the core promoter 
sequence to form the preinitiation complex (PIC) (Smale and Kadonaga, 2003, 
Kornberg, 2005). The PIC is then recognised by RNA polymerase II (Pol II). 
Three distinct classes of DNA sequence elements direct RNA Pol II. The first 
includes DNA sequences within the core promoter generally a TATA-box 
(consensus TATAAA); the second is a proximal-promoter element cis-
regulatory element and the third and distal-promoter element termed enhancer. 
Enhancers are positioned at distant sites in chromatin and modify the rate of 
initiation complex formation by mechanisms that are still poorly understood 
(Roeder, 2005). PIC formation is followed by promoter melting and formation 
of an "open" initiation complex (Figure 1.1). Once RNA Pol II has recognised 
the PIC the synthesis of RNA is initiated although recent studies estimate only 1 
in 90 polymerases proceed to elongation (Darzacq et al., 2007) suggesting 
polymerase and transcription complex assembly is an inefficient process (Hager 
et al., 2009). Promoter escape, pausing, elongation, and transcriptional 
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termination are all additional steps in eukaryotic gene expression reviewed in 
(Fuda et al., 2009, Lee and Young, 2000, Orphanides and Reinberg, 2000). It 
should be noted that although the PIC been implicated in selecting the accurate 
transcription start site (TSS), promoter melting, and Pol II promoter escape 
(Matsui et al., 1980, Roeder, 1996, Goodrich et al., 1996) the details as to how 
this essential complex assembles remain elusive (He et al., 2013). 
 
 
Figure 1.1: Transcription initiation; association of RNA polymerase II and 
GTFs to core promoter.  
A schematic showing the core promoter elements: TATA-box, promoter-proximal 
elements and promoter-distal elements interacting with RNA polymeraseII and the 
general transcription factors during transcription (adapted  from B. Lewin, Genes 
IX). 
 
Holoenzyme recruitment to promoter regions and polymerase pausing were 
believed to be the key regulatory steps in the expression of most protein-coding 
genes (Margaritis and Holstege, 2008, Ptashne and Gann, 1997, Roeder, 2005, 
Core and Lis, 2008, Muse et al., 2007, Seila et al., 2009, Zeitlinger et al., 2007).  
This view was recently extended to include promoter melting as an additional 
step to globally regulate transcription in eukaryotes based on studies mapping 
single-stranded DNA (ssDNA) across the genome (Kouzine et al., 2013b). 
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1.1.2 Transcription Dynamics  
Transcription factors can move rapidly through the nucleus by diffusion, in 
no specific direction and requiring no cellular energy (Misteli, 2001). Diffusion 
coefficients range from ~0.5 to 5 µm
2
s-
1
 depending on the transcription factors 
shape, size, and the nature of its chromatin interactions (Misteli, 2001, Gorski et 
al., 2006). This rapid rate of diffusion means a molecule can cover the length of 
a typical mammalian nucleus in a few seconds and enables a single transcription 
factor to visit the volume of the nucleus in minutes (Hager et al., 2009). 
Transcription factor – chromatin binding is highly transient and dynamic; with 
interactions occurring in the order of seconds. Recent quantitative fluorescence 
recovery after photobleaching (FRAP) analysis suggests a range of milliseconds 
to ~ 100 seconds (Sprague et al., 2004, Farla et al., 2004, Gorski et al., 2006, 
Phair et al., 2004). Data has emerged to suggest that transcription factors may 
spend most of their time bound to chromatin (Elf et al., 2007, Phair et al., 2004). 
The estimated time between interactions is on the order of 50 – 250ms (Hager et 
al., 2009) although the majority of these interactions are non-specific, highly 
transient and as such not functional. This 3D hopping continues until the 
molecule finds a specific site, binding for an extended period in order to elicit a 
functional response. This has been described as the random 3D scanning model 
(Misteli, 2001), (Figure 1.2). It has been proposed that once bound the 
transcription factor is then able to perform a local search of the DNA through 
scanning, hopping or directed motor driven motion (Gorman and Greene, 2008, 
Gowers et al., 2005, Halford and Marko, 2004). 
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Figure 1.2 Random 3D scanning model of transcription factor binding 
 
Transcription factors diffuse rapidly through the nuclear space and by random 
collision associate with chromatin. The majority of encounters are at non-target 
sites and as such are highly transient. When a specific binding site (red) is found 
a prolonged interaction occurs to elicit a functional response. When the 
transcription factor binds it might embark upon local motion along the 
chromatin fibre by sliding along the DNA, hopping or by directed, motor driven 
motion.( Adapted from Hager et al., 2009) 
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1.1.3 Chromatin organisation 
In order to fit the 2m length of DNA into the 6μm nucleus of eukaryotic 
cells, DNA must be densely packaged as chromatin. The fundamental unit of 
chromatin is the nucleosome, in which 147 DNA base pairs are wrapped 1.65 turns 
around the core histone octamer. Histones are small basic proteins consisting of 
globular domains and a charged amino-terminus (N-terminus) tail. The core histone 
octamer consists of two copies of each of the histones H2A, H2B, H3 and H4 (Luger 
et al., 1997, Kornberg and Thomas, 1974).  These strong and repetitive interactions 
between DNA and histones occur as a result of the negatively charged phosphate 
backbone of the DNA molecule, and the charged amino-terminus (N-terminus) tail 
of the histone; one fifth of these amino acids are positively charged (lysine and 
arginine). More than 14 contact points exist between histones and DNA which make 
the nucleosome a stable protein-DNA interaction under physiological conditions. 
Short stretches of naked DNA termed linker regions connect nucleosomes to one 
another. Linker DNA ranges in length between 20 and 90 bp and varies between 
different species and even within a single cellular genome (Woodcock et al., 2006, 
Godde and Widom, 1992). Decondensed chromatin; 11-nm fibre is often referred to 
as ‘beads on a string’, with each ‘bead’ a nucleosome and the ‘string’ the linker 
DNA.  The binding of a fifth histone creates a more condensed higher-ordered 
structure. The next level of compaction is termed ’30-nm fibre’ which is organised 
by the linker histone H1 binding to the linker DNA and a nucleosome on either side. 
The 30-nm fibre is further condensed forming looped domains termed ‘300-nm 
fiber’. The final level of compaction is the looped ‘300-nm fibre’ being further 
folded, giving rise to the characteristic metaphase chromosome (Felsenfeld and 
Groudine, 2003). 
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Figure 1.3 Levels of chromatin organisation.  
Organization of DNA into the various levels of chromatin structure, a. Duplex DNA, 
b. 11nm  nucleosome, c. 30nm nucleosome, d. 300nm nucleosome e. Section of 
condensed chromosome, f. mitotic chromosome. (Adapted from Felsenfeld and 
Groudine, 2003). 
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1.1.4 Chromatin Remodelling 
As transcription factors are traversing the nuclear landscape it is essential 
they can access the DNA in order to interact with it and orchestrate their regulatory 
function. Due to the strong binding energy between nucleosomes and DNA, 
reorganisation of the nucleosome structure must accompany any transcription factor-
DNA interaction (Hager et al., 2009).  Further, in-vivo experiments have provided 
significant evidence indicating that disruption of nucleosome structure is required for 
proper elongation;  identifying the fact that nucleosome disruption travels along the 
gene faster than the rate of RNA polymerase II translocation (25 nucleotides per 
second) (Petesch and Lis, 2008, Izban and Luse, 1992).  
The original studies (Wu et al., 1979) describe DNaseI hypersensitive sites 
(DHS), which represent chromatin  regions sensitive to nucleolytic agents 
specifically DNaseI and micrococcal nuclease (MN), indicating that these regions 
have disrupted nucleosome structures. Global studies now estimate 2% of the 
mammalian genome has disrupted nucleosome structure (Hesselberth et al., 2009, 
Boyle et al., 2008). Transcriptional regulatory elements are strongly associated with 
these DHS sites (John et al., 2008) therefore chromatin remodelling is implicitly 
related with binding of transcription factors.  
The traditional way to view these nuclear disruptions was in terms of 
switching between static positions (Becker, 2002, Mellor, 2005, Aoyagi et al., 2002), 
however studies have since indicated that nucleosome structural remodelling at DHS 
sites is a continuous and dynamic process. Therefore data generated using static 
techniques that utilize fixed or broken cell preparations in fact represents alterations 
in the equilibrium distribution of dynamic states (Fletcher et al., 2002, Nagaich and 
Hager, 2004, Boeger et al., 2008).  
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1.1.5 Genetic variability  
1.1.5.1 Allelic variation: micro-, mini-satellites, repeats and Variable Number 
Tandem Repeats (VNTR)  
 
Over 500,000 micro- or mini-satellites have been identified in the human 
genome. 10–100 nucleotides repeated several times in tandem and bordered by 
unique DNA sequences are defined as mini-satellites. Micro-satellites also called 
Short Tandem Repeats (STRs) have smaller sequence repeats e.g., tetra and di-
nucleotide sequence repeats (Figure 1.4). 
Some degree of degeneration is usually observed in the repeating units; 
where one repeat may be slightly different to the next but the overall core consensus 
sequence is maintained. In order to determine whether a repeat unit is variable, 
genotyping is used; this enables identification  of different allelic copy numbers 
existing between individuals in a population, for example at the same allelic loci, one 
individual may have 8 copies of a repeat, whilst another may have 10 copies 
(Warburton et al., 2014). 
Variable Number Tandem Repeats (VNTR) are defined as having sufficient 
DNA sequence in the repeat to act as a sequence specific DNA binding site for 
proteins. Proteins able to bind these sites include transcription factors suggesting 
VNTRs can act as transcriptional regulatory domains (Haddley et al., 2008) (Figure 
1.5). These domains are similar to the regulatory repeat domains seen in retroviruses 
or herpesviruses (Quinn et al., 1987, Quinn et al., 1998, Quinn et al., 1989). Most 
VNTRs with the potential to act as transcriptional regulatory domains are located in 
non-coding regions of the genome. These repeat regions contain potential cis-
regulatory elements or transcription factor binding sites which produce localised 
hubs. These multiple binding sites could have implications for gene expression 
29 
 
(Soeby et al., 2005, Lovejoy et al., 2003, Klenova et al., 2004). In support of the 
hypothesis that VNTRs are able to act as modulators of gene expression many are 
located at higher density in gene enriched areas compared to non-genic regions 
(Breen et al., 2008). Potential regulatory VNTRs have been identified in the 
serotonin transporter (5-HTT), dopamine transporter (DAT1), N-methyl-Daspartame 
receptor 1 (GRIN1/NMDAR), dopamine D4 receptor (DRD4), and monoamine 
oxidase A (MAOA). VNTRs are predicted to act as endogenous modulators of 
transcription or to alter post transcriptional properties of the gene such as mRNA 
stability. Based on published data by the Quinn group, VNTRs can function in both a 
tissue-specific and stimulus-inducible manner to fine-tune gene expression (Haddley 
et al., 2012, Vasiliou et al., 2012). This control over gene expression could be 
mechanistically correlated with normal physiological function, variation between 
individual, and a number of diseases and disorders (Ali et al., 2010). A further 
implication is that if stimulus inducible expression is variable based on a specific 
polymorphism associated with a disorder then that may in turn have implications on 
the response to specific pharmacological treatment (Fiskerstrand et al., 1999, 
MacKenzie et al., 2000, MacKenzie and Quinn, 1999, Lovejoy et al., 2003, Klenova 
et al., 2004, Roberts et al., 2007). 
 
 
 
Figure 1.4 Examples of the various polymorphisms 
Polymorphisms at locus A and locus B are Single Nucleotide Polymorphisms 
(SNPs). Locus C is a micro-satellite polymorphism, or Short Tandem Repeat (STR). 
Locus D is a Variable Number Tandem Repeat (VNTR). 
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1.2 DNA structure and topology 
 
1.2.1 DNA structure and topology  
The dynamics and function of proteins interacting with DNA are indeed 
central to transcriptional regulation, however evidence is emerging to suggest that 
DNA itself in terms of its structure and topology may play a role in gene regulation 
and as such should no longer be thought of solely as a passive information repository 
(Kouzine et al., 2013a, Lavelle, 2009). 
Genetic processes such as transcription and replication apply physical forces 
to DNA (Figure 1.4), and in turn alter the molecules structure (Baranello et al., 
2012). The structural changes that distort the double helix are known as supercoiling 
or DNA torsional stress and occur as over twisting, under twisting and associated 
loop-like plectoneme structures (Vologodskii et al., 1992).  According to the “twin 
domain” theory DNA is thread through the transcription machinery, forcing it to  
revolve around its axis (Osborne et al., 2004, Iborra et al., 2001, Boeger et al., 2005, 
Cook, 1995); leaving negative supercoils (untwisted) in its wake and driving positive 
supercoils (over twisted) ahead of the translocating RNA polymerase (Liu and 
Wang, 1987, Vologodskii et al., 1992). Supercoiling is mediated by topoisomerases 
which transiently break and re-join the DNA backbone in turn removing positive and 
negative supercoils (Roca, 2011a). Topoisomerases play an essential role in 
maintenance of the double helix topology as without them torsional stress would rise 
to such an extent that all genomic processes would be disrupted (Roca, 2011b, 
Lavelle, 2009).  
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1.2.2 The role of DNA supercoiling  
DNA supercoiling has a direct influence on nucleosome structure, with 
positive DNA supercoiling facilitating unwrapping of DNA from the histones, and 
negative supercoiling promoting nucleosome formation (Freeman and Garrard, 
1992). It has therefore been suggested that a burst of transcription which drives 
positive supercoiling ahead of the translocating RNA polymerase (Liu and Wang, 
1987, Vologodskii et al., 1992) could in fact be “clearing the way” for polymerase to 
elongate through a  nucleosome dense landscape (Recouvreux et al., 2011, Zlatanova 
and Victor, 2009). Negatively supercoiled DNA left behind the transcription 
machinery would be conducive of rapid nucleosome re-formation in the wake of the 
elongating complex (Baranello et al., 2012). Taking these data into account, it is 
likely that by varying the intensity and polarity of supercoiling, chromatin formation 
could be directly regulated to meet transcriptional demands in real-time. This 
assertion fits with the modern view of chromatin remodelling being a continuous and 
dynamic process (Hager et al., 2009). 
 
Figure 1.5 Supercoiling generated during transcription and replication.  
 
Polymerases moving without rotation screw the DNA through the protein 
complexes, causing the template to rotate around its axis (adapted from Baranello et 
al., 2012). 
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1.2.3 Alternative DNA structure (Non-B DNA) 
 
In addition to nucleosome arrangement and the covalent modification of 
histones, alternative DNA conformation provides another source of structural 
diversity in determining gene activity. Further these alternative DNA structures may 
contribute to the transmission of epigenetic states (Kouzine and Levens, 2007), 
through their ability to modify transcription factor binding sites and influence 
nucleosome structure. Non-B DNA structures include single-stranded DNA 
(Michelotti et al., 1996b), H-DNA  (Htun and Dahlberg, 1989), Z-DNA (left handed 
double helix) (Rich and Zhang, 2003), G-quadruplex DNA (Simonsson, 2001), 
triplex DNA  (Gilbert and Feigon, 1999), slipped-strand DNA (Pearson and Sinden, 
1996), sticky DNA (Son et al., 2006), S(stretched)-DNA (Cluzel et al., 1996) and 
cruciforms (Shlyakhtenko et al., 1998).  
Although the double helix is dynamic and breathes (opening of DNA 
bubbles) at physiological temperatures, the opening of bubbles is localized and short 
lived. Hydrophobic and electrostatic base-stacking and base-pairing create 
thermodynamic and kinetic barriers which prevent large segments of DNA from 
adopting alternative DNA conformations (Yakovchuk et al., 2006). However these 
barriers can be overcome and duplex destabilization can occur through high levels of 
transcription induced negative supercoiling (Kouzine et al., 2013a). This  makes it 
possible for the double helix to adopt a variety of alternative structures, depending 
on the sequence composition (Kouzine and Levens, 2007). The promoter region of c-
MYC is the best characterised region in terms of its ability to form either a single-
stranded or a non-B DNA conformation. (Chung and Levens, 2005, Levens et al., 
1997, Marcu, 1987, Michelotti et al., 1996b, Kouzine et al., 2008) 
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1.2.3.1 G-Quadruplex  
G-quadruplexes are four-stranded DNA structures, the sequence of DNA that 
enables these structures to form is (G3+ N1-7 G3+ N1-7 G3+ N1-7 G3). This 
sequence arrangement creates two or more G-tetrads; four hydrogen-bonded 
guanines in a planar arrangement (Figure 1.7).  Transcription induced negative 
supercoiling makes it energetically possible for duplex DNA to adopt the G-
quadruplex formation, stabilized by monovalent cations, such as K+ and Na+, that 
intercalate between the G-tetrads and coordinate bonds with the guanine carbonyl 
groups (Dapic et al., 2003, Sun and Hurley, 2009). 
Mounting evidence suggests that G-quadruplex may play an important 
physiological role. Putative G-quadruplex motifs are highly prevalent in human 
promoter regions with up to 40% of human gene promoters containing at least one 
G-quadruplex (Huppert and Balasubramanian, 2005, Huppert and Balasubramanian, 
2007, Verma et al., 2008) and analyses of human cells revealed a correlation 
between the extent of gene expression and predicted G quadruplexes at promoters 
(Du et al., 2008). Furthermore, at skeletal muscle promoters, formation of G- 
quadruplexes impacts the recruitment of MyoD during differentiation (Shklover et 
al., 2010, Yafe et al., 2008).  A disproportionatly  high incidence of G-quadruplex 
motifs have been observed in the promoters of oncogenes, in contrast to the 
promoters of tumour suppressors which exhibit an extremely low G-quadruplex 
formation potential (Eddy and Maizels, 2006). Of particular interest is the structure-
specific antibody engineered by the Balasubramanian group which has allowed them 
to visualize quantitatively DNA G-quadruplex structures in human cells. They also 
show that G-quadruplex formation in DNA is modulated during cell cycle 
progression (Biffi et al., 2013). 
34 
 
1.2.3.2 G-quadruplex DNA as therapeutic targets 
A wide range of G-Quadruplex structures are possible (Figure 1.6) this 
topological diversity is a result of variations in sequence, strand directionality, loop 
length,  and the number of tetrad stacks (Gonzalez and Hurley, 2010a). This diverse 
spectrum provides an opportunity to development specific molecules that can 
modulate the formation or stabilize these structures and in turn regulate gene 
expression.  
 
Figure 1.6 Possible of G-quadruplex formations 
 
Models of the conformations of potential G-quadruplexes, determined by varying 
sequence arrangement, coloured dots refer to specific base pairs: red – G, blue-C 
yellow – A, green -T the gene in which they are located is detailed above (adapted 
from (Gonzalez and Hurley, 2010a)) 
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For example the G-quadruplex that forms within the CT element of c-MYC 
has been demonstrated to function as a repressor element (Siddiqui-Jain et al., 2002). 
Therefore developing compounds that can stabilize this structure could be used to 
specifically repress c-MYC expression.  c-MYC has been implicated in most aspects 
of tumour biology with deregulation generally due to gene amplification, 
translocation, altered ploidy and increased transcription (Marcu et al., 1992, Spencer 
and Groudine, 1991). Therefore selectively targeting its aberrant expression would 
be an attractive therapeutic intervention. In fact a number of molecules have been 
explored as potential G-quadruplex stabilising agents, including TMPyP4, which 
was shown to decrease c-MYC expression at both the mRNA and protein levels, as 
well as lower the level of several c-MYC–regulated genes (Grand et al., 2002). More 
recently the Balasubramanian group have identified pyridine-2,6-bis-
quinilodicarboxamide derivative, pyridostatin5 (PDS) as an exciting G-quadruplex 
stabilising ligand.(Murat et al., 2013, McLuckie et al., 2013, Muller et al., 2012) 
 Cancer is not the not the only disease where molecules targeting G-
quadruplex are applicable; a recent study has identified the G-quadruplex present in 
the promoter of HIV-1and states that the structure may be critical for HIV-1 gene 
expression and is potentially a novel target for anti-HIV-1 drug development  
(Amrane et al., 2014).  
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1.3 Genes analysed for G-quadruplex DNA  
1.3.1 c-MYC. 
c-MYC is a transcription factor and 10–15% of genes are regulated by this 
protein (Fernandez et al., 2003, Li et al., 2003, Zeller et al., 2006). c-MYC has been 
shown to interact with numerous transcription and chromatin regulators (Cheng et 
al., 1999, Cowling and Cole, 2006, Eilers and Eisenman, 2008, Rahl et al., 2010, 
Wasylishen and Penn, 2010) and is implicated in most aspects of tumour biology, 
including apoptosis, proliferation metastasis, angiogenesis and changes in the tumour 
microenvironment (Oster et al., 2002, Eisenman, 2001). c-MYC is the key example 
used by Weinstein to describe the concept of “oncogenic addiction” whereby some 
cancers appear to rely on one or a few genes to maintain the malignant phenotype, 
therefore genes such as c-MYC may be the “Achilles heel” in specific cancers 
(Weinstein et al., 1997, Weinstein, 2002). A seminal paper by the Levens Lab 
addresses the “addiction” to c-MYC, through a simple rule which explains the 
majority of c-MYC biology: c-MYC is not an on-off specifier of gene activity, but a 
nonlinear amplifier of expression. This means it acts universally at active genes 
except for a class of genes termed ‘immediate early’ genes that are induced before c-
MYC (Nie et al., 2012). c-MYC transcriptional regulation is a complex process 
involving numerous promoters (P0, P1, P2, P3) and start transcriptional start sites 
(Gonzalez and Hurley, 2010a), (Figure 1.7).  
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Figure 1.7 c-MYC promoter structure  
c-MYC promoter contains 5 NHE domains NHE I – V, with arrows to identify 
location within the promoter. NHE III1 is the CT element, expanded in the insert 
below to show G-rich and C-rich regions of the sequence, (adapted from (Gonzalez 
and Hurley, 2010a) 
 
The c-MYC promoter contains seven nuclease hypersensitive elements 
(NHEs) (Figure 1.8), the NHE III1 region (CT-element), is able to form non–B-DNA 
structures in supercoiled DNA as well as in its endogenous location (Travers and 
Muskhelishvili, 2007, Liu and Wang, 1987, Michelotti et al., 1996b, Kohwi and 
Kohwi-Shigematsu, 1991). The CT element is located –142 to –115 base pairs 
upstream of the P1 promoter and studies have attributed up to 90% control of the 
total c-MYC transcription to it (Davis et al., 1989, Berberich and Postel, 1995). The 
CT element is made up of a cytosine-rich (C-rich) coding strand and a guanine-rich 
(G-rich) noncoding strand that are able to engage in a slow equilibrium between B-
form duplex DNA, single-stranded DNA, and tetra-stranded DNA (Gonzalez and 
Hurley, 2010a). The guanine rich strand is able to adopt G-quadruplex structure 
(Figure 1.8) and the complementary cytosine strand is able to adopt an i-motif or i 
tetraplex. 
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Figure 1.8 Sequence and structures of the G‑quadruplex the CT element 
 
Four guanine residues form a tetrad, and three tetrads can stack to form an 
intramolecularly linked G-quadruplex with a 1/2/1 looping pattern. (Figure adapted 
from Brooks and Hurley, 2009). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hoogsteen base pairing 
 
5’-ATGGGGAGGGTGGGGAGGGTGGGGAAGGTGGGGA-3’ 
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1.3.1.1 G-quadruplex formation within the CT element of c-MYC 
 
 
The discovery of the Non-B DNA structures; G-quadruplex and i-motif 
within the CT element of the c-MYC promoter (Sun and Hurley, 2009) led to the 
suggestion that these structures may play a role in the regulation of c-MYC. One 
model that has been proposed describes the transition of the CT element through 
three DNA structural motifs, two of which lead to activation and one that results in 
repression of c-MYC (Figure 1.19). 
When in duplex form, the transcriptional factor Sp1 binds to the CT element 
and activates transcription (DesJardins and Hay, 1993). This increased level of 
transcription could result in the accumulation of supercoiling and flip the CT 
element into the single-stranded conformation. This would allow the single strand 
DNA binding proteins hnRNP K and CNBP to bind the purine-rich and pyrimidine-
rich strands, respectively in turn maintaining the active state (Brooks and Hurley, 
2009, Tomonaga and Levens, 1996, Michelotti et al., 1995). In addition to single-
stranded conformation, the CT element can adopt stable non-B DNA structures, a G-
quadruplex on the purine-rich strand and an i-motif on the pyrimidine-rich strand 
(Sun and Hurley, 2009). These globular structures sequester the standard B-DNA 
transcription factor binding sites and potentially silence transcription.  
This model describes a situation in which the same sequence of DNA is able 
to bind different sets of transcriptional regulators, based not on the sequence 
specificity but on structural specificity. The result is that gene specific responses 
could be achieved using ubiquitous transcriptional factors. The DNA itself in terms 
of its structure and topology is playing an active role in gene regulation, through 
local flipping between different DNA conformations induced by torsional stress. The 
structural elements forming within the CT element act like molecular switches 
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selecting which transcriptional factors to employ based on the physical signals from 
the cell. 
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Figure 1.9 A model describing the dynamic transition trough alternative DNA 
conformations at the CT element.  
a.CT element in standard duplex DNA without proteins bound. b. Binding of Sp1 to 
the duplex structure, resulting in activation of c-MYC expression. c. Binding of 
single stranded binding proteins hnRNP K and CNBP to the single stranded C and G 
rich regions, respectively, results in activation of c-MYC transcription. d. The 
formation of the G-quadruplex and i-motif sequestering duplex DNA binding sites 
resulting in repression of c-MYC transcription.  
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1.3.2 Monoamine oxidase A (MAOA)  
 
MAOA is a key brain enzyme which metabolises monoamines, preferentially 
serotonin (5-HT), noradrenaline (NA) and dopamine (DA). Modulation of the 
expression of MAOA, resulting in differential levels of active protein, is implicated 
in the pathophysiology of numerous neuropsychiatric disorders (Reif et al., 2013, 
Fan et al., 2010). The gene is considered an excellent model for gene x environment 
(GxE) interactions that underlie mental health (Caspi et al., 2002). 
1.3.2.1 MAOA polymorphic regions (VNTRs) 
The polymorphic repetitive domain termed the µVNTR  (variable number 
tandem repeat) is considered a major mediator of MAOA gene expression (Sabol et 
al., 1998). Approximately 20% of MAOA manuscripts address the action of the 
µVNTR . The µVNTR  is a 30 base pair repeat element that is found as 2, 3, 3.5, 4 
and 5 copy number variants in the general population. Alleles containing 2, 3 and 5 
copy VNTRs are defined as low expressers of MAOA whilst the 3.5 and 4 repetition 
VNTRs are high expression variants, demonstrating a 2 to 10 fold increased 
expression. The µVNTR s accepted mode of action is as a transcriptional regulator. 
These low and high expression alleles can represent either a risk factor or a 
protective factor depending on the disorder studied (Melas et al., 2013). However 
such associations are further complicated as the MAOA gene is located on the X 
chromosome, which makes it potentially more susceptible to sex-linked differences. 
This is reflected in the fact that genetic associations for MAOA in many disorders 
have a tendency to demonstrate gender differences including pronounced effects on 
ADHD and anxiety in females whereas the opposite is true for autism, bipolar 
disorder and aggressive behaviour in males (Melas et al., 2013, Reif et al., 2012). 
Consequently many studies of MAOA GxE interactions study only males due to the 
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compounding effects of gene dosage especially in females heterozygous for the 
µVNTR  (Caspi et al., 2002, Kim-Cohen et al., 2006). This would be consistent with 
the studies that have found sex differences utilising the µVNTR  association.  The 
original hypothesis of X chromosome inactivation of one MAOA allele in the female 
has more recently been questioned with potentially 15% of genes on the X 
chromosome escaping inactivation (Mugford et al., 2014, Joo et al., 2014). Whether 
MAOA escapes X chromosome inactivation is not fully resolved in the literature 
however there is evidence to support a model in which it escapes inactivation (Carrel 
and Willard, 2005). 
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1.3.3 The serotonin transporter (SLC6A4 / 5-HTT) 
Serotonin (5-hydroxytryptamine / 5-HT) is a monoamine neurotransmitter 
and a known neuromodulator of emotional behaviour and psychological states. 
Instabilities in the serotonergic system are associated with the pathophysiology of 
many CNS-related disorders including depression (Ressler and Nemeroff, 2000, 
Lesch et al., 2003), aggression and antisocial behaviour (Lesch and Merschdorf, 
2000), anxiety (Ressler and Nemeroff, 2000, Lesch et al., 2003), suicide (Arango et 
al., 2002) and addiction (Kreek et al., 2005). 
The serotonin transporter also termed (5-HTT, SLC6A4, SERT) is a Na
+
/Cl
-
 
dependent transporter member of the solute carrier gene family (SLC). In the CNS, 
5-HT and 5-HTT localise predominantly in the perisynaptic membrane of neurons 
within the raphe nuclei. Raphe nuclei processes innervate a number of brain areas 
thought to be involved in behaviour regulation and cognition (McLaughlin et al., 
1996, Zhou et al., 2000). Once 5-HT has been released into the synaptic cleft, the    
5-HTT mediates its presynaptic reuptake to be recycled by the cell or degraded by 
monoamine oxidases resulting in serotonergic neurotransmission termination 
(Rudnick and Wall, 1993). The 5-HTT plays an essential role in regulating the 
spatiotemporal fine-tuning of the 5-HT neurotransmission by  determining the 
duration and amplitude of 5-HT synaptic signal (Blakely et al., 1991). 
Modulation in the expression or action of 5-HTT is therefore associated with 
behaviour and mood having been strongly linked to depression (Owens and 
Nemeroff, 1994, Owens and Nemeroff, 1998). 
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1.3.3.1 Serotonergic signalling pathway a drug target  
Antidepressants known as selective 5-HT reuptake inhibitors or SSRIs target 
the 5-HTT to increase the bioavailability of 5-HT in the synaptic cleft (Roman et al., 
2003). Tricyclic antidepressants (TCA) such as amtriptyline also target the 5-HTT 
and despite the undesirable side effects are still in widespread (Roman et al., 2003). 
 
1.3.3.2. 5-HTT 5’ linked polymorphic region (LPR) VNTR  
The 5-HTT gene encompasses 14 exons spanning ~ 39 Kb on chromosome 
17q11.2, encoding a 630 amino acids protein that has twelve hydrophobic 
transmembrane domains (Lesch et al., 1994). Two non-coding polymorphic regions 
are present within the 5-HTT gene. The linked polymorphic region within the 5’-
promoter region is present as 14 (short/deletion) or 16 (long/insertion) copies of 22 
or 23 bp elements. Stin2 within intron 2 is present as three variants containing; 9, 10 
or 12 copies of a 16 or 17 bp element (Figure 1.11).  The LPR has been studied 
extensively for GxE associations (Caspi et al., 2003, Uher and McGuffin, 2008), 
both have been suggested as predisposing genetic factors for a number of 
neurological disorders, reviewed in (Haddley et al., 2008). The 5’LPR and Stin2 
VNTRs have been identified as transcriptional regulatory domains, despite 
conflicting evidence in the literature (Lotrich and Pollock, 2004). Modulation of 
their function could therefore affect levels of 5-HTT expression in a tissue-specific 
and stimulus inducible manner as reviewed in (Haddley et al., 2008). The 
transcription factor CTCF has been characterized as a regulator of both VNTRs 
(Klenova et al., 2004, Roberts et al., 2007, Ali et al., 2010). 
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Figure 1.10 Schematic representation of the 5-HTT gene.  
Diagram highlights chromosome position, the 5’-LPR and Stin2 VNTRs (white 
boxes), transcription start site, black arrow with +1 and coding exons and (grey 
boxes) and non-coding exons (black boxes), (adapted from (Ali et al., 2010)). 
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1.4 Transcription factors involved in gene regulation via G-quadruplex 
1.4.1 Sp1 
The transcription factor Sp1 is ubiquitously expressed in mammalian cells 
and plays an important role in the regulation of a number of genes central to many 
cellular activities including metabolism, cell growth, differentiation, angiogenesis 
and apoptosis (Deniaud et al., 2009). Sp1 is a 785-amino-acid, 100- to 110-kDa 
DNA binding protein and is characterized by three Cys2His2-type zinc finger motifs. 
These zinc fingers interact with the decanucleotide consensus sequence 
5’(G/T)GGGCGG(G/A)(G/A)(C/T)-3’ in double-stranded DNA (Song et al., 2001). 
However its binding sequence is known to be degenerate; binding a number of  GC-
rich motifs (such as 5’ -G/T-GGGCGG-G/A-G/A-C/T-3’ or 5’-G/T-G/A-GGCG-
G/T-G/A-G/A-C/T-3’ ) with high affinity (Briggs et al., 1986, Kadonaga and Tjian, 
1986, Kadonaga et al., 1987). Sp1 is able to mediate the expression of TATA-
containing and TATA-less genes through protein-protein interactions or via dynamic 
interplay with additional transcription factors (Olofsson et al., 2007). Such genes 
include c-MYC  (Parisi et al., 2007), c-Jun (McDonough et al., 1997), and  Stat1 
(Canaff et al., 2008). Interactions with chromatin-modifying factors such as p300 
(Suzuki et al., 2000) and histone deacetylases (HDACs) (Zhao et al., 2003), suggest 
a role for Sp1 in chromatin remodelling.  
There are five Sp1 binding sites within the c-MYC promoter, three upstream 
of P1 and two upstream of P2. The binding sites at the CT element and the one 
located at –44 base-pairs from the P1 promoter are particularly high-affinity Sp1 
binding sites (Geltinger et al., 1996, Wierstra and Alves, 2006). Sp1 binds to the CT-
element after serum stimulation of c-MYC, suggesting that it is involved in the 
serum-induced activation of c-MYC transcription (Liu and Levens, 2006). 
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Interestingly, it has been reported that for promoters containing multiple Sp1 binding 
sites, such as the c-MYC promoter, Sp1 exerts its transcriptional synergism through 
direct protein-protein interaction, in which Sp1 forms higher-order complexes that 
are able to bind to multiple sites (Mastrangelo et al., 1991, Su et al., 1991). A recent 
study of the Sp1 binding site within the promoter region of the c-KIT oncogene has 
suggested that it is able to bind both, canonical Sp1 duplex DNA as well as G-
quadruplex structures in vitro (Raiber et al., 2012) 
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1.4.2 CTCF   
 CTCF is a ubiquitously expressed zinc finger DNA-binding protein which is 
highly conserved in higher eukaryotes. The full length protein contains an eleven 
zinc finger central DNA-binding domain that displays close to 100% homology 
between mouse, chicken, and human (Ohlsson et al., 2001). Combinatorial use of 
different zinc fingers give CTCF its ability to bind to a wide range of variant 
sequences in addition to specific co-regulatory proteins leading to its description as a 
“multivalent factor” (Filippova et al., 1996). This unique structural feature confers a 
versatile role in genome regulation (Phillips and Corces, 2009), including promoter 
repression, enhancer insulation and more recently, long-range interactions (Dixon et 
al., 2012). CTCF functions also extend to roles in differentiation and development 
(Torrano et al., 2005), regulation of cell proliferation (Rasko et al., 2001), tumour 
suppression (Filippova et al., 1998, Filippova et al., 2002) and apoptosis (Docquier 
et al., 2005).Thousands of CTCF DNA-binding sequences are present in the genome, 
including the CT element within the promoter of c-MYC, (Lobanenkov et al., 1990, 
Klenova et al., 1993) and the 5’ LPR VNTR within the promoter of 5-HTT (Ali et 
al., 2010, Vasiliou et al., 2012). 
 
1.14 DNA logo representing CTCF-binding motif. 
   
Traditional CTCF consensus is shown in black, colored letters of various height 
represent  the relative frequency at which the nucleotide  occurs at each position, 
(adapted from (Kim et al., 2007)). 
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1.4.2 Nucleolin  
 
Nucleolin is a 110-kDa multifunctional nucleolar phosphoprotein with an 
active role in numerous cellular processes;  including ribosome biogenesis, cell 
proliferation, chromatin decondensation, differentiation and maintenance of neural 
tissue, transcriptional regulation, and apoptosis (Storck et al., 2007, Mongelard and 
Bouvet, 2007, Grinstein et al., 2007, Grinstein et al., 2002, Ginisty et al., 1999). 
Nucleolin is described as a modular protein as it can be structurally divided into 
three discrete domains: 1) The N-terminal, consisting of highly acidic regions 
punctuated by basic sequences housing multiple phosphorylation sites. 2) The central 
domain, which contains four RNA-binding motifs. 3) The C-terminal, defined by 
spaced RGG repeats punctuated by amino acids. It is the association of these 
structural domains that allow nucleolin to interact with different proteins and RNA 
sequences (Ginisty et al., 1999). 
  
Of particular note are the circular dichroism (CD) spectroscopy studies which 
have shown that nucleolin will bind to G-quadruplex DNA. It has been shown that 
the interaction of nucleolin with the CT element within the c-MYC promoter induces 
the formation of a G-quadruplex from single-stranded DNA (Gonzalez and Hurley, 
2010b). Gonzalez et al.,2002 also demonstrated G-quadruplex selectivity as 
nucleolin appears to preferentially bind to parallel G-quadruplexes with short loops 
as in the c-MYC G-quadruplex over other G-quadruplex formations. The group also 
suggest that nucleolin may regulate c-MYC transcription by modulating the structure 
of the CT element based on the high affinity and selectivity of nucleolin for the c-
MYC G-quadruplex structure. 
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1.4.4 hnRNP K 
hnRNP K is a 463-residue modular nucleic acid binding protein characterized 
by the presence of KH domains. Unlike most transcription factors this class of 
binding protein does not target double stranded DNA.  In vivo and in vitro studies 
have shown these proteins to specifically bind and transactivate single-stranded cis 
elements within the c-MYC promoter.  (Matunis et al., 1992, Bomsztyk et al., 1997, 
Ostareck-Lederer et al., 1998).  
Interactions with nucleic acids (ssDNA and RNA) are mediated by three KH 
domains (Tomonaga and Levens, 1995). hnRNP K interacts with single-stranded 
nucleic acids via folding of the KH domains to form an elongated groove on the 
proteins surface.  This groove is the site at which the protein – DNA interaction 
occurs via hydrogen bonds and van der Waals contacts (Tomonaga and Levens, 
1995). hnRNP K KH1 (residues 32–112) and KH2 (residues 142–217) are located at 
the N-terminal end of the protein, separated by a 30-residue linker (Braddock et al., 
2002). hnRNP K KH3 is isolated from the other two KH domains and located at the 
C-terminal end of the protein (residues 389–459). The intervening 172-residue 
stretch between KH2 and KH3 is involved in protein–protein interactions with 
multiple partners that include other transcription factors (such as TATA binding 
protein and various zinc finger-containing transcriptional repressors). This is in 
addition to proteins involved in diverse signal transduction pathways (such as a 
number of tyrosine and serine/threonine kinases, and the Vav proto-oncoprotein) 
(Bomsztyk et al., 1997). hnRNP K therefore has regulatory roles in transcription and 
translation and participates in a number of signalling systems  (Bomsztyk et al., 
1997, Ostareck-Lederer et al., 1998). 
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 Given the fact that hnRNP K binds preferentially to single-stranded nucleic 
acids any interactions with DNA are associated with duplex melting due to increased 
levels of negative supercoiling (Duncan et al., 1994).  In support of this, hnRNP K 
has been identified as binding to the pyrimidine-rich single strand of the CT element 
and activating the promoter of c-MYC in vivo and in vitro (Duncan et al., 1994, 
Michelotti et al., 1996a, Tomonaga and Levens, 1996).  
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1.4.5 CCHC-type zinc finger nucleic acid binding protein (CNBP) 
 
CCHC-type zinc finger nucleic acid binding protein (CNBP) is a 
multifunctional protein comprised of seven cysteine-cysteine histidine-cysteine zinc 
knuckles and an arginine-glycine-glycine (RGG) domain. The protein has been 
shown to control cell proliferation and survival, implicating it  in embryonic 
development, especially in forebrain and craniofacial development  (Chen et al., 
2003). 
CNBP has been shown to bind to the purine-rich single strand of the c-MYC 
CT element followed by induction of c-MYC expression, it has therefore been 
suggested that CNBP may function to mediate c-MYC expression (Michelotti et al., 
1995, Armas et al., 2008b). A function for CNBP in the regulation of c-MYC is 
supported by studies into CNBP−/− mouse embryos, which have been shown to have 
a substantial reduction in cell proliferation, correlating with the absence of c-MYC 
expression (Chen et al., 2003). The RGG domain of CNBP has been identified as 
essential for its nucleic acid binding activity and induction of c-MYC expression. 
The zinc knuckles of the protein only partially contribute towards its function in this 
capacity, as identified by functional mutation analysis (Armas et al., 2008a). 
Interestingly proteolytic mechanisms have been proposed as the way in which 
CNBP’s biochemical activity is regulated owing to the identification of truncated 
forms of the protein (lacking the RGG domain) naturally occurring (Flink and 
Morkin, 1995). 
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Aims and objectives:  
 
1. Address the potential for repeat elements in the promoter of selected genes to 
form G-quadruplex using both in-silico and preliminary biochemical 
analysis; transcription factor binding and methylation status at the promoters 
of selected genes. 
 
2. Use AAV targeting vectors to destabilise G-quadruplex structures to assess 
directly the capacity of and mechanism through which G-quadruplex 
influences gene expression, initially validating the approach in the c-MYC 
promoter with the well characterized CT element. 
 
3. Combine emerging technology CRISPR-Cas system with the traditional 
AAV targeting vectors to produce a highly efficient, high fidelity and 
streamlined approach to gene editing. 
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Chapter 2 
Materials and Methods 
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2.1 Materials 
2.1.1 Commonly used solutions and reagents 
2.1.1.1 General Molecular Biology 
5x TBE buffer 
54 g Tris(hydroxymethyl)methylamine (Tris) (BDH), 27.5 g  boric acid (Sigma), 20 
ml 0.5 M Ethylenediamine Tetraacetic Acid (EDTA) (Sigma) and dH2O up to 1 litre. 
 
6x agarose gel loading buffer      
0.25% (w/v) Bromophenol blue, 0.25% (w/v) xylene cyanol, , 1 mM EDTA, 30% 
glycerol and 70% water. 
 
2.1.1.2 Chromatin Immunoprecipitation (ChIP) 
Cell lysis buffer 
50mM Hepes-KOH pH7. 5, 140mM NaCl,  1mM EDTA, 10% glycerol, 0.5% NP-
40, 0.25% Triton X-100, protease inhibitor cocktail (Sigma Cat No. P8340) 
Nuclear lysis buffer  
10mM Tris-HCl, pH8.0, 200mM NaCl, 1mM EDTA, 0.5mM EGTA, protease 
inhibitor cocktail (Sigma) 
ChIP dilution buffer   
16.7 mM Tris–HCl, pH 8.1, 167 mM NaCl, 1.1%Triton X-100, 0.01% SDS, 1.2 
mM, EDTA, protease inhibitor cocktail (Sigma) 
 
Magnetic beads 
Dynabeads Protein G (Invitrogen™ 10003D)  
Low-salt wash buffer                                                                                                                
20 mM Tris–HCl, pH 8.1, 150 mM NaCl, 0.1% SDS, 1% Triton X-100, 2 mM 
EDTA,  
High-salt wash buffer  
20 mM Tris–HCl, pH 8.1, 500 mM NaCl, 0.1% SDS , 1% Triton X-100, 2 mM 
EDTA. 
Lithium chloride (Li Cl) wash buffer   
10 mM Tris–HCl, pH 8.1, 250 mM LiCl, 1% Igepal, 1% sodium deoxycholate, 1 
mM EDTA. 
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TE buffer   
10 mM Tris–HCl, pH 8.0, 1 mM EDTA. 
 
Elution buffer 
50 mM Tris–HCl, pH 8 1 mM EDTA, 1%SDS, 50 mM NaHCO 3, 2. 5 M NaCl. 
 
RNAse 
RNAse A: 20 mg/ml. (Sigma) 
 
SDS 10%. 
Sodium dodecyl sulfate (Sigma) 10% w/v in dH2O 
 
Proteinase K.  
Proteinase K solution (Qiagen) 
 
2.1.1.3 Microbiology 
Super optimal growth media with catabolite repression (SOC)  
20 g/L Tryptone, 5 g/L Yeast Extract, 4.8 g/L MgSO4, 3.603 g/L dextrose, 0.5g/L 
NaCl, 0.186 g/L KCl. 
Luria broth (LB) media 
10.0 g/L trypton, 5.0 g/L yeast extract and 10.0 g/L NaCl. 
 
LB agar 
10.0 g/L trypton, 5.0 g/L yeast extract and 12 g/L agar. 
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2.1.1.4 Chemical stimuli given to cells 
 
1 M Lithium chloride (Sigma Cat. No. L9650) 
0.42 g in 10 ml of dH2O, used at 1 mM (1 l in 1 ml of appropriate tissue culture 
media). 
 
1 mM Cocaine hydrochloride (Sigma Cat. No. C5776) 
0.0034 g in 10 ml of dH2O, use at 1 µM (1 l in 1 ml of appropriate tissue culture 
media) or at 10 µM (10 l in 1 ml of appropriate tissue culture media).  
 
10mM Valproic acid sodium salt (Sigma Cat. No. P4543)  
0.16g in 10ml of dH₂O sterile filtered and used at 2µM (8µl in 40ml appropriate 
tissue culture media). 
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2.1.1.5 Cell and tissue culture media 
 
JAr cell line media  
RPMI-1640 medium (Sigma) supplemented with 10% heat-inactivated foetal 
calf serum (Sigma), 2 mg/ml glucose, 1 mM sodium pyruvate, 2 mM L-glutamine, 
10 mM HEPES and 1% (v/v) 100x penicillin/streptomycin (equates to a final 
concentration of 100 units penicillin/100 µg streptomycin (Sigma-Aldrich; Cat. No. 
P0781). 
 
SH-SY5Y cell line media 
1:1 solution of Eagle's minimal essential medium (EMEM) media and 
nutrient mixture F12 HAM media supplemented with 10% (v/v) heat-inactivated 
foetal bovine serum (Sigma), 1% of L-Glutamine 2mM, 1% of Sodium Pyruvate 
1mM  and 1% penicillin 100 units/ml / streptomycin 0.1 mg/ml (Sigma).  
 
HCT-116 cell line media 
Dulbecco's Modified Eagle's medium (DMEM), (Sigma Cat No. 5546) 
supplemented with 2mM Glutamine and 10% Foetal Bovine Serum (Sigma Cat. No. 
F3018) 1% penicillin 100 units/ml / streptomycin 0.1 mg/ml (Sigma).  
 
HCT-116 selection media 
DMEM (Sigma Cat No. 5546) supplemented with 2mM Glutamine and 10% 
Foetal Bovine Serum (Sigma Cat. No. F3018), 0.05uM G418 
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HEK-293 cell line media 
Dulbecco’s minimum essential media (DMEM)  F12, supplemented with 
10% foetal bovine serum, 1% l-glutamine [200 mM], 1% sodium pyruvate [100 
mM], and 1% penicillin [10,000 u/mL]/streptomycin [10 µg/mL]. 
 
2.1.1.6 Plasmids 
Reporter gene plasmids cloned and used during this study are listed in Table 
2 of the appendix. 
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2.2 Methods 
2.2.1 General cloning methods 
2.2.1.1 PCR primer design  
Primers were designed with the aid of primer design programme; primer3 
http://biotools.umassmed.edu/bioapps/primer3_www.cgi, secondary structure and 
primer dimer formation were prevented with the aid of integrated DNA 
technologies (IDT), oligonucleotide analysis software; oligoanalizer 
http://www.idtdna.com/analyzer/Applications/OligoAnalyzer/. Primers were 
generally designed between 20-25 bp in length, with a melting temperature of 50-
65°C and GC content between 40-60%. 
 
2.2.1.2 Standard PCR          
 PCR was used as a method for analysing mRNA expression and to amplify 
specific DNA fragments for use in molecular cloning. PCR amplifications were 
carried out on a peqSTAR 2X Gradient Thermocycler (PeqLab).  25µl PCR 
reactions contained  5-100 ng  DNA template, 0.5mM dNTP (Sigma), 0.4 μM primer 
(Eurofins or IDT), 0.625u GoTaq® DNA Polymerase / HotStart GoTaq® DNA 
Polymerase (Promega), 5× Green GoTaq® Reaction Buffer (Promega) specific 
primer  and  PCR conditions are detailed in Table 1 of the appendix. 
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2.2.1.3 PCR purification 
To purify double-stranded DNA fragments post PCR (Section 2.2.1.2), 
restriction enzyme digestion (Section 2.2.6) and ChIP (Section 2.6) for accurate 
quantification or downstream reactions such as Gibson Isothermal Assembly, 
Wizard® SV Gel and PCR Clean-Up System was used following manufacturer’s 
instructions. Briefly; equal volume of membrane binding solution was added to the 
PCR amplification, an SV minicolumn was inserted into the collection tube, to 
which the prepared PCR product was added, incubated at room temperature for 1 
minute, and centrifuged at 16,000 × g for 1 minute. The flow through was discarded 
and the minicolumn reinserted  into collection tube, which was washed by adding 
700μl of membrane wash solution and centrifuged at 16,000 × g for 1 minute. 
The  flow through was discarded and minicolumn  reinserted into the Collection 
Tube, this wash step was then repeated with 500μl membrane wash solution and 
centrifuged at 16,000 × g for 5 minutes. The collection tube was emptied and the 
column assembly re-centrifuged for 1 minute with the microcentrifuge lid open to 
allow evaporation of any residual ethanol. To elute; the minicolumn was transferred 
to a clean 1.5ml microcentrifuge tube and  50μl of nuclease-free water was added  to 
the minicolumn. This was then incubated at room temperature for 1 minute 
and centrifuged at 16,000 × g for 1 minute, the minicolumn was discarded and DNA 
stored  at 4°C or –20°C. 
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2.2.1.4 Analysis of DNA using agarose gel-electrophoresis  
Agarose gel-electrophoresis was used to analyse PCR products or fragments 
generated by restriction digestion, 1-2% agarose (multi-purpose agarose, Bioline, 
Cat. No. BIO-41025) was melted in 120ml 0.5x TBE buffer and supplemented with 
6μl ethidium bromide (10 mg/ml aqueous solution, Sigma E-5134). Gels of 120 ml 
were cast in 12x14 cm or 20.5x10 cm trays and the appropriate combs inserted. Gels 
were left at room temperature for 30 minutes to set, and were then submerged in 
horizontal gel electrophoresis tanks (Hybaid turn and cast submarine gel system, 
Hybaid, or Savant HG 350 tank) containing 0.5x TBE buffer. Samples were mixed 
with 6x loading buffer (1x final concentration) and loaded into the wells. The size of 
a PCR product or restriction digest fragments was determined by loading a DNA 
ladder (100bp ladder; Promega Cat. No. G2101 or 1Kb ladder; Promega, Cat. No. 
G5711). In general, gels were run for between 45-180 minutes at 120V (Hybaid) 
depending on the fragment or combination of fragments (as in the case of VNTR’s) 
Electrophoretically separated DNA was visualised using a UV transilluminator  
(BioDoc-it Imaging System).(BioDoc-it Imaging System) at a wavelength of 302 
nm.  
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2.2.1.5 Recovery of DNA from agarose-gels 
PCR products and restriction digestion fragments were isolated by running 
the PCR reaction or the restriction digest on agarose gels. The bands which 
corresponded to products of the predicted size were excised from the agrose gel 
under long wave UV translumination using a clean blade. The DNA was recovered 
from the gel slice using the Wizard SV Gel and PCR Clean-Up System, following 
manufacturer’s instructions. Briefly; the gel slice was placed in a 1.5ml 
microcentrifuge tube, 10μl Membrane Binding Solution was added per 10mg of gel 
slice and vortexed and incubated at 50–65°C until the gel slice completely dissolved. 
Once dissolved an SV Minicolumn was inserted into the Collection Tube, to which 
the gel mixture was added. This was incubated at room temperature for 1 minute, 
and centrifuged at 16,000 × g for 1 minute, the flow through was discarded and the 
Minicolumn reinserted  into Collection Tube. The Collection Tube was washed by 
adding 700μl of Membrane Wash Solution and centrifuged at 16,000 × g for 1 
minute. The  flow through was discarded and Minicolumn  reinserted into the 
Collection Tube, this wash step was then repeated with 500μl Membrane Wash 
Solution and centrifuged at 16,000 × g for 5 minutes. The Collection Tube was 
emptied and the column assembly re-centrifuged for 1 minute with the 
microcentrifuge lid open to allow evaporation of any residual ethanol. To elute; 
the Minicolumn was transferred to a clean 1.5ml microcentrifuge tube and  50μl of 
nuclease-free water was added  to the Minicolumn. This was incubated at room 
temperature for 1 minute and centrifuged at 16,000 × g for 1 minute, the Minicolumn 
was discarded and DNA stored  at 4°C or –20°C. 
 
 
65 
 
2.2.2 Gibson Isothermal Assembly  
2.2.2.1. Gibson Isothermal Assembly design 
 Gibson Isothermal Assembly is a high-efficiency DNA end-linking 
technique using three enzymes to join two or more sequences of blunt ended or 3’ 
overhang dsDNA in a single 1hour reaction. The technique was used to construct 
recombinant rAAV vectors, a detailed description of the biochemistry and approach 
is given in chapter 4.3.2.2.  
 
2.2.2.2  Removal of 3’ overhangs – T4 DNA polymerase treatment 
When assembling DNA fragments linearized by or isolated from vectors 
using restriction enzymes which leave a 3’ overhang, the ends were blunted using T4 
DNA polymerase. DNA was dissolved in 1x NEBuffer supplemented with 100 μM 
of each dNTP, 1 unit of T4 DNA Polymerase per microgram of DNA was added and 
then Incubated for 15 minutes at 12°C, The reaction was stopped by adding EDTA 
to a final concentration of 10 mM and heating for 20 minutes at 75°C.  
 
2.2.2.3. Gibson Isothermal Assembly reaction  
A total of 0.02–0.5 pmols (weight in ng) x 1,000 / (base pairs x 650 daltons) 
of DNA fragments (blunt ended or 3’ overhang) were used when assembling 1 or 2 
fragments into a vector and 0.2–1.0 pmoles of DNA fragments when assembling 4-6 
fragments, with a 4 fold excess of insert to vector. DNA fragments were diluted in 
nuclease free water to a volume of 10μl and mixed with 10μl of 2X Gibson 
Assembly Master Mix (NEB Cat. No. E2611S) to a total volume of 20 μl, in a 50 µl 
PCR tube on ice, followed by 1 hr incubation at 50°C. 
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2.2.3 Clustered Regularly Interspaced Short Palindromic Repeats - CRISPR 
associated system (CRISPR-Cas) specific cloning methods. 
 
2.2.3.1 Annealing oligonucleotides 
 In order to anneal the sense and anti-sense single stranded oligonucleotides 
which become the guide RNA (gRNA)  5 µl of each oligonucleotides (1 µg/µl) were 
added to 85 µl of nuclease free H2O and 5 µl of ligase buffer NEB, heated at 95 °C 
for 5 minutes and allowed to cool to room temperature (~60 min). 
 
2.2.3.2 Golden Gate cloning 
Golden Gate cloning was used as strategy to insert gRNA (annealed oligos) 
into the pGUIDE vector (a kind gift from Dr Patrick Harrison; University College 
Cork) rather than gel purifying the backbone. 150ng of pGUIDE plasmid was mixed 
with 150ng CRISPR gRNA oligos (annealed in Section 2.2.3.1), 1 μl BseRI (NEB), 
1μl T4 ligase (Promega), 2 μl ligase buffer (Promega) and dH2O to a total volume of 
20μl. The reaction was incubated at 37 °C for 5 min, then 16 °C for 10 min for 10 
cycles, followed by 30 mins at 37°C and finally 20 mins at 80°C to heat inactivate 
the enzymes.   
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2.2.3.3 Transformation of chemically competent E. Coli cells DH5α™ 
Once the generation of recombinant plasmid DNA was confirmed by 
enzymatic digest (Section 2.2.5) and sequencing (Section 2.2.6), plasmids were 
transformed into strains of competent E. coli cells (DH5α™, InvitrogenTM Cat 
No.18265-017). Briefly, 50μl aliquot of competent cells was defrosted on ice, the 
ligation reaction (10µl) or 10ng of plasmid DNA were added to the defrosted cells 
and subsequently incubated on ice for 30 minutes. The cells were subjected to 
heatshock in a water bath for 45 seconds at 42°C and then incubated on ice for 2 
minutes. 950 µl of pre-warmed LB broth was added to the cells, and the culture 
incubated at 37 °C for 1 hour on a shaker at 225 rpm. 50-200 µl of this culture was 
spread onto LB agar plates supplemented with 100 g/ml ampicillin, and grown at 
37 ˚C overnight. 
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2.2.4 Isolation of DNA constructs from bacteria 
2.2.4.1 Mini-preparation of plasmid DNA 
A small scale preparation of plasmid DNA, for up to 20 μg, was used for 
screening plasmids after manipulation for molecular cloning. The QIAprep Spin 
Miniprep Kit (Qiagen, Cat No. 27106) was used for this purpose. This kit uses a 
modified alkaline lysis method, and the lysate is neutralised and adjusted to high salt 
binding conditions. The neutralised lysate is cleared by centrifugation, before being 
applied to a silica-gel membrane which selectively absorbs DNA in high-salt 
conditions. Endonucleases are removed by a wash with buffer PB, and salts are 
removed by a wash with buffer PE (both part of the kit). The plasmid DNA was 
eluted in nuclease-free water. 
 
2.2.4.2 Maxi-preparation of plasmid DNA 
For the isolation of up to 500 μg of plasmid DNA the QIAGEN Plasmid 
Maxi Kit (Qiagen, Cat No. 12165) was used. The kit utilizes a modified alkaline 
lysis procedure which results in a cell lysate containing plasmid DNA among 
protein, chromosomal DNA and other cell debris. Debris is cleared from the lysate in 
a neutralising potassium acetate buffer, and the plasmid DNA contained in the 
supernatant is bound to an anion-exchange column under high salt and low pH 
conditions. Medium-salt washes remove RNA, proteins etc. and the plasmid DNA is 
eluted with a high-salt wash. The eluted DNA is then precipitated with isopropanol, 
washed with 70% ethanol, and resuspended in nuclease-free water.  
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2.2.5 Analytical restriction enzyme digests 
Restriction enzymes were used for molecular cloning and to verify the 
insertion and position of DNA fragments into plasmid vectors. Restriction enzyme 
(~5 unit/1 µg DNA) digests were carried out in 1x restriction enzyme buffer. The 
digests were carried out at the appropriate temperature for the respective enzyme for 
a minimum time of 1 hour. DNA double digestion sequentially using two restriction 
endonuclease enzymes was performed when the two enzymes buffer salt 
concentration were not compatible, in such cases the initial reaction was performed 
using the enzyme that functioned in a low salt buffer, followed by digestion with the 
second enzyme that function in the high salt buffer. The second digest was set up 
adjusted to the volume of the first reaction. Enzymes were obtained from Promega 
and NEB. The fragments generated by restriction enzyme reaction were visualized 
after gel electrophoresis in a UV light translluminator. 
 
2.2.6 Sequencing  
DNA sequencing was performed by Source Bioscience Life Sciences Sanger 
sequencing service (Source BioScience LifeSciences, 1 Orchard Place, Nottingham, 
Business Park, Nottingham, NG8 6PX). 
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2.2.7 Measurement of nucleic acid  concentration by spectrophotometry 
Nucleic acid concentrations were quantified using the NanoDrop™ 8000 
Spectrophotometer (Thermo Scientific) with samples showing 260/280 ratios of 
~1.8. for DNA and ~2 for RNA. A NanoDrop™ 8000 Spectrophotometer was 
calibrated using 1 µl dH2O  or TE buffer (TE buffer 10 mM Tris-Cl, pH 7.5 1 mM 
EDTA) as blank, 1 µl of sample was then loaded onto the pedestal, the arm was 
closed  to form a sample column, the measurement was performed. 
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2.2.8 Cell and tissue culture 
2.2.8.1 Culture of JAr (human placental chorocarcinoma) cells 
JAr cells (ATCC HTB-144; American Type Culture Collection, 
Manassas,VA) were maintained as monolayers in supplemented RPMI-1640 
medium (Sigma) (Section 2.1.1.5). Sub-confluent cultures were split at (70-80%) 1:3 
to 1:10 i.e. seeding at 1-3x10,000 cells/cm
2
 using 0.25% trypsin or trypsin/EDTA; 
5% CO2; 37°C. 
 
2.2.8.2 Culture of SH-SY5Y (human derived neuroblastoma) cells  
SH-SY5Y cells were maintained as monolayers in 1:1 solution of Dulbecco’s 
EMEM media and nutrient mixture F12 HAM (Section 2.1.1.5) Sub-confluent 
cultures were split at  (70-80%) 1:3 to 1:10 i.e. seeding at 1-3x10,000 cells/cm
2
 using 
0.25% trypsin or trypsin/EDTA; 5% CO2; 37°C. 
 
2.2.8.3 Culture of HEK-293 (Human embryonic kidney ) cells 
HEK-293 cells, were maintained in monolayers in DMEM, (Section 2.1.1.5) 
Sub-confluent cultures were split at  (70-80%) 1:3 to 1:10 i.e. seeding at 1-3x10,000 
cells/cm
2
 using 0.25% trypsin or trypsin/EDTA; 5% CO2; 37°C. 
 
2.2.8.4 Culture of HCT-116 (human colorectal carcinoma) cells 
 HCT-116 cells (Sigma Cat. No. 91091005) were maintained as monolayers 
in McCoy′s 5a (Described in Section 2.1.1.5) sub-confluent cultures were split 
at  (70-80%) 1:3 to 1:10 i.e. seeding at 1-3x10,000 cells/cm
2
 using 0.25% trypsin or 
trypsin/EDTA; 5% CO2; 37°C. 
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2.2.8.5 Lithium, cocaine and sodium valproate cell treatments 
Cells were incubated in appropriate medium (see Section 2.1.1.5) for 24 hrs 
and supplemented with either 1 mM lithium chloride,  2µM sodium valproate or 10 
µM cocaine (described in Section 2.1.1.4) for 1hr. Following treatment the cells 
were harvested. Lithium, cocaine and sodium valproate treated cells were 
subsequently used in, standard PCR, chromatin immunoprecipitation (ChIP) and 
methylation (MethylQuest) assays. 
 
2.2.9 Co-transfection of rAAV and CRISPR-Cas plasmids. 
2.2.9.1 Lipofectamine LTX transfection (rAAV) 
Lipofectamine LTX transfection reagent (Invitrogen) was used to co-
transfect recombinant AAV vectors rAAV-G4-KO-CT or rAAV-LoxP-CT with the 
helper plasmids, pDG or -pDP2rs (Plasmid Factory), into HEK-293 cells, enabling 
assembly of functional AAV. For transfection, x10 T75 flasks containing 4x10
6
 cells 
in 10 ml DMEM were incubated for 72 hours. Following incubation, the media was 
replaced with 9 ml of new media and incubated for a further 30 minutes. For each 
transfection, 1 ml serum free DMEM was supplemented with plasmid DNA, 18.75 
µg pAAV-G4-KO-CT or pAAV-LoxP-CT  and 18.75 µg pDG or -pDP2rs in 
addition to 37.5 µl Plus reagent (Invitrogen). This was followed by a 5 minute 
incubation at room temperature. 56 µl Lipofectamine LTX was then added to the 
serum-free DMEM and incubated for a further 30 minutes at room temperature. 
Following incubation 1 ml of the Lipofectamine LTX/media  mix was aliquot across 
each flask, to ensure even distribution flasks were briefly rocked back and forth; 
cells were incubated for a further 72 hours. 
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2.2.9.2 TurboFect transfection (CRISPR-Cas) 
The TurboFect transfection reagent (Thermo scientific) was used for 
transfection of CRISPR plasmids pGUIDE and Cas9-WT DNA into SH-SY5Y cells. 
The TurboFect transfection reagent is comprised of a proprietary cationic polymer in 
water, the polymer forms positively-charged, complexes with DNA, these complexes 
are compact and stable thus protecting the DNA from degradation and facilitate 
efficient plasmid delivery into eukaryotic cells.   
24 hrs prior to transfection, 3x10
5
 cells were seeded into 12-well plates in 
400 μl of growth medium to give a confluency of 70-90% at the time of transfection. 
Equal molar concentrations of pGUIDE and Cas9-WT (3μg) plasmid DNA was 
diluted in 20 μl of serum-free DMEM. TurboFect reagent was briefly vortexed and 
12μl was added to the diluted DNA, this was then mixed immediately by vortexing, 
followed by a 20 minute incubation at room temperature. 20 μl of the transfection 
reagent/DNA mixture was added in a drop-wise manner to each well. The plate was 
gently rocked to achieve even distribution of the complexes; plates were 
then incubated at 37 °C in a CO2 incubator. 
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2.2.10         mRNA analysis 
2.2.10.1 Extraction of total RNA from JAr, SH-SY5Y and HCT-116 cells. 
Total RNA was extracted from cells grown in 6-well culture plates to 70-
80% confluency. Cell media was removed, followed by two washes with 1x PBS, 
the cells were lysed directly by adding 1 ml of TRIzol reagent (Invitrogen), 
transferred to a 1.5 ml microcentrifuge tube and incubated for 5 minutes at 15-30 °C 
to permit the complete dissociation of nucleoprotein complexes. DNA and protein 
were removed through phase separation by adding 200 μl of chloroform solution; 
samples were mixed by inversion for 15 seconds and incubated for 2-3 minutes at 21 
°C. Samples were then centrifuged at 12,000x g for 15 minutes at 4 °C. Following 
centrifugation the mixture separated into lower red, phenol-chloroform phase, an 
interphase, and a colourless upper aqueous phase. The RNA containing aqueous 
phase was transferred to a sterile-RNase free microcentrifuge tube containing 500 μl 
100% isopropanol and incubated for 10 minutes at 21°C. The total RNA was 
precipitated by centrifugation at 12,000 x g for 10 minutes at 4°C. Total RNA pellet 
was washed with 75% ethanol, and centrifuged again at 7,500x g for 5 minutes at 
4°C. The RNA pellet was then left to dry for 15 minutes at room temperature to 
allow evaporation of residual ethanol. To dissolve the RNA, the pellet was 
resuspended in 20 μl of RNase free water and incubated for 10 minutes at 
55°C; RNA samples were stored at -80˚C.  
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2.2.10.2 DNase digestion of total RNA extraction 
        Harvested total RNA was digested with RQ1 RNase-free DNase (Promega), in 
order to ensure that all DNA contaminants were removed. 1 μg of total RNA was 
digested with 1 μl (1unit) RQ1 RNase-free DNase in a 10 μl volume reaction 
containing 1 μl of RQ1 10x buffer (Promega). The reaction was performed at 37 ˚C 
for 30 minutes. 1 μl of Stop-solution (Promega) was added, and the enzyme was 
inactivated at 65 ˚C for 10 minutes. Successful removal of DNA was determined by 
visualisation of RNA and DNase treated RNA on a 1% agarose gel in 
electrophoresis. The RNA concentration was determined with NanoDrop™ 8000 
Spectrophotometer (Section 2.2.7) 
 
2.2.10.3 cDNA synthesis  
Promega’s Reverse Transcription System (Cat. No. A3500) was used for the 
reverse transcription step following manufacturer’s instructions. Briefly 1μg of 
DNase treated RNA was used as template in each RT- PCR reaction.  
Standard reverse transcription (RT) reaction: 
MgCl2, 25mM      4 μl 
Reverse Transcription 10x Buffer               2 μl 
dNTP Mixture, 10 mM    2 μl 
Recombinant RNasin Ribonuclease Inhibitor  0.5 μl 
AMV Reverse Transcriptase                15u 
Random Primers     0.5 μg 
Total RNA      1 μg 
Nuclease-Free water to a final volume of   20μl 
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In order to achieve first strand cDNA synthesis the reverse transcription 
reaction mix was incubated at room temperature for 10 minutes, followed by 15 
minutes at 42 ˚C, then 95˚C for 5 minutes and rapidly cooled to 4 ˚C for 5 minutes. 
As a negative control the reaction was carried out with dH2O alone in the absence of 
RNA. The cDNA concentration was determined using the NanoDrop™ 8000 
Spectrophotometer (Section 2.2.7). For quantitative PCR the resulting cDNA was 
diluted to10 ng/μl in nuclease-free water and subsequently 0.5-10 μl (5-100 ng) of 
this dilution were used as template in PCR’s. 
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2.2.10.4 PCR to analyse mRNA expression     
PCR was used as a method for analysing mRNA expression. PCR was 
performed in a peqSTAR 2X Gradient Thermocycler.  Promega’s GoTaq DNA 
polymerase and dNTPs were generally used unless otherwise stated. Primers (IDT or 
Eurofins genomics) were prepared as a 100 μM stock and stored at -20 ˚C (see Table 
1 in Appendix for primer sequences). 5-100 ng of first-strand cDNA was used in the 
PCR reaction as below: 
30ng first-strand cDNA   3 μl 
dNTPs Mixture, 10mM    0.5 μl 
MgCl2, 25mM     1.5 μl   
5x Buffer                5 μl  
Forward primer     50 pmol 
Reverse primer     50 pmol 
Taq DNA polymerase    2.5 units 
Nuclease-Free water to a final volume of  25 μl 
 
PCR programmes were adapted from a standard protocol. The annealing 
temperature varied according to the melting temperature of the primer pairs used and 
the extension time was adapted to the size of the expected product, with 1 minute 
extension time for each 1000bp as a guideline. The most commonly used reaction 
conditions were; one cycle of 94 ˚C for 10 min, followed by 35 cycles of: 
denaturation at 94 ˚C for 1 min, annealing: 60 ˚C for 1 min, extension: 72 ˚C for 1 
min and final extension to complete strands: 72 ˚C for 10 min.    
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2.2.10.5 Quantitative real time PCR 
 Quantitative real-time PCR was use to quantify viral DNA to obtain a 
viral titre. The reaction was performed in a qPCR machine (Bio-rad CFX Connect™ 
Real-Time PCR Detection System) using the GoTaq® qPCR Master Mix (Promega). 
This formulation includes a proprietary dsDNA-binding dye, which excites in the 
presence of dsDNA and the level of fluorescence is directly proportional to the copy 
number of amplicons produced. Standards were prepared by diluting rAAV plasmid 
in nuclease free H2O in a series of 5-fold serial dilutions, ranging from 1 µg/ ml to 
2x10
-8
 µg/ ml. 12.5 μl GoTaq® qPCR Master Mix master mix (containing GoTaq® 
Hot Start DNA polymerase, optimized PCR buffer, 5 mM MgCl, dNTP mix 
including dUTP) and 0.18 μM of each primer (see Table 1 of the appendix for 
primer sequences) were added to each of the diluted standards or AAV DNA sample, 
performed in triplicate. The GoTaq® Hot Start DNA polymerase incorporates a non-
specific DNA-binding domain that lends physical stability to the polymerase-DNA 
complex. qPCR cycling steps were carried out as outlined in the BioRad qPCR 
machine (block pre heating 95 °C for 10 min, denaturation 94°C for 30 seconds, 
annealing 60 °C 40 seconds for 45 cycles.) Data was analysed using BioRad CFX 
manager software. 
 
 
 
 
 
 
 
79 
 
2.2.10.6 PCR for amplification of DNA fragments enriched by ChIP and 
methylation assays 
A range of PCR reaction conditions were used to amplify the various 
VNTR’s and fragments of interest, specific cycling and reaction conditions can be 
found in Table 2 of the appendix. In general PCR reactions contained 5ng DNA 
template, 0.5mM dNTP, 0.4 μM primer, 0.625u GoTaq® DNA Polymerase, 5× 
Green GoTaq® Reaction Buffer and betaine (Sigma) at the final concentration of 
0.5M. The PCR amplifications were carried out on a peqSTAR 2X Gradient 
Thermocycler (PeqLab) under the following touch-down protocol: initial 
denaturation step (95 °C for 10 min); first cycles of denaturation (95 °C for 0.5 min); 
annealing (65 °C for 0.5 min); elongation (72 °C for 1.5 min), followed by repeated 
cycles with a 1°C decrease in annealing until 56 °C is reached followed by 30 cycles 
of denaturation (95 °C for 0.5 min); annealing (55 °C for 0.5 min); elongation (72 °C 
for 1.5 min),  final elongation step (72 °C for 30 min). PCR products were analysed 
using a 1.5% agarose gels stained with ethidium bromide solution (Sigma) and 
visualised using a UV transilluminator (BioDoc-it Imaging System). 
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2.2.11 Chromatin Immunoprecipitation (ChIP) 
2.2.11.1 Cell fixation and chromatin isolation  
 Human SH-SY5Y cells were grown to 80% confluency (~3x10
7
 cells) in a 
T175 culture flask, when ready to harvest, cells were fixed by adding 1% (v/v) of 
37% formaldehyde (Sigma) directly to culture media and incubated on a shaking 
platform for 8 minutes, cross linking was quenched by adding 4ml of 1.25 M glycine 
to a final concentration of 125mM. Cells were washed three times with 10ml ice-
cold 1x PBS (Sigma) supplemented with 10μl protease inhibitor cocktail (PIC) 
(Sigma) and 100μl 0.1M PMSF (Sigma). Cells were resuspended in 5 ml cellular 
lysis buffer (Section 2.1.1.2) including PIC and incubated end over end for 10 
minutes at 4°C followed by centrifugation at 3,500 rpm for 5 minutes at 4°C, 
supernatent was aspirated off and this step was repeated using nuclear lysis buffer 
(Section 2.1.1.2). Following centrifugation the supernatant was once again aspirated 
off and the lysate pellet resuspended in 1.5 ml sonication buffer (Section 2.1.1.2 ) 
 
2.2.11.2     Shearing of chromatin using sonication. 
The 1.5ml chromatin aliquots were sheared by sonication, using a BioRuptor 
(Diagenode) set at 50 cycles of 30 second pulses followed by 30 second pauses on 
high power.  The sonicated lysate was transferred to a 1.5ml microcentrifuge tube on 
ice and centrifuged at 10,000 × g for 10 min at 4°C to pellet the cell debris. The 
supernatant (containing the chromatin) was transferred to a new 1.5ml 
microcentrifuge tube. 50ul was taken from the supernatant, for fragment size 
analysis and the remaining sonicated sample stored at −80°C. 
To estimate the sonicated DNA concentration and fragments size, 50ul 
nuclease free water, 6 ul 5M NaCl and 2ul RNase1 (promega) (10u/ul) was added to 
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the 50ul sample of sonicated chromatin.  This was then vortexed and incubated at 
37°C for 30mins. 2ul Proteinase K was added to the RNase digested sample which 
was then vortexd and incubated at 65 °C for 2hrs. DNA was then purified using the 
Wizard SV Gel and PCR Clean-Up System (Promega). 1µl of the purified DNA was 
then quantified using the NanoDrop™ 8000 Spectrophotometer (Thermo Scientific). 
Fragment size was determined by gel electrophoresis; running 5µl of the purified 
DNA on a 1% agarose gel with 1Kb DNA ladder. 
 
2.2.11.3 Chromatin capture using magnetic beads. 
In order to capture chromatin on magnetic beads 20 µg sheared chromatin 
was incubated overnight with the appropriate antibody (see Table 3 of the appendix) 
Chromatin Antibody mix was then incubated with Dynabeads Protein G (invitrogen) 
for 2hrs. 
 
2.2.11.4 Chromatin elution, cross-link reversal and protein degradation. 
Immunoprecipitated samples were briefly spun to collect any liquid in 
the microcentrifuge tube lid.  Dynabead-protein-DNA complexes were captured 
using a magnetic rack and washed with 1ml low salt, high salt, lithium Chloride and 
TE wash buffers. Immune complexes were then eluted by adding 100 μl of elution 
buffer containing 2.5μl (50 μg/ml) proteinase K to the magnetic Dynabead-protein–
DNA complexes. These were mixed at 62°C for 2 h to release the protein bound 
DNA and reverse the cross-linking. The supernatant was then removed and 
transferred to a new tube using the magnetic racks. The protein–DNA complex mix 
was then incubated at 95°C for 10 min to denture the proteins and inactivate the 
proteinase K.  
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DNA was recovered using The Wizard® SV Gel and PCR Clean-Up System 
(Promega) and quantified using a NanoDrop™ 8000 Spectrophotometer (Thermo 
Scientific) followed by normalization with nuclease free H20 to 1ng/µl.  
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2.2.12 Methylation analysis 
2.2.12.1 Isolation of genomic DNA 
Genomic DNA was isolated from cells using the QIAmp® DNA Mini Kit (Qiagen) 
following manufacturers guidelines. Briefly, cell pellet was resuspended in 200 μl 
PBS, to which 20 μl proteinase K was added and mixed by pipetting. 200 μl Buffer 
AL was then added to the sample and mixed by pulse-vortexing for 15 seconds. 
Followed by incubation at 56°C for 10 min, the 1.5 ml microcentrifuge tube 
containing the sample was then centrifuged briefly  to remove drops from the inside 
of the lid. 200 μl ethanol (96–100%) was added to the sample and mixed again by 
pulse-vortexing for 15 s. After mixing, the  1.5 ml microcentrifuge tube containing 
the sample was once again centrifuged briefly  to remove drops from the inside of 
the lid and the contents applied to the QIAamp Mini spin column (in a 2 ml 
collection tube) and centrifuged at 6000 x g for 1 min. The QIAamp Mini spin 
column was then placed in a clean 2 ml collection tube  and the tube containing the 
filtrate discarded. 500 μl Buffer AW1 was then added to the QIAamp Mini spin 
column and centrifuged at 6000 x g for 1 min. The QIAamp Mini spin column was 
placed in a clean 2 ml collection tube and the collection tube containing the filtrate 
was discarded. 500 μl Buffer AW2 was added to the QIAamp Mini spin column 
and centrifuged at  20,000 x g for 3 min. The QIAamp Mini spin column was then 
placed in a clean 1.5 ml microcentrifuge tube, and the collection tube containing the 
filtrate was discarded. 200 μl Buffer AE was then added to the QIAamp Mini spin 
column and incubated at room temperature (15–25°C) for 1 min, and then 
centrifuged at 6000 x g (8000 rpm) for 1 min. 
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2.2.12.2 Isolation of methylated DNA 
Genomic DNA isolated using QIAmp® DNA Mini Kit (Qiagen) was then 
fragmented by sonication using the Bioruptor Plus (Diagenode) set at 10 cycles of 
30s 30 second pulses followed by 30 second pauses on high power. 300ng of 
fragmented gDNA was then incubated with CpG MethylQuest beads (GST-MBD 
fusion protein) and binding buffer at room temperature for 1hour with gentle mixing. 
Beads were then washed to remove DNA fragments not bound by the methyl domain 
binding protein (supernatant stored for subsequent analysis)  methylated DNA was 
then eluted, both methylated DNA (eluted) and unmethylated DNA (supernatant) 
were analysed by PCR of the specific region, with primer sets identified in Table 1 
of the appendix. 
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2.2.13 Adeno-associated virus (AAV) gene editing 
2.2.13.1 Antibiotic death curve 
The antibiotic resistance Neo
R 
gene driven by a thymidine kinase (TK) 
promoter was integrated into the viral genome which would be incorporated into the 
genome of SH-SY5Y cells via homologous recombination to isolate resistant cell 
colonies. It was necessary to determine the concentration of the antibiotic which 
killed wild-type SH-SY5Y cells; the death curve. The death curve determined the 
minimum concentration of the antibiotic used to culture potentially targeted cells and 
kill any cells which did not express the resistance gene and left targeted cells 
unaffected. G418 (Sigma) was dissolved to a working concentration of 100 mg/ml, 
which was subsequently diluted in DEMEM to give 11 concentrations ranging from 
0.1 mg/ml to 1.5 mg/ml of G418. SH-SY5Y cells were diluted to 15,000 cells/ ml in 
DEMEM media, and 100 µl was aliquoted across a 96 well plate. Each row of the 96 
well plate was supplemented with 100 µl of one of the 11 neomycin concentrations 
with the final row containing 100 µl antibiotic free media, this was repeated in 
triplicate and plates were incubated at 37
o
C in 5% CO2 for 10 days. 
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2.2.13.2 Generation of infectious AAV 
2.2.13.2.1 Harvesting AAV from HEK-293 cells 
72 hours post co-transfection both cells and media should contain live 
recombinant virus, the cell suspension media (containing virus) was harvested from 
the 10 T75 flask’s, pooled and transferred to 50 ml conical tubes.  The 10 T75 flasks 
were washed with 3 ml PBS to remove any residual media. The PBS wash 
(containing virus) was transferred into a separate 50 ml conical tube. Cells 
(containing virus) were then harvested by adding 2 ml trypsin to each T75 flask and 
incubated for 5 minutes; during the incubation stage, the three tubes containing the 
cell suspensions were centrifuged at 1000 rpm for 5 minutes. The trypsinized cells 
were then re-suspended in 2 ml DMEM, pooled and transferred to a 50 ml conical 
tube which was centrifuged for 5 minutes at 1000 rpm. The PBS wash solution was 
removed and discarded, leaving the cell pellet intact. The clarified supernatant from 
the initial centrifugation step was decanted into clean 50 ml conical tubes. The cell 
pellets and PBS wash pellet were re-suspended in 10 ml DMEM centrifuged for 5 
minutes at 1000 rpm and decanted into a clean 50 ml conical tube, clarified 
supernatants and cell pellets were stored at -80
o
C prior to purification. 
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2.2.13.3 AAV purification  
To purify the virus from the lysate, the virions had to be released. This is 
achieved by repetitive freeze thaw cycles of the lysate. Viral supernatant and cell 
pellet were transferred to a 37
o
C water bath. After 10 minutes, the cell pellet was 
thawed and re-suspended in 3 ml lysis buffer (Section 2.1.1.6). The tube containing 
the cell pellet was snap frozen in a dry ice ethanol bath for 10 minutes.  Once frozen 
the tube was returned to the water bath for an additional 10 minutes, followed by 
vortexing to disrupt the cells; the freeze-thaw cycles were repeated twice. The cell 
suspensions and thawed supernatant were combined and aliquoted between 50 ml 
conical tubes, before being centrifuged at 2900 rpm for 30 minutes. After 
centrifugation, the supernatants were transferred to a sterile T75 and 1 µl Benzonase 
nuclease (Sigma) was added to each 10 ml viral supernatant (to remove any 
contaminating DNA in the supernatant). The mixture was then incubated for 30 
minutes. The virus was purified using the AAV purification kit (VIRAPUR, Cat. No 
003063). The kit was set up according to manufacturer’s instructions; briefly the 
fibre-glass disc was washed with 4 ml PBS prior to use, then a vacuum pump was 
applied to the filter bottle. The flask with the Benzonase-treated virus was gently 
poured into the top of the filter and was allowed to be collected in the reservoir 
bottle below the filter. After filtration, 1 part dilution buffer 1 was added to 9 parts 
filtered supernatant. The purification filter assembly was attached to a 5 ml syringe 
filled with sterile PBS, and PBS was passed through the syringe. After the PBS was 
discarded, the 5 ml syringe was removed and the purification filter assembly was 
rearranged and attached to a 20 ml syringe. The supernatant was pulled through the 
filter assembly at rate of 20 ml/minute, discarding the supernatant when the syringe 
was filled. After the remaining supernatant had passed through, a new 20 ml syringe 
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was used to pass 30 ml of wash buffer 2 over the filter. Finally, 1.5 ml of elution 
buffer 3 was passed between two 5 ml syringes to elute it from the filter. 
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2.2.13.4 Virus quantification 
The purified virus was quantified by quantitative real-time PCR (Section 
2.2.10.5). To obtain linear rAAV DNA from the viral capsid a number of enzymatic 
steps were employed. To digest residual and contaminating DNA, 5 µl of virus was 
added to 5 µl DNaseI buffer (10x) and 10 U DNaseI (Promega). The solution was 
made up to 50 µl with nuclease free water and was incubated at 37
o
C for 30 minutes, 
then at 95
o
c for a further 2 minutes. To digest the viral capsid 100 µl of proteinase K 
solution (Qiagen), was added to each sample and incubated at 56
o
C for 1 hour, then 
at 95
o
c for a further 5 minutes to inactivate the proteinase K. This mix was then 
diluted 1:10 in nuclease free H2O ( an important step as undiluted samples failed to 
be amplified in  qRT-PCR possibly due to the presence of residual inhibitory 
substances). 
To ensure accurate quantification through RT-QPCR a standard curve was 
created using standards prepared by diluting rAAV-G4-CT (containing the Neo
R 
gene) in nuclease free H2O in a series of 5-fold serial dilutions, ranging from 1 µg/ 
ml to 2x10
-8
 µg/ ml as shown in the table below. 
 
Table 2.1 standard curve using dilutions of rAAV-G4-CT. 
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Obtaining a viral titre using RT-QPCR does not quantify infectious viral 
particles but quantifies copies of single stranded copies of neomycin
R
. The 
calculation of single stranded copies neomycinR/ml makes the following 
assumption: 
Number of single stranded copies of neomycinR in 1 μg double stranded rAAV = 
(2 x 6.02 x 1023) / (610x 7000 x 106) = 2.821 x 1011 where: 
Number of copies of single stranded neomycinR gene per double stranded plasmid 
6.02 x 10
23
 = number of molecules (copies) per mole of a substance 
610 = average MW (g/mole) of one nucleotide bp 
7000 = average size of a rAAV plasmid in bp 
10
6
 = number of μg per g 
For each reaction a 20 x PCR master mix was assembled: 
0.225 μl forward primer (100 μM) 
0.225 μl reverse primer (100 μM) 
0.05l probe (100 μM) 
0.75 μl H20 
 
For each reaction a final qRT-PCR mix was assembled: 
1.25μl 20 x PCR master mix (above) 
12.5μl GoTaq® qPCR Master Mix 
10.25μl H20 
 
Reactions were performed under the following cycling conditions: 
Temperature       Time      Cycles 
95°C                       3 min          1 
95°C                     15 s            40 
60°C                     60 s            40 
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The data was analysed using BioRad CFX manager software, following the 
basic guidelines: Baseline and threshold values were set in the region of the 
exponential phase, with the replicates within 0.5 (threshold cycle) Cts. To obtain the 
standard curve (a plot of initial copies of single stranded neomycin
R
 gene/ml vs Ct), 
the following specifications were: i.) correlation coefficient ≥ 0.99; ii.) efficiency: 
95-105%. To calculate the virus titre in genome copies (GC)/ml, the value of initial 
copies of single stranded neomycin
R
 gene/ml were multiplied by 300 (the dilution 
factor used in the initial preparation of the virus for qRT-PCR; DNaseI and 
proteinase K treatment).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
92 
 
2.2.13.5 Infection of HCT-116 cells with rAAV-G4KO-CT and rAAV-LoxP-CT 
HCT-116 cells were seeded at a density of 5x10
5
 in 6x T75 flasks 24 hours 
prior to infection, to ensure cells were below 40% confluence at time of infection. A 
range of multiplicities of infection (MOI’s) were used to identify the optimum ratio 
of viral particle to cell; 25, 50 and 100 µl of purified rAAV-G4KO-CT viral particles 
were added to 5 ml DMEM media in separate conical tubes, alongside this 25, 50 
and 100 µl of purified rAAV-LoxP-CT viral particles were added to 5 ml media in 
separate conical tubes. Existing media was aspirated from the cells and was replaced 
with 5ml of virus-treated media; the cells were then incubated for 72 hours. 
 Infected cells were trypsinised, counted and plated at a range of cell densities 
(1000, 500, 250, 100, 50, 10 cells/ well) in 200µl selection media (0.5uM G418) 
across x6  96 well plates (1 plate per cell density) this was repeated for each of the 
three MOI’s and for both targets (rAAV-G4KO-CT and rAAV-LoxP-CT) to give a 
total of x18, 96 well Cells were then returned to the incubator at 37 
o
C 5% CO₂ for 
14 days.  
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2.2.13.6 Screen of infected cells to identify recombination events 
2.2.13.6.1 Visual screen of 96 well plates to identify colony formation 
After 14 days, the plates were visually screened to identify wells with 
successful colony formation, wells with 1 or more colonies were marked as potential 
positives and returned to the incubator for an addition 2-4 weeks to reach 50-70% 
confluence. 
 
2.2.13.6.2 PCR screen of positive wells identified through visual screen. 
Once infected cells reached 50-70% confluency they were lysed to release 
gDNA which was then PCR screened; to identify successful homologous 
recombination events. A positive and negative primer set was used to screen the 
gDNA. The positive set was specific for the targeted allele with the forward primer 
in the neomycin resistance cassette while the reverse primer was in located at the 
genomic region outside of the homology arms. Using this primer set only wells 
containing cells which had undergone homologous recombination of the neomycin 
selection cassette and therefore targeted sequence would give a PCR product. The 
negative primer set was wild-type specific. (Specific primers can be found in Table 1 
of the appendix). 
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2.2.13.6.2.1 Release of genomic DNA (gDNA) from cells 
To release the gDNA from the cells Direct PCR Lysis reagent (Viagen 
biotech Cat. No. 302-c) was used. The following reaction buffer was prepared per 96 
well plate: 
Reaction size                20 μl 
Volume of cells             2 μl 
Number of reactions     110 
Direct PCR Buffer        2100 μl 
Proteinase K                  21 μl 
 
20μl of Lysis buffer was aliquoted in to each well of a 96-well PCR plate. HCT-116 
media (sectionwas removed, cells were then washed with PBS. Following aspiration 
of PBS, 25μl of Trypsin was added to each well, plates were then incubated at 37oC 
for 10 minutes. Following incubation cell suspensions were mixed by gentle 
pipetting, 5μl of cell suspension was then transferred to the PCR plate containing 20 
μl lysis buffer. To the remaining cells 200μl of media was added and 96 well plates 
were returned to the incubator. 
The 96 well plates containing cell lysis suspension were sealed using a heat 
seal and incubated in the peqSTAR 2X Gradient Thermocycler (PeqLab) under the 
following conditions 
Step Cycles Temp (
o
C) Incubation (min) 
1         1          55                 15 
2         1          85                 45 
Lysed cells were transferred to 4
o
C for short term storage until subsequent PCR 
Screen. 
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2.2.13.6.3 PCR screen setup 
The 96-well plate containing direct PCR and control DNA was thawed on ice, 
the below master mix was then prepared on ice reaction size (μl) 20: 
Volume of template 2 μl 
number of reactions 100 
buffer (5x) 400 μl 
primer 1 (100μM) 15 μl 
primer 2 (100μM) 15 μl 
dNTP's (25mM each) 20 μl 
MgCl2 (25mM) 120 μl 
DMSO 120 μl 
H2O, PCR grade 1090 μl 
enzyme (5μ/μl) 20 μl 
 
18μl of the PCR master mix was aliquoted across each well of the 96-well PCR 
plate, followed by 2μl of template DNA, the PCR plate was then sealed and with a 
heat sealer, briefly centrifuged to collect the content in the bottom of the well and 
transferred to the peqSTAR 2X Gradient Thermocycler (PeqLab) PCR machine, 
touchdown PCR cycling conditions are detailed bellow:  
Step Cycles Temp (
o
C) Incubation (secs) 
1          1         94                180 
2          3         94                 15 
                       64                 30 
                       70                 90 
3          3         94                 15 
                       61                 30 
                       70                 90 
4          3         94                 15 
                       58                 30 
                       70                 90 
5           35      94                 15 
                       57                  30 
                       70                  90 
6           1        70                 300 
7                     4                   Hold 
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The plate was then removed from the PCR machine and stored at 4
o
C. PCR 
analysis was performed using Gel electrophoresis, loading 10 μl of PCR product and 
1.8 μl 6X loading dye into a 1% agarose gel. 
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2.2.13.6.4 Expansion of positive targeted pools 
The initial PCR screen only identified pools of positive clones therefore it 
was necessary to isolate single cells from this pool to ensure a clonal population 
giving rise to a truly isogenic cell line. Once pools were identified as positive for 
targeting, the cells within that well were expanded to a 48-well plate. Expansion 
typically occurred 1-4 days post-harvest for the PCR screen, once the 24 well plate 
reached 70% confluence each well was expanded across 24 well plates ensuring the 
cells were robust enough to undergo single cell dilution (SCD). 
 
2.2.13.6.5 Single cell dilution of targeted pools 
 Each of the 9x positive pools identified in the PCR screen were diluted 
across 3x 96 well plates 1x plate at a concentration of 1 cell/well x1 plate at  0.5 
cells/well, and x1 plate at 3 cells/well, plates were transferred to an incubator at 37
 
o
C 5% CO2    for 14 days. 
 
2.2.13.6.6 Visual screen of SCD cells to identify clonal cell colony formation 
After 14 days incubation at 37
 o
C, 5% CO2   SCD plates were visually 
screened for clear single colonies, these were marked by circling the well on the lid 
and record in a spreadsheet. When colonies reached 70% confluence, if there were 
greater than 20 colonies per plate, they were harvested for a PCR screen. Plates with 
less than 20 colonies per plate were consolidated onto a new 96-well plate and 
allowed to grow to 50-70% confluency before repeating the PCR screen. 
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2.2.14 CRISPR-Cas targeting efficiency – T7 endonuclease 1  (T7E1) assay  
 
PCR and T7 endonuclease assay was used to determine efficiency of 
CRISPR-Cas targeting. CRISPR-Cas targeting introduces double strand breaks at or 
around the target region (Mir-137), the natural cellular process of NHEJ will repair 
these double strand breaks leaving bp errors, these can be detected by the mismatch 
sensitive enzyme T7E1. PCR amplicons of the target region Mir-137 (primer set can 
be found in Table 1 of the appendix) were isolated from the agarose gel using 
Wizard® SV Gel and PCR Clean-Up System (Section 2.2.1.5) and resuspended in 
100 µl of nuclease free H2O. the samples were heated at 95 °C for 5 minutes and 
allowed to cool to room temperature (~60 min). DNA annealed to form heteroduplex 
DNA, which was treated with 5 units of mismatch-sensitive T7 endonuclease 1 
(NEB) for 20 mins at 37°C and then analyzed by 2% agarose gel electrophoresis.  
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Chapter 3   
Repeat sequences in the promoter of 
selected genes have the potential to 
form the secondary DNA Structure     
G-quadruplex 
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3.1 Introduction 
To date the vast majority of work surrounding G-quadruplex and its potential 
functionality in gene regulation has been in relation to cancer (Figure 3.15) 
 
 
Figure 3.1 G-Quadruplex present in genes implicated in cancer 
A schematic diagram showing the six hallmarks of cancer as defined in (Hanahan 
and Weinberg, 2000) correlated to a specific G-Quadruplex element in the promoter 
of a Cancer gene (Figure adapted from (Brooks and Hurley, 2009). 
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The G-quadruplex located within the CT element of c-MYC is the most well 
studied G-quadruplex as described in Section 1.3.1. Given the prevalence of c-MYC 
in so many cancers as outlined in Section 1.3.1.1 the ability to selectively target its 
aberrant expression would be an incredibly attractive intervention. If the G-
quadruplex elements do indeed function as on off switches and are amenable to 
small molecule targeting as detailed in Section 1.2.3.1 then their therapeutic 
potential should not be limited to Cancer. Therapeutic G-quadruplex targeting could 
be extrapolated to genes involved in other diseases which would benefit from a 
switch to control the rate of transcription.  In this chapter I expand the role of G-
quadruplex from its implication in cancer into the field of neuroscience and explore 
the mechanism through which G-quadruplex may function at to regulate selected 
genes associated with neurological disorders. 
 
3.2 Aims 
1. Address the potential for repeat elements in the promoter of selected genes to 
form G-quadruplex using both experimental and in-silico analysis. 
i. ssDNA mapping 
ii. Potential G-quadruplex sequence analysis: Quadparser programme 
2. Determine whether ssDNA binding protein hnRNP K and CTCF, both 
regulators of chromatin architecture and transcription bind to the promoter 
regions of selected genes. 
3. Explore G-quadruplex associated transcription factor binding and 
methylation status at the promoters of selected genes. 
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3.3 Results  
3.3.1 Mapping repeat elements with the potential to form G-quadruplex 
in the promoters of selected genes associated with cancer and neurological 
disorders 
In order to begin exploring the hypothesis that repetitive sequences of DNA 
within 1500bp of transcriptional start sites can form secondary DNA structures 
termed G-quadruplex I performed both experimental and in-silico bioinformatic 
analysis to identify such regions of DNA. The following search criteria were used:  
i. Regions within 1500bp of the transcriptional start site. 
ii. Regions of high ssDNA  
iii. Sequences with the  potential to form G-quadruplex 
As detailed in Section 1.2.2.2 although DNA is a highly dynamic molecule its 
overall conformation is stable in duplex form despite continuous transient 
transactions such as transcription and DNA replication. Duplex DNA’s 
conformational stability is a result of its hydrophobic and electrostatic base-stacking 
and base-pairing (Yakovchuk et al., 2006). It is therefore energetically favourable for 
the molecule to maintain a duplex form and will only alter its structural 
conformation if significant mechanical force is applied to it. Transcription induced 
dynamic supercoiling is one such force and is able to spread ~1.5 kilobases upstream 
of the start sites of active genes (Kouzine et al., 2013a).  This data provides the 1
st
 
search criteria; analyse sequences located within 1500bp of the transcriptional start 
site as these are susceptible to transcription induced dynamic supercoiling. 
For duplex DNA to adopt alternative conformations including G-quadruplex, 
the B-DNA must first undergo unwinding (negative supercoiling) as detailed in 
Section 1.2.2.2. This unwinding of the double helix forces the DNA to become 
single stranded in part. The ssDNA protocol described in (Kouzine et al., 2013b) 
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provides a unique method to capture these regions and is therefore a very 
informative tool when analysing regions of DNA which may form G-quadruplex.  In 
vivo ssDNA-seq data generated by the Levens Lab (Kouzine et al., 2013b) has been 
used to generate a ssDNA mapping track on UCSC genome browser which identifies 
regions of the Raji cell genome that adopt ssDNA. This ssDNA mapping track forms 
the basis of the second search criteria; regions which have high areas of ssDNA are 
likely to form G-quadruplex. It should be noted that the ssDNA mapping assay has a 
bias against G-quadruplex as the potassium permanganate (KMnO4) treatment 
modifies ssDNA by oxidizing pyrimidine bases with preference for thymidine so 
although the assay will locate ssDNA guanine (G) rich areas will not peak as highly 
as the surrounding thymine (T) rich areas. 
The potential for a sequence of DNA to form G-quadruplex is determined by 
the arrangement of G bases, specifically x3 G’s, repeated four times with between 1 
and 7 residues between each run of GGG as defined  by the ‘Quadparser’ algorithm: 
(G3+ N1-7 G3+ N1-7 G3+ N1-7 G3). The Quadparser algorithm was used to create 
a potential G-quadruplex mapping track on UCSC by Dr. Ashutosh Gupta a 
colleague in the Levens Lab. This track highlights any regions which have a 
sequence which falls into the range G3+ N1-7 G3+ N1-7 G3+ N1-7 G3 and thus 
forms the 3
rd
 search criteria. 
The Levens Lab’s focus is on cancer biology (where most of the literature on 
G-quadruplex has previously been focused) and the Quinn Lab’s primary research 
interest is in neurological disorders. However both labs are interested in the 
underlying mechanisms of transcriptional regulation common to both sets of disease.  
With this in mind a number of cancer and neuroscience genes were screened using 
University California Santa Cruz (UCSC) genome browser and the tracks outlined 
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above to identify 3 genes associated with cancer and 3 genes associated with 
neurological disorders that met the search criteria previously specified.  Figure 3.2 a 
– g. details C-MYC, hTERT and VEGFA as the selected cancer target genes, having 
been previously identified as containing potential G-quadruplex forming regions 
(Brooks and Hurley, 2009).  5-HTT, MAOA and DAT1 are the focus of ongoing 
studies in the Quinn Lab and were selected as the neurolocical target genes. These 
genes have no literature describing them as having potential G-quadruplex sequence 
but my analysis has identified repetitive regions of DNA overlapping potential G-
quadruplex (pG4) sequence within 1.5 kb of the transcriptional start site within 
regions of ssDNA.  
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3.3.2   hnRNP K and CTCF bind to the promoters of c-MYC and 5-HTT. 
 
 The ssDNA binding protein and transactivator  hnRNP K is known to 
bind to the CT element and regulate c-MYC  (Tomonaga and Levens, 1995) 
(Tomonaga and Levens, 1996, Michelotti et al., 1996a). The regulator of chromatin 
architecture & transcription; CTCF is known to bind to the CT element in the 
chicken c-MYC gene (Lobanenkov et al., 1990, Klenova et al., 1993) and has been 
shown to bind to the 5-HTT 5’ LPR and influence expression of 5-HTT (Ali et al., 
2010, Vasiliou et al., 2012). I decided to validate hnRNP K binding at the CT 
element in the human c-MYC gene and examine its binding at the 5-HTT 5’ LPR in 
HCT-116 cells through ChIP. ChIP analysis of the CT element was performed under 
normal growth conditions. ChIP analysis of the 5-HTT 5’ LPR was performed under 
normal growth conditions and following 1 hour treatment with 10µM cocaine. 
Cocaine is known to effect the monoamine pathway and has previously been shown 
to influence CTCF binding at the long and short alleles of the LPR VNTR at this 
concentration and time course (Ali et al., 2010). In HCT-116 cells, hnRNP K and 
CTCF bind to the CT element (Figure 3.3). hnRNP K and CTCF bind to the LPR 
region under normal growth conditions with  binding of CTCF increasing in 
response to  cocaine (1hr), (Figure 3.4). This preliminary biochemical analysis 
implicated hnRNP K and CTCF in the regulation of two of the target regions. 
Enabling me to move forward and begin to address the mechanism that could 
correlate with potential alternative DNA structure at these regions. 
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Figure 3.3. ChIP analyses of the CT element in c-MYC HCT-116 cells. 
Agarose gel showing PCR products amplified following ChIP identifies hnRNP K 
and CTCF binding to the CT element c-MYC under normal growth conditions 
 
 
Figure 3.4. ChIP analyses over the LPR region, in HCT-116 cells. 
 
Agarose gel showing 550bp PCR products amplified following ChIP identifies 
hnRNP K and CTCF binding to the LPR with CTCF binding appearing to increase in 
response to cocaine (1hr). 
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3.3.3 Allelic specific interactions of hnRNP K and CTCF at the LPR region   
 
Owing to the dynamic nature of G-quadruplex formation discussed in section 
1.3.1.2 along with the limitations of ChIP discussed in Section 4.4 it is difficult to 
gain a complete and accurate picture of transcription factor binding activity at the 
regions of interest.  ChIP will capture a single frame across a population of cells, all 
of which may be at different points in the process of G-guadruplex formation. I 
therefore identified the JAr cell line which is heterozygous for the 14 copy (short) 
and 16 copy (long) LPR VNTR. Based on my Quadparser analysis (Figure 3.16) of 
this region the sequence of the short allele has the potential to form two G-
quadruplex structures whereas the long allele has the potential to form four G-
quadruplex structures (Figure 3.2e). This heterozygosity enabled comparison of 
factor binding between the two alleles within the same assay. Under normal growth 
conditions hnRNP K and CTCF both interact with the short allele where as in 
response to 1 hr exposure to 10µM cocaine both transcription factors are seen to 
interact with the long and short allele, with CTCF preferentially binding to the long 
allele (Figure 3.5).  
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Figure 3.5 JAr cell line (heterozygous for long and short LPR) identifies allelic 
specific interactions at the region 
 
Agarose gel showing PCR products amplified following ChIP of the 5HTT gene 
promoter. The LPR region is identified as two bands in ‘input 1% chromatin’ and 
confirmed by positive control Histone 3 (H3). hnRNP K and CTCF bind only to the 
short allele under basal conditions,  in response to 10µM Cocaine (1hr) CTCF and 
hnRNP K bind to the long allele with  CTCF showing preferential binding to the 
long over the short. 
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3.3.4 A model to explain the potential biophysical mechanism though which the 
CT element is able to form G-quadruplex and regulate c-MYC.  
As previously mentioned in Section 1.3.1.2  the CT element has been shown 
to adopt non-B DNA structures in supercoiled DNA in vitro and in its endogenous 
location in vivo (Michelotti et al., 1996b, Kohwi and Kohwi-Shigematsu, 1991). 
When in B DNA form, CTCF can bind to the CT element (Klenova et al., 1993, 
Lobanenkov et al., 1990). The transcriptional activator Sp1 is also able to bind to the 
CT element in turn activating transcription (Hay et al., 1987, Geltinger et al., 1996). 
This activated transcription induces supercoiling which could accumulate and force 
the element into the single-stranded conformation. This new single stranded 
transcriptional landscape would enable alternative single strand  specific 
transcriptions factor hnRNP K and CCHC-type zinc finger nucleic acid binding  
protein (CNBP) to bind the purine-rich and pyrimidine-rich strands, respectively, 
maintaining the active state (Brooks and Hurley, 2009, Tomonaga and Levens, 1996, 
Michelotti et al., 1995). Upon removal of the single stranded transcription factors, 
the G rich CT element is able to adopt stable non-B DNA structures; a G-quadruplex 
on the purine-rich strand and i-motif on the pyrimidine-rich strand (Sun and Hurley, 
2009). These globular structures create a third transcriptional landscape across the 
same region of DNA by masking the standard B-DNA transcription factor binding 
sites within the structure. This potentially creates a new G-quadruplex specific 
transcription factor binding site to which nucleolin can bind (Gonzalez and Hurley, 
2010b) and therefore silence transcription by stabilizing the G-quadruplex. It has 
recently be recently proposed that Sp1 itself can bind to the G-quadruplex (Raiber et 
al., 2012) with unknown effects (Figure 3.6). 
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3.6 A model to explain the potential biophysical mechanism though which the 
CT element is able to form G-quadruplex and regulate c-MYC 
 
a. A duplex representation of the promoter with CTCF binding and silencing b. 
Binding of Sp1 to the duplex structure activates transcription leading to negative 
supercoiling. c. Binding of hnRNP K and CNBP to the single stranded C and G rich 
regions, respectively, could lead to the activation of c-MYC.  d. The repression of c-
MYC transcription when hnNRP K and CNBP are not bound leads to the formation 
of the G-quadruplex and i-motif, which create a new transcriptional landscape 
enabling G-quadruplex factors to bind. 
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3.3.5 Transcription factor binding at the CT element of c-MYC 
The model in Section 3.3.3 which details the biophysical mechanism though 
which the CT element is able to form G-quadruplex implicates CTCF, Sp1,     
hnRNP K, CNBP and nucleolin in the process. I therefore performed further ChIP 
analysis for these factors across the CT element in the HCT-116 cell line.  Under 
normal growth conditions hnRNP K, Nucleolin, Sp1 and the positive histone mark 
H3k9me3 bind at the CT element however CTCF does not appear to bind. 
 
Figure 3.7 Transcription factor binding at the CT-element of C-Myc. 
 
Agarose gel showing PCR products of (550bp) amplified following ChIP. Under 
basal conditions hnRNP K, Nucleolin, Sp1 and the positive histone mark H3k9me3 
bind at the CT element, CTCF does not. 
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3.3.6 Transcription factors implicated in G-quadruplex formation bind in an 
allele specific manner  at the 5’LPR of 5-HTT gene. 
The ChIP data in Section 3.3.4 showed many of the factors in the G-
quadruplex formation model (Section 3.4.3) binding to the CT region. Based on 
these findings I wanted to explore whether the same model may be relevant at other 
previously unidentified potential G-quadruplex sites. I therefore performed ChIP 
analysis for the same factors across the 5’ LPR in the JAr cell line. This was in the 
hope that transcription factor binding profiles across this region may point to a 
common, dynamic structural regulatory mechanism. Such a mechanism could then 
be extrapolated to a number of promoter regions with potential G-quadruplex 
sequences within 1.5kb of their transcriptional start site.  
 In addition to normal growth conditions (basal) and 10µM cocaine (1hr), 
analysis was performed in response to 1mM Lithium (1hr). Lithium is a mood 
stabilising drug previously shown to regulate the 5-HTT gene in part, by repressing 
the binding of CTCF to the alleles of the 5’ LPR (Ali et al., 2010). 1mM 
concentration was used during this study as this concentration is known to be 
clinically relevant (Wang et al., 2011), and further at higher concentrations was 
found to have non-specific metabolic effects (Roberts et al., 2007). 
Under basal conditions CNBP, hnRNP K and CTCF were observed to bind at 
both alleles but preferentially to the short allele under the same conditions. Nucleolin 
and Sp1 bound only to the short allele. In response to 1mM Lithium; CNBP and 
hnRNP K bound preferentially to the short allele, CTCF binding was lost at the long 
allele and nucleolin and Sp1 remained bound to the short allele.  After 1hr treatment 
with 10µM cocaine, binding of CNBP and hnRNP K was lost at the long allele. 
CTCF was observed to bind equally to both alleles and nucleolin and Sp1 were both 
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seen to bind preferentially at the short allele but cocaine resulted in binding of 
nucleolin and Sp1 at the long allele.  
In essence a switch is observed at the long allele in response to cocaine: 
Single stranded binding proteins CNBP and hnRNP K bind to the long allele and G-
quadruplex binding proteins do not bind to the long allele under normal growth 
conditions and in response to lithium. However in response to cocaine the reverse is 
observed; binding of CNBP and hnRNPK is lost and binding of nucleolin and Sp1 is 
gained. 
 
Figure 3.8 G-quadruplex associacted transcription factors bind in an allele 
specific manner  at the 5’ LPR.  
 
Agarose gel showing PCR products of the 5’LPR amplified following ChIP analysis 
in the JAr cell line for CNBP, hnRNPK, CTCF, nucleolin and Sp1, identifies allelic 
specific interactions at the 5’ LPR region identified as two bands in ‘input 1% 
chromatin’ top band is the L allele , S allele is the bottom band. 
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3.3.7 Transcription factors bind in an allele specific manner  at the MAOA 
promoter. 
Given the interesting and informative allele specific binding patterns across 
the 5-HTT 5’ LPR in Section 3.3.6 I wanted to interrogate binding across another 
polymorphic region in a cell line heterozygous for the region. The neuroblastoma 
cell line SH-SY5Y is both female and heterozygous for the 3 and 4 copies of the 
proximal µVNTR (Figure 3.9b) and 9 and 10 copies of the distal dVNTR (Figure 
3.9c) in the promoter of the MAOA gene found on the X chromosome. gDNA 
extracted from SH-SY5Y (Section 2.2.12.1) was amplified by PCR using primer sets 
MAOA distal (Table 1 of the appendix) and MAOA proximal (Table 1 of the 
appendix) using the PCR protocol detailed in Section 2.2.1.2. When amplifying 
repetitive sequence as in the case of VNTR’s a PCR amplification bias is often 
observed between the two alleles (Ali et al., 2010, Vasiliou et al., 2012). 
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Figure 3.9 MAOA promoter contains a proximal (µ) VNTR and a distal (d) 
VNTR. 
 
(a) Schematic of MAOA VNTR repeats along with 2 transcriptional start sites (a). 
(b) Agarose gel showing PCR amplified µVNTR from gDNA extracted from SH-
SY5Y cells, heterozygous for 3 and 4 copies of the repeat.  (c) Agarose gel of PCR 
amplified dVNTR from gDNA extracted from SH-SY5Y cells, heterozygous for 9 
and 10 copies of the repeat. 
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It is not possible to differentiate between the µVNTR and the dVNTR in 
ChIP analysis due to the limited sequence of 400bp between the two regions. The 
chromatin shearing range is 500 – 1500 bp therefore fragments undergoing 
subsequent immunoprecipitation with specific antibodies are likely to incorporate 
both VNTR sequences. As such PCR amplification of one VNTR would not be 
accurate in defining factors binding to a specific VNTR because both regions will be 
enriched for despite specific primer sets. PCR results of the ChIP material at this 
region must refer to the MAOA promoter in general. However when ChIP data is 
correlated with in-silico sequence analysis detailing predicted specific transcription 
factor binding sites (Figure3.10), more specific inferences may be made. Consensus 
sequences for CNBP, hnRNPK and Sp1 can be found in the distal VNTR but not the 
proximal µVNTR. 
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ChIP analyses over the MAOA promoter region was performed under basal 
growth conditions and in response to 10 µM cocaine as in previous experiments, 
with the addition of the mood stabilizer sodium valproate at a physiologically 
relevant concentration of  2µM (Pan et al., 2005). 
The ChIP analysis identified allelic specific interactions in the heterozygous 
SH-SY5Y cell line (identified as two bands in ‘input 1% chromatin’). Histones are 
only bound to the 3 copy variant and the active H3K9me3 mark is increased in 
response to cocaine (1hr). Binding of transcription factors is only observed on the 3 
copy allele until exposure to valproate and cocaine when we can see binding of 
hnRNP K and CNBP to both alleles and CTCF after cocaine exposure.  
 
Figure 3.11 G-quadruplex associacted transcription factors bind in an allele 
specific manner  at the MAOA promoter. 
 
Agarose gel showing PCR amplified fragments across the MAOA promoter. Binding 
of transcription factors is only observed on the 3 copy allele until exposure to 
valproate and cocaine when we can see binding of hnRNPK and CNBP to both 
alleles.  
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3.3.8 Both 3 and 4 copy alleles of MAOA µVNTR  are actively transcribing. 
           The unusual histone binding patterns observed inFigure 3.11; specifically no 
histones including “ubiquitous” H3 positive control antibody observed to bind the 4 
copy allele would suggest unusual chromatin architecture. I performed ChIP for an 
active RNA polymerase (anti-RNA pol II CTD phospho Ser5 antibody) to determine 
if active Pol II was loaded on one allele but not the other.  Active Pol II binds to both 
alleles of the MAOA µVNTR  (Figure 3.12a) which would suggest both alleles are 
actively transcribing. I confirmed this by analysing cDNA from SH-SY5Y cells by 
PCR over the µVNTR  demonstrating that both alleles are expressed in fact they are 
differentially expressed in response to sodium valproate (Figure 3.12b). 
 
Figure 3.12 Both 3 and 4 copy alleles of MAOA µVNTR  are actively 
transcribing in SH-SY5Y cells.  
 
a. Agarose gel showing PCR amplified fragments across the MAOA promoter, ChIP 
analysis identifies active RNA polymerase II binding to  both 3 and 4 copy µVNTR  
alleles under normal growth condidtions. b. Agarose gel showing PCR amplified 
cDNA reveals both alleles are expressed. 
 
a. b. 
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3.3.9 Nucleosome exclusion regions overlap with MAOA distal VNTR 
A recent publication (Shumay and Fowler, 2010) gave a comprehensive 
bioinformatic analysis of the MAOA promoter region interrogating genomic features 
and attributes that might modulate its epigenetic sensitivity. Of particular interest 
were the identified nucleosome exclusion regions, highlighted in Figure 3.13.  The 
most striking nucleosome exclusion peak (N.Ex) was highlighted in the publication 
but not described in any detail as the analysis focused primarily on the well 
characterized µVNTR. When combined with my own bioinformatic analysis, this 
peak overlaps with the potential G-quadruplex site identified in Figure 3.2g, termed 
MAOA distal VNTR. This nucleosome exclusion data is in support of the unusual 
histone binding I identify at the MAOA promoter detailed in Figure 3.11. 
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Figure 3.13 Bioinformatic analysis of MAOA promoter. 
 
Top to bottom: ssDNA peak represents UCSC genome browser track of 
experimentally verified ssDNA at this region, nucleosome exclusion (N.Ex) peaks 
represent regions of Nucleosome exclusion generated using UCSC custom track. Ref 
DNA – gene as detailed in hg-19. Human mRNA x2 identified MAOA transcripts. 
G4 DNA; regions of potential G-quadruplex formation as predicted by Quadparser 
algorithm, VNTR Variable Number Tandem Repeats as identified by UCSC, CpG 
islands as identified by UCSC. 
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3.3.10 Methylation status of  potential G-quadruplex target regions  in SH-
SY5Y cells. 
The Balasubramanian group have suggested Sp1 could itself bind G-
quadruplex (Raiber et al., 2012) and highlight the fact that that Sp1 elements have 
been found to protect CpG islands from de novo methylation (Brandeis et al., 1994). 
The group also detail a genome-wide study showing G-quadruplex structures can 
restrict methylation of CpG dinucleotides (Halder et al., 2010). The 
Balasubramanian group therefore imply that Sp1 might bind to G-quadruplex 
regions and prevent subsequent methylation of the sequence. Many promoter regions 
of housekeeping genes, which are regulated by Sp1, contain methylation free islands 
suggesting an epigenetic role for Sp1 (Bird, 1986, Holler et al., 1988). In light of this 
information I performed methylation analysis using a high affinity recombinant 
methyl-binding domain (MBD) protein pre-bound to magnetic beads (Section 
2.2.12.2) across the potential G-quadruplex target regions. The CT element had 
MBDP bound under normal growth conditions, under vehicle control and after 1 hr 
10µM cocaine treatment implying this region is methylated under all conditions 
(Figure 3.14a.). The 5-HTT 5’ LPR  had MDBP bound to the short allele only under 
the same conditions as above implying only the short allele is methylated (Figure 
3.14 b). MAOA promoter (µVNTR primer set) had MBDP bound to the 3 copy 
allele under normal growth conditions (Figure 3.15a,b), after 1 hr 2µM Valproate 
MDBP was seen to bind to both 3 and 4 copy alleles (Figure 3.15 a) and in response 
to 10µM cocaine MDBP was lost at both alleles (Figure 3.15 b) implying the 3 copy 
allele is methylated under normal conditions, both 3 and 4 are methylated in 
response to valproate and methylation is lost in response to cocaine.   
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Figure 3.14 a,b Methylation at the CT element, 5-HTT LPR 
 
Agarose gel showing PCR amplification of sheared gDNA post CpG methylQuest 
treatment:  unmethylated DNA; not bound to methyl domain binding protein (CpG 
MethylQuest™ Protein) Methylated   DNA bound to methyl domain binding protein 
(CpG MethylQuest™ Protein). a. Agarose gel showing PCR amplification of CT 
element of c-MYC identifying the region is methylated under normal growth 
conditions and in response to cocaine. b. Agarose gel showing PCR amplification of 
5-HTT 5’ LPR short allele identifying it is methylated under normal growth 
conditions and in response to cocaine. (Sheared Hela DNA is used as a positive 
control) 
 
 
 
 
 
a. 
b. 
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Figure 3.15 a,b Methylation at the MAOA promoter 
 
Agarose gel of PCR amplification of sheared gDNA post CpG methylQuest 
treatment:  unmethylated DNA; not bound to methyl domain binding protein (CpG 
MethylQuest™ Protein) Methylated  DNA bound to methyl domain binding protein 
(CpG MethylQuest™ Protein) . a Agarose gel showing PCR amplification of 
MAOA, µVNTR  4 copy allele identifying it is methylated under basal conditions,  
in response Na valproate both 3 and 4 copy alleles are  methylated. b. Agarose gel 
showing PCR amplification of MAOA, µVNTR  identifying methylation is lost at 
the 4 copy allele in response to cocaine ( Sheared Hela DNA is used as a positive 
control). 
 
 
 
 
 
b. 
a. 
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3.4. Discussion   
An extensive bioinformatic analysis of the promoters of selected genes 
implicated in cancer (c-MYC, VEGFA and hTERT) and genes implicated in 
neurological disorders (5-HTT, MAOA and DAT1) was performed. Within the 
promoters of these genes I identified repetitive sequences of DNA within 1.5kb of 
the transcriptional start site, that also have the potential to form G-quadruplex as 
determined by the Quadparser algorithm. These sequences are located within regions 
of DNA known to adopt ssDNA conformation and have previously been implicated 
as regulatory regions, however not through their ability to adopt the non B-DNA 
conformation; G-quadruplex. When considered in the context of the following 
findings: 
 
i. Transcription has the capacity to modify mechanically DNA topology, DNA 
structure, and nucleosome arrangement (Kouzine et al., 2013a)  
ii. G-quadrpulex structures  form in the genome of mammalian cells (Biffi et al., 
2013) 
 
This in-silico analysis becomes an informative data set to support further 
biochemical analysis of the regions. I therefore proceeded to interrogate the 
transcription factor binding profiles and methylation status of the selected regions. 
The model of G-quadruplex formation at the CT element described in Figure 
3.6 is adapted from (Brooks and Hurley, 2009) which is in turn based on data from 
the Levens group (Sun and Hurley, 2009, Michelotti et al., 1995, Tomonaga and 
Levens, 1996, Tomonaga and Levens, 1995). Although this model is indeed 
plausible based on the aforementioned studies compelling in vivo data detailing the 
function of G-quadruplex in cells is lacking.  
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One way to interrogate these regions for the adoption of G-quadruplex is to 
examine the specific factors known to bind to the three alternate DNA 
conformations: CTCF and Sp1 to duplex DNA, hnRNP K and CNBP to ssDNA and 
nucleolin and potentially Sp1 to bind G-quadruplex DNA. Initial ChIP analysis for 
the G-quadruplex related factors CTCF, hnRNPK, Sp1, and nucleolin at the CT 
element in the HCT-116 cell line identified all factors except CTCF as binding  
under normal growth conditions. It was encouraging to see the factors implicated in 
the dynamic transcription dependent model of G-quadruplex formation present at the 
CT element however no real interpretation can be made or conclusions drawn due to 
the complex and dynamic nature of the proposed model. ChIP will capture a single 
frame across a population of cells, all of which may be at different points in the 
process of G-quadrplex formation and therefore no clear signal is distinguishable. 
In an effort to overcome the limitations of ChIP I moved to the identified 5’ 
LPR target region which is polymorphic and as such heterozygous for the 14 copy 
(s) allele and 16 copy (l) VNTR the in the JAr cell line. This is of interest as the 
short allele has sequence with the potential to form 2 discrete G-quadruplexs, 
whereas the long allele has the potential to form 4 discrete G-quadruplexs (Figure 
3.16) 
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Figure 3.16 G-Quadruplex within the 5-HTT 5’ LPR (long and short). 
 
UCSC display magnified to show the 4 potential G-quadruplex sequences within the 
5’ LPR long (orange line).  A BLAT search for the 5’ LPR short sequence identifies 
2 potential G-quadruplex within it. 
 
 
 
The heterozygosity for the polymorphic VNTR’s gives an additional layer of 
information which may provide further clues as to the mechanism behind G-
quadruplex formation. The heterozygosity also enables comparison of factor binding 
between the two alleles in the same assay which is a unique internal control. When 
coupled with environmental challenges in the form of lithium and cocaine additional 
layers of information are available to draw upon when assessing a role for factors 
and alternative structure in the regulation of these regions.  These challenges which 
are known to impact on the expression of 5-HTT through the 5’LPR (Ali et al., 2010, 
Vasiliou et al., 2012, Roberts et al., 2007) should trigger the regulatory mechanism 
at play and therefore present a different transcriptional landscape possibly though the 
structural perturbations as identified in the G-quadruplex formation model. 
Under normal growth conditions CNBP, hnRNPK and CTCF bind to both 
alleles, (preferentially to the short allele in all cases). Whereas Nucleolin and Sp1 
bind only to the short allele, the same binding pattern is observed in response to 
lithium with the exception of CTCF which is lost at the long allele. Binding in 
response to cocaine is of interest as it appears there is a direct switch between 
ssDNA factors and G-quadruplex factors on the long allele.  CNBP and hnRNPK 
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binding is lost and nucleolin and Sp1 binding is gained at the long allele, if the 
model is accurate this could be representative of a change in the conformation of 
DNA from ssDNA to G-quadruplex at the longer (x4 discrete G-quadruplex sites). 
  The factor binding patterns of the short allele does not change in response to 
either challenge which would imply the long VNTR is more susceptible to 
modulation in response to challenge potentially through G-quadruplex formation. 
This may correlate to the methylation status observed in Section 3.3.10 as the short 
allele appears to be methylated under normal growth conditions and in response to 
cocaine whereas no methylation is observed at the long allele perhaps implying that 
the long allele is protected by G-quadruplex as suggested by (Raiber et al., 2012) 
As described in Section 3.3.6 the neuroblastoma cell line SH-SY5Y is 
heterozygous for two VNTR’s within the MAOA promoter. The 3 and 4 copy 
proximal µVNTR (Figure 3.9b) and 9 and 10 copy distal dVNTR (Figure 3.9c). The 
MAOA µVNTR is one of the most well characterised GxE interactions in the 
literature and the accepted hypothesis states that it regulates the differential 
expression of MAOA in response to the environment. The µVNTR  was originally 
described as being 1.2kb 5’ of the transcriptional start site of the MAOA gene 
however  bioinformatic analysis of data in the Hg19 sequence of the human genome 
demonstrates there is a 2
nd
 transcriptional start site which is 5’ of the µVNTR , now 
locating this domain in the 5’UTR of the MAOA gene, Figure 3.9a.  The distally 
located VNTR has largely been ignored, possibly due to the complexity of the PCR 
required to amplify the region due to its highly repetitive GC rich sequence. 
However in light of the newly described transcriptional start site it is possible that 
the two VNTR’s each regulate an individual transcript.  
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As described in Section 3.3.6 PCR amplification of ChIP material with a 
primer set specific for one of the VNTR’s would not be accurate in defining factors 
binding to the specific VNTR as both regions will be enriched for; despite specific 
primer sets, rather results must refer to the MAOA promoter region in general. 
However when ChIP data is correlated to in-silico sequence analysis detailing 
specific transcription factor binding sites (figure 3.10), more specific inferences may 
be made. Consensus sequences for CNBP, hnRNPK and Sp1 can be found in the 
distal VNTR but not the proximal µVNTR. The primer set used to amplify the 
MAOA promoter (sequences can be found in table 1 of the appendix) are for the 
µVNTR as amplification of the distal VNTR proved inconsistent and generally 
unsuccessful after many attempts under a wide range of conditions. Interestingly the 
µVNTR sequence does not contain consensus sequence for the factors identified as 
binding there so it is reasonable to assume these factors are in fact binding to the 
distal VNTR. 
ChIP across the MAOA promoter in the heterozygous SH-SY5Y cell line 
offers another opportunity to assess allele specific G-quadruplex related factor 
binding to identify potential patterns between the two target regions in response to 
cocaine and the mood stabiliser sodium valproate. Of particular interest was the fact 
that proteins including the ubiquitous Histone 3 positive control only appeared to 
bind to the short allele under normal growth conditions and in response to valproate 
the ssDNA binding factors bind to both the short and the long allele and in response 
to cocaine ssDNA binding factors and CTCF bind to both alleles. This data in 
conjunction with the overlapping nucleosome exclusion regions (Shumay et al., 
2012) detailed in Figure 3.10 would suggest there is unusual chromatin structure at 
this region. This potential G-quadrpulex area could be nucleosome free as in the case 
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of the CT-element, this raises the question are the nucleosomes shifted at the MAOA 
promoter and if so what is the cause? It is know that alternative DNA structure such 
as G-Quadruplex is unable to bind to histones (Wong et al., 2007). To add further 
complexity; when ChIP was performed with an antibody for active RNA polymerase 
(anti-RNA pol II CTD phospho Ser5 antibody) binding was observed at both alleles 
suggesting that both alleles are active despite the unusual chromatin architecture.  
Taken collectively the bioinformatic interrogation, transcription factor 
binding analysis and assessment of methylation at the target regions, provide some 
evidence to support the model of G-quadruplex formation outlined in section 3.3.4. 
However there is no robust or compelling evidence that has captured and fully 
described such a mechanism or G-qudaruplex function. Owing in part to limitations 
of the approach, specifically the standard ChIP assay is not kinetically sensitive 
therefore is unable to able capture the dynamic nature of the model.   
The ChIP assay can accurately determine the location at which proteins bind 
to DNA in vivo (Rhee and Pugh, 2011) and as such has provided fundamental insight 
into where and how gene regulatory processes occur in cells (Poorey et al., 2013). 
However recent publications have drawn attention to the limitations of the assay and 
advised caution when analysing ChIP data (Poorey et al., 2013, Teytelman et al., 
2013, Schmiedeberg et al., 2009). Poorey et al., 2013 discuss the fact that ChIP 
signals fail to differentiate between high-occupancy stable binding or low occupancy 
dynamic binding.  As discussed in Section 1.1.2 many chromatin interactions are 
short lived with function likely to relate to binding kinetics (Hager et al., 2009).  
Therefore the time it takes formaldehyde to crosslink the transcription factor to the 
DNA and the nature of this cross linking is critically important. It is clear from the 
aforementioned studies that a complete understanding of this process itself is 
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lacking. This is illustrated in Figure 3.16 which describes four possible cases in 
which crosslinking kinetics and transcription factor binding dynamics contribute to 
the increase in ChIP signal observed with increasing formaldehyde incubation time 
(Poorey et al., 2013). 
 
 
Figure 3.17 Formaldehyde crosslinking kinetics and TF binding dynamics   
 
In cases 1 and 2, crosslinking kinetics is assumed to be much faster than 
transcription factor (TF) - chromatin binding dynamics. In Cases 3 and 4, TF-
chromatin binding dynamics is much faster than crosslinking kinetics (Adapted from 
(Poorey et al., 2013) 
 
 
As shown in Figure 3.17, it has not yet been resolved which set of crosslinking 
kinetics and transcription factor binding dynamics actually occur. Further a complete 
description of the time it takes formaldehyde to crosslink the protein to the DNA is 
lacking. In vitro reaction rates of ~10
4
 M
-1
s
-1
 have been reported for the covalent 
modification of DNA bases with formaldehyde (McGhee and von Hippel, 1975, 
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Siomin et al., 1973).  However these do not describe the time taken to crosslink a 
complete protein and it should be noted that not all proteins are equal with 
crosslinking times likely to vary between proteins and further variation is likely 
between chromatin sites to. Perhaps this is explained by recent analysis of 
crosslinking of MeCP2 to chromatin with studies indicating complete crosslinking 
time of ~5 seconds with MeCP2 mutants residing in heterochromatin for less than 
2.5 seconds on average failing to be captured by crosslink chemistry (Schmiedeberg 
et al., 2009). These data would support case 3 of Figure 3.17. These findings are 
striking when we consider the fact that if a protein – DNA interaction occurs and 
dissociates before the crosslink has time to form, the interaction will not be captured. 
Schmiedeberg et al., 2009 also proposed formaldehyde-ChIP may depend upon the 
presence of histones and associated proteins to topologically trap the DNA via cross 
linking to them, rather than covalent linkages to DNA itself. Further consideration to 
be noted are the range of possible cross linking events that can occur when 
formaldehyde enters the cell, as detailed in Figure 3.18. 
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Figure 3.18: Schematic describing possible events that can occur when 
formaldehyde enters a cell. 
 
Membrane represented by the dotted line, transcription factors shown as the light 
blue circles, chromatin shown as the thick green line, and formaldehyde molecules 
as red circles. The orange chromatin segments are specific transcription factor 
binding sites and red circles on the transcription factor or chromatin represent 
chemical crosslinking events. 
 
 
In addition to considerations relating to binding dynamics, a recent study has 
described “hyper-ChIPable” loci. These represent an artefact in ChIP that results in 
reproducible but biologically irrelevant enrichment of proteins at highly expressed 
genes caused by high levels of RNA Pol II and RNA Pol III transcription possibly 
due to non-specific interactions between some antibodies and polymerase. 
(Teytelman et al., 2013).  
 Despite a lack of conclusive evidence describing the G-quadruplex 
formation, studies at the MAOA promoter revealed other interesting findings. These 
findings call into question the accepted dogma that X chromosome inactivation by 
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methylation of one allele normalises this gene for behaviour between males and 
females. 
Data on the MAOA µVNTR  in the SH-SY5Y cell line indicated distinct 
epigenetic structures on each female allele (Figure 3.15) consistent with the view 
that one allele is methylated.  However using the heterozygosity of the µVNTR , I 
was able to observe active RNA Pol II binding and expression from both alleles. 
This indicates they are in fact both transcriptionally active (Figure 3.12) and 
differentially bind transcription factors consistent with their modulation by drug 
action (Figure 3.11).  
Recent work on the X chromosome indicates methylation is not necessarily 
correlated with gene repression. This may be related more generally to the model in 
which local genomic regulation allows 15% of the X chromosome genes to escape X 
inactivation (Mugford et al., 2014, Joo et al., 2014). Complex methylation at this 
locus would be consistent with data on the epigenetic status of the MAOA locus in a 
longitudinal study of twins (Wong et al., 2010). 
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A strategy to destabilize G-quadruplex 
in the promoter of c-MYC via 
homologous recombination 
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4.1 Introduction  
Despite aforementioned studies (Section 3.3.1) detailing the ability of G-
quadruplex to form in vitro and Section 3.4.3 detailing the mechanism presented as 
to how they may form in vivo and in turn describing how they may function to 
regulate downstream targets, much skepticism remains in the scientific community. 
Whether these structures exist under physiological conditions is still a topic of 
debate and even more controversy exists when considering G-quadruplex biological 
relevance. It is assumed that any proposed regulatory function of these elements is a 
result of transcription factor binding; specifically Sp1 with the consensus sequence 
(GGGCGGGG) which is in essence the main body of a G-quadruplex sequence. The 
doubt surrounding G-quadruplex formation and function is understandable as a 
compelling in vivo demonstration of G-quadruplex function is lacking. As discussed 
in Section 3.5, ChIP analysis of the regions we analysed  to determine transcription 
factor binding in the hope that factors would correlate to alternative DNA topology 
is  variable and inconclusive; preventing the assertion of any definitive conclusions.  
Here I present a strategy to assess directly the capacity of and mechanism 
through which these secondary structures influence gene expression. AAV- targeting 
vectors have been used to re-engineer the G-quadruplex forming elements in c-MYC 
by homologous recombination. I have designed strategic mutations that destabilize 
secondary structures, while maintaining Sp1 binding sites and attempted to insert 
them into the promoter of c-MYC in the HCT-116 cell line via homologous 
recombination. In addition I have designed mutant sequences to destroy Sp1 binding 
sites while preserving G-Quadruplex and reengineered these back into HCT-116. 
QPCR and ChIP analysis of the relative expression and factor binding profiles of G-
quadruplex, Sp1 targeted and wild-type alleles  will enable a more definitive 
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structure function analysis of basal or induced expression; determining whether these 
secondary structures have a functional role in regulating gene expression and the 
factors involved. 
4.2 Aims 
Assess directly the capacity of, and mechanism through which G-quadruplex 
influences gene expression, initially validating the approach in the c-MYC promoter 
with the well characterized CT element 
1. Design mutant sequences to destabilize G-quadruplex while maintaining Sp1 
binding sites in the 6 target regions of selected genes. 
 
2. Design mutant sequences to destroy Sp1 binding sites while preserving G-
quadruplex in the 6 target regions of selected genes. 
 
3. Construct AAV targeting vectors with strategic mutations that destabilize G-
quadruplex while preserving Sp1 binding sites at the promoter of c-MYC. 
 
4. Construct AAV targeting vectors with strategic mutations that destroy Sp1 
binding sites while preserving G-quadruplex at the promoter of c-MYC. 
 
5. Use AAV targeting vectors to introduce strategic mutations that destroy Sp1 
binding sites while preserving G-quadruplex into the promoter of c-MYC in 
the HCT-116 cell line via homologous recombination. 
 
6. Use AAV- targeting vectors to introduce strategic mutations that destabilize 
G-quadruplex while preserving Sp1 binding sites, into the promoter of c-
MYC in the HCT-116 cell line via homologous recombination. 
 
7. Use qPCR and ChIP analysis of the relative expression and factor binding 
profiles of targeted and wild-type alleles to provide definitive structure 
function analysis of basal or induced expression; determining whether these 
secondary structures have a functional role in regulating gene expression and 
the factors involved. 
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4.3 Results  
 
4.3.1 Mutant sequence design 
 
The potential for a sequence of DNA to form G-quadruplex is determined by 
the arrangement of Guanine (G) bases, specifically X3 G’s, repeated four times with 
between 1 and 7 residues between each run of GGG as defined  by the ‘Quadparser’ 
algorithm: (G3+ N1-7 G3+ N1-7 G3+ N1-7 G3+) (Huppert and Balasubramanian, 
2007) used in the preliminary in-silico analysis (Figure 3.2). The full Sp1 consensus 
sequence  is defined as: GGAGGGAGGGATCGCG, however as with many zinc 
finger transcription factors, this is degenerate sequence and Sp1 is known to bind a 
core sequence of GGNGGG (DesJardins and Hay, 1993) this was the reference 
benchmark core sequence when designing mutations to destroying Sp1 binding sites. 
The G-quadruplex and Sp1 sites within each of the WT target sequences have 
been identified (Figure 4.1) and multiple base pair substitutions made to create G-
quadruplex knock out (G4-KO) sequences. These base pair substitutions ensured G-
quadruplex structure was unable to form and Sp1 core binding sequence was 
preserved. A separate mutant sequence was designed; Sp1 KO with base pair 
substitutions to ensure Sp1 core binding sequence was destroyed while G-
quadruplex structure was able to form. 
 
 
 
 
 
 
145 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a. Key:  
Mutated base pairs  
Sp1 Binding Site 
Potential G-quadruplex  Sequence (pG4) 
b. c-MYC CT element:  Chromosome  8, strand  -, position:  128748166 - 128748222     57bp 
 
 
WT – Sp1 sites (X4) pG4 (X2) 
GGGAACCCGGGAGGGGCGCTTATGGGGAGGGTGGGGAGGGTGGGGAAGGTGGGGAGG 
Sp1-KO – x 2 pG4 maintained 
GGGAACCCGCGAGGGGCGCTTATGGGCAGTGTGGGGAGTGTGGGGAAGGTGAGGAGG 
G4-KO – x 4 Sp1 sites maintained 
GCGAACCCGGGAGGGGCGCTTATCGGGACGGTGGGGAGGGTGGCGAAGGTGGGGAGG 
 
c. hTERT:  Chromosome  5, strand +, position: 1295204-1295271     68bp 
 
WT:  Sp1 sites (x4) pG4 sequences (x1):    
GGGGAGGGGCTGGGAGGGCCCGGAGGGGGCTGGGCCGGGGACCCGGGAGGGGTCGGGACGGGGCGGGG 
SP1–KO: (x1) pG4 site maintained:             
GGGGATGGGCTGGCAGGGCCCGCAGGGGGCTGGGCCGGGGACCCGGGAGGGGTCGGGACGGCGCGGGG 
 
G4-KO:  (x3 )Sp1 sites maintained:              
GGGGAGGCGCTCGGAGGGCCCGGAGGGGGCTGCGCCGCGGACCCGAGAGGCGTCGTGACGGGGCGGGG 
 
 
d. VEGFA: Chromosome  6, strand  +, position:  43737860 -43737909     50bp 
 
WT:  Sp1 sites (x3) potential pG4 sequences (x1):    
GGGGCGGGCCGGGGGCGGGGTCCCGGCGGGGCGGAGCCATGCGCCCCCCC 
 
SP1–KO (x1 potential pG4 site maintained):               
GGCGCGGGCCGGGGGCCGGGTCCCGGCGGGCCGGAGCCATGCGCCCCCCC 
G4-KO (x3 Sp1 sites maintained):                               
GCGGCGGGCCGGCGGCGGGGTCCCGGCGGGGCGGAGCCATGCGCCCCCCC        
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e. 5-HTT 5’ LPR:  Chromosome 17   + strand,   position  28564146 – 28564362,    217bp 
 
 
WT – Sp1 sites (X1) pG4 (X3)  
ATGCTGGAGGGGTGCAGGGGGGATGCCGGGGGTGCATGGGGGGATGCTGGGGGGTGCAGGGGGGATACTGCGAGGGG
TGCAGGGGGGATAATGGGGGTTGCAGGGGAGATCCTGGGAGAGGTGCAGGGGGATGCTGGAAGGGCTGCAGGGGGGA
TGCTGGGGGTGCAGGGGAGATGCTGGGGGGGCTGCAGGGGGGATGCTGGGGGTGCAGGGGGGA 
 
Sp1-KO – x 3 pG4 maintained 
ATGCTGGAGGGGTGCAGGGGGGATGCCGGGGGTGCATGGGGGGATGCTGGGGGGTGCAGGGGGGATACTGCGAGGGG
TGCAGGGGGGATAATGGGGGTTGCAGGGGAGATCCTGGGAGAGGTGCAGGGGGATGCTGGAAGGGCTGCAGGGGGGA
TGCTGGGGGTGCAGGGGAGATGCTGGGGGGGCTGCAGGGGGGATGCTGGGGGTGCAGGGGGGA 
 
G4-KO – x 1 Sp1 site maintained 
ATGCTGGAGGGGTGCAGGGGCGATGCCGGGCGTGCATGGGGGGATGCTGGGGGGTGCAGGGGGGATACTGCGAGGGG
TGCAGGGGGGATAATGGGGGTTGCAGGGGAGATCCTGGGAGAGGTGCAGGGGGATGCTGGAAGGGCTGCAGGGGGGA
TGCTGGGGGTGCAGGGGAGATGCTGGGGGGGCTGCAGGGGGGATGCTGGGGGTGCAGGGGGGA 
 
g. MAOA Distal VNTR: Chromosome  X,  strand  -,  position: 43513713 -43513824,    112bp 
 
WT – Sp1 sites (X11) pG4 (X5)  
GGGCGGGGCGGGGAGGGGCGGGGAGGGGCGGGGAGGGGCGGGGAGGGGCGGGGAGGAGCGGGGAGGGGCGGGG
AGGAGCGGGGAGGGGCGGGGAGGAGCGGGGAGGGGCGGG  
Sp1-KO – x 4 pG4 maintained 
GCGCGGGGCCGGGACGGGCGGCGAGGGGCCGGGACGGGCGGGGACGGGCCGGGAGCAGCGGGCAGGGGCAGGGAG
GAGCGGGGACGGGCGGGCAGGAGCGGGGACGGGCAGG 
G4-KO – x 10 Sp1 sites maintained 
CGGCGGGGCGGGGAGGCGCGAGGAGGGGCGCGGAGGGGCGCGGAGGGGCGCGGAGGAGCGGGGAGGCGCCGGGAG
GAGCCGGGAGGGGCGCGGAGGAGCCGGGAGGGGCGGG 
f. DAT 1: Chromosome 5, strand   - , position : 1446653  - 1446726,     74bp 
 
 
WT – Sp1 sites (X4) pG4 (X2) 
GGGGAGCGGGGGAGCGGGGGGCGGGGAGGGGAGTGGTGGTGTGCGGGGAGTGCGGGGCGGGCGCAGGGGGTGGG 
Sp1-KO – x 2 pG4 maintained 
GGGGAGCGGGGGAGCGGGGCGCGGGCAGGGGAGTGGTGGTGTGCGGGGAGTGCGGGACGGGCGCAGGGGCTGGG 
G4-KO – x 4 Sp1 sites maintained 
GGGGAGCGGCGGAGCGGGCGGCGGGGAGGCGAGTGGTGGTGTGCGGGGAGTGCGGGGCGGCCGCAGGGGGTGGG 
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Figure 4.1 Mutated sequence design.  
 
a. Key to identify, mutated base pairs (Green bold underlined), Sp1 core binding 
sites (highlighted yellow) and potential G-quadruplex forming sequence (Red Bold 
underlined).  b-g. Target genes c-MYC, hTERT, VEGFA, 5-HTT 5’ LPR, MAOA 
and DAT1 detailing location, bp length, wild type sequence and base pair 
substitutions made to create G4-KO and Sp1-KO sequences. 
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4.3.2 Assembly of AAV targeting vectors 
 
The CT element 115bp upstream of c-MYC is the most widely studied G-
quadruplex target  (Brooks and Hurley, 2010) making it the most compelling 
target to pursue. Owing to the time and cost of AAV targeting vectors as a 
strategy to generate isogenic cell lines, I decided to pursue one target in isolation 
and the success of c-MYC editing would inform how to proceed with the 
remaining 5 targets. 
 
4.3.2.1 AAV targeting vector design 
AAV targeting vectors used to introduce the mutant sequence into the HCT-
116 genome rely on a neomycin selectable marker gene to provide resistance to 
cells having undergone homologous recombination to incorporate the mutant 
sequence. This selection cassette relies on the Cre-Lox system to remove the 
selectable marker post selection leaving a scar of 34bp (LoxP site) once the 
selectable marker is removed.   It was essential to design the targeting vector in 
such a way that the remaining 34bpb had no effect on the regulation of 
transcription as this could mask effects of G-quadruplex destabilising mutations. 
This was achieved by designing the vector to leave the LoxP scar downstream of 
the transcriptional start site.  To control for potential transcriptional modulation 
by the LoxP scar, an internal control target cell line was engineered alongside the 
G4-KO target. The internal control target was termed AAV-LoxP-CT (Figure 
4.11), this had no G-quadruplex destabilizing substitutions within the CT 
element but left the 34bp LoxP insertion at the same location as the AAV-G4-CT 
(Figure 4.10) LoxP scar (a full list of vectors is shown in table 2 of the 
appendix). Comparison between wild type, AAV-G4-CT and AAV-LoxP-CT 
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would enable me to determine any possible impact of the LoxP insertion on 
downstream analysis assays. The LoxP insertion also acts as a tag to identify the 
targeted alleles, distinguishing them from the respective unmodified alleles. 
Further design considerations include maximum homology of the AAV targeting 
vector to ensure highest efficiency of homologous recombination events (Deng 
and Capecchi, 1992). This is limited by the 4.7 kb packaging capacity of AAV, 
the rAAV TK accepter has 3kb available for homology.  
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4.3.2.2 AAV targeting vector assembly.  
Left  and right homology arms was constructed from strands of synthetic 
dsDNA, this simplified the mutagenesis procedure considerably as base pair 
substitutions designed in Section 4.3.1 were incorporated into the synthetic 
sequence ordered as gBlocks from Integrated DNA Technologies (IDT). The 
gBlocks and pAAV-TK-accepter vector DNA were assembled by Gibson 
isothermal assembly (Gibson et al., 2009) a recently developed cloning strategy 
which enables up to 20 fragments of linear DNA to be assembled in a single 1 
hour reaction. Fragments of double stranded DNA with homologous ends (12-
20bp overlap) are incubated with T5 exonuclease a mesophilic digester with 
5´→3´ single-strand-specific endonuclease activity which chews back the 5’ 
strand exposing a 3’ ssDNA overhang (T5 exonuclease is inactivated at 50 ˚C. 
The ssDNA overhangs then align with the complementary strand, hydrogen bonds 
form and proof reading polymerase phusion now active at 50 ˚C fills in the 
missing bp, the remaining nick in the phosphodiester backbone is sealed with Taq 
ligase (Figure 4.2). 
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Figure 4.2 Gibson Isothermal Assembly 
 
Schematic detailing the cloning strategy used to join multiple strands of linear 
DNA together in a single reaction detailed in section 4.3.2.2. 
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4.3.2.2.1 Left homology arm assembly 
The left homology arm was assembled from x3 gBlocks including the mutated 
sequence within gBlock 3 in a single isothermal assembly reaction as follows.   
1. gBlock 1 (Figure 4.3) begins with 20bp homologous to the multiple cloning 
site of  pAAV-TK-accepter; specifically the 20bp prior to the BamH1 
restriction site (Figure 4.4a). The remaining 460bp are homologous to the 
endogenous c-MYC promoter region.  
2. gBlock 2 (Figure 4.3) begins with 20bp homologous to the last 20bp of 
gBlock 1 (overlap sequence) with the remaining 480bp also homologous to 
endogenous DNA, with the exception of the 4bp substitutions which prevent 
G-quadruplex formation making this the mutant.  
3. gBlock 3 (Figure 4.3) begins with a 20bp overlap of the last 20bp of gBlock 
2 ( Figure 4.3)  the next 460bp are once again homologous to endogenous 
DNA and the last 20bp are homologous to the 1
st
 20bp after the BamH1 
restriction site.  
4. gBlock 1,2,3 (Figure 4.3) are assembled via Gibson Isothermal assembly 
outlines in Section 4.3.2.2 to create a 1.5kb fragment of dsDNA. 
 
 
Figure 4.3 Left homology arm assembly    
 
gBlock 1,2,3 to be assembled via Gibson isothermal assembly to make the Left 
Homology arm. 
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4.3.2.2.2 Right homology arm assembly 
The right homology arm is gBlock 4 which  starts with 20bp homologous to 
the 2
nd
 multiple cloning site of pAAV-TK-accepter; specifically the 20bp prior to 
the SacII restriction site, the next 460bp are homologous to endogenous c-MYC 
promoter region, continuing from the endogenous sequence in gblock3 , prior to 
its 20bp vector overlap. The right homology (gBlock 4) is inserted into the 
pAAV-TK-accepter via isothermal assembly detailed in Section 4.3.3.5. 
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4.3.2.2.3 Construction of the pAAV-G4-CT targeting vector 
 The construction of the pAAV-G4-CT vector occurred in two phases (two 
individual isothermal assembly reactions). Although it is possible to assemble 6 
fragments in one reaction a double digestion of pAAV-TK-accepter at SacII and 
BamHI would have exposed x2 identical overlap regions; the LoxP sites. This would 
have resulting in erroneous assembly due to lack of specificity in the form of 
repeated overlapping sequence. 
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4.3.2.2.3.1 Linearization of pAAV-TK-accepter and insertion of RHA (gBlock 4) 
pAAV-TK-accepter plasmid was linearized by digestion with SacII (Section 
2.2.5), once digested the linearized vector was treated with T4 DNA polymerase 
(Section 2.2.2.2)  to blunt end the 3’ overhangs created by SacII digestion. The 
linearized, blunt ended pAAV-TK accepter was isolated by gel electrophoresis 
(Section 2.2.1.4), (Figure 4.4) and purified using gel wizard gel clean up (Section 
2.2.1.5).  
 
 
 
 
Figure 4.4 Linearized pAAV-TK-accepter 
 
Agarose gel showing pAAV-TK-accepter linearized by digestion with sacII, x4 
samples were analysed using gel electrophoresis to reveal a band of 4.2kb.  
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Purified pAAV-TK-accepter was combined with the RHA (gBlock 4) via Gibson 
Isothermal Assembly (Section 2.2.2), (Figure 4.5) 
 
 
 
Figure 4.5 Insertion of RHA (gBlock 4) into the pAAV-TK-accepter. 
 
pAAV-TK-accepter was linearized by digestion with SacII, the RHA (gBlock 4) was 
inserted at the SacII site via Gibson Isothermal Assembly. 
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`The pAAV-TK-accepter + RHA (rAAV-Gb4) plasmid was transformed 
using XL Gold ultracompotent cells (Section 2.2.3.3). 20 colonies were picked, 
expanded and purified (Section 2.2.4.1) then screened by restriction enzyme 
digestion (section2.2.5). pAAV-Gb4 was digested with restriction enzyme AatII to 
cut once and linearize the plasmid to enable comparison against uncut. pAAV-Gb4 
was also digested with restriction enzyme puvII which cut in four locations, twice in 
the insert and twice in the backbone. Therefore 4 fragments (500bp, 700bp, 815bp 
and 2.7kb) will be present on the agarose gel analysis (Figure 4.6) if successful 
assembly had occurred. 
 
 
 
Figure 4.6 Restriction enzyme digestion analysis of rAAV-Gb4. 
 
Gel electrophoresis of uncut purified plasmid, cut x1 (digested with AatII) and cut 
x4 digested puvII, 4 fragments identify successful assembly. 
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4.3.2.2.3.2 Linearization of pAAV-Gb4 and insertion of LHA (gBlock 1,2,3) 
pAAV-Gb4 was re-linearized with restriction enzyme BamHI (Section 2.2.5) and 
isolated by gel electrophoresis (Section 2.2.1.4). The linearized band was purified 
using gel wizard gel clean up (Section 2.2.1.5). The Isolated, linearized pAAV-Gb4 
was combined with gBlocks 1,2,3 (LHA) and fragments were once again assembled 
via Gibson Isothermal assembly (Section 2.2.2) to create a circular plasmid; pAAV-
Gb4 + LHA inserted in the BamHI site giving rise to rAAV-G4-CT (figure4.7), this 
was verified by restriction enzyme digestion (figure4.8), The enzyme restriction 
enzyme AccI cut once in the insert and once in the vector therefore 2 bands of the 
correct size (3.7 and 2.5) identify a successful Isothermal Assembly event. 
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Figure 4.7 Construction of the pAAV-G4-CT targeting vector. 
 
a. gBlocks 1,2,3,4 each 500bp, colour coded to identify overlapping regions, 
designed for Gibson Isothermal Assembly, to each other and into the vector 
backbone. b.LHA consisting of gBlock1+2+3 c. pAAV-Gb4 detailing restriction site 
BamHI for insertion of LHA via Gibson Isothermal Assembly. d. LHA, and RHA 
inserted to form rAAV-G4-CT. 
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Figure 4.8 Restriction enzyme digestion analysis of rAAV-G4-CT targeting 
vector 
 
Gel electrophoresis of uncut purified plasmid, cut x1 (digested with AatII) and cut 
x2 (digested AccI) 2 fragments identify successful assembly. 
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4.3.2.3 Production of infectious AAV particles  
 
In order to obtain the infectious AAV particles the recombinant expression 
plasmid (pAAV-G4-CT)  was  co-transfected into the  HEK-293 cells (Section 
2.2.9.1) with pHelper (carrying adenovirus-derived genes) and pAAV-RC (carrying 
AAV-2 replication and capsid genes). Together these vectors supplied all of the 
trans-acting factors required for AAV replication and packaging in the HEK-293 
cells.  
 
Figure 4.9 AAV virus particle production 
 
 Co-transfection of pAAV-G4-CT, pAAV-RC and pHelper together supplying all 
trans-acting factors required for AAV replication and packaging in the Hek-293 cells 
(Adapted from AAV-helper free system Instruction manual; Agilent technologies) 
Co-Transfect Hek-
293 cells with:  
1. rAAV-G4-CT  
2. rAAV-RC  
3. pHelper 
 
Produce AAV 
particles in         
Hek-293 cells  
 
+ 
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4.3.2.4 Overview of AAV targeting approach 
Recombinant AAV-2 viral particles prepared from infected HEK-293 cells 
were then used to infect HCT-116 cells. AAV vector genomes are efficiently 
uncoated and transported to the nucleus where single stranded forms are available 
for pairing with homologous genomic sequence, homologous recombination occurs 
at higher frequencies than are observed with conventional approaches (Hirata and 
Russell, 2000) 
 
 
Figure 4.10 Overview of AAV targeting approach to KO G-quadruplex at the 
CT element. 
 
Overview of the AAV targeting strategy used to introduce 4 base pair substitutions to 
prevent G-quadruplex formation at the CT element 115bp upstream of the c-MYC 
promoter, in the HCT-116 cell line via homologous recombination.  
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 Figure 4.11 Overview of AAV targeting approach to introduce LoxP  internal 
control at the CT element. 
 
Overview of the AAV  targeting strategy used to introduce neutral base changes 
(LoxP scar) to the 5´-UTRs of the targeted alleles, distinguishing them from their 
respective unmodified homologous partners whilst acting as an internal negative 
control for remaining Lox P site in the G4-KO cell line (a. above). 
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4.3.3 AAV targeting strategy 
4.3.3.1 AAV targeting strategy 1 
Viral particles were generated, HCT-116 cells infected and subsequently 
plated out based on the protocol outlined in  (Kim et al., 2008) , an overview of the 
approach can be seen in Figure 4.12. Once cells were plated out in selection media, 
unfortunately no colonies grew, suggesting no recombination events had occurred, a 
detailed examination as to the possible causes can be found in the discussion Section 
of this chapter (Section 4.5). 
 
 
Figure 4.12 AAV targeting strategy 1:  
 
Details the 1
st
 strategy used to generate live AAV viral targeting vectors, infect 
HCT-116 cells and select clone. 
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4.3.3.2 AAV targeting strategy 2  
 Based on analysis and troubleshooting of the previous approach to 
AAV targeting, a modified strategy was designed. Modifications of strategy 2 
included: 
1.  Altered co-transfection protocol using Lipofectamine LTX (Section 2.2.9.1) 
2.  Alternative helper plasmid system -pDP2rs (Plasmid Factory) 
3.  Increased incubation periods up from 48hrs to 72 hrs 
4.  Extensive virus purification (VIRAPUR AAV purification Kit) detailed in 
section2.2.13.3. 
5. Increased range of virus to cell ratio; MOI.  
6.  Increased range at with infected cells were plated into 0.5ml/mg G418 
selection media (Section 2.2.13.5) 
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Figure 4.13 AAV targeting strategy 2 
 
Details the modified strategy used to generate live AAV viral targeting vectors, 
infect HCT-116 cells and select clones. 
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4.3.3.2.1 Co-transfection of pDP2rs pAAV-G4-CT / pAAV-LoxP-CT. 
As part of the modified strategy a helper plasmid tagged with red fluorescent 
protein (RFP) was chosen to allow confirmation of successful Co-transfection. In 
order to asses transfection efficiency of pDP2rs pAAV-G4-CT or pAAV-LoxP-CT 
into HCT-16 cells, 24 hours post transfection, cells were fixed and imaged using an 
Evos digital inverted microscope. RFP expression from helper plasmid pDP2rs was 
observed (Figure 4.14) when co-transfected. Transfection efficiency was estimated at 
30%.  
 
   
 
 
 
 
 
 
 
 
Figure 4.14 Co-transfection efficiency - pDP2rs rAAV-G4-CT 
 
Lipofectamine LTX transfection reagent used to transfect pDP2rs pAAV-G4-CT into 
HCT-116 cells at 70% confluency  estimated transfection efficiency is 30%.  
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4.3.3.2.2 Range of cell to virus ratio (MOI) and range at which infected cells 
were plated (cell / well). 
 
A further amendment in the revised strategy was the need to increase the 
range of MOI and the range at which infected cells were plated as having these 
variables at the  optimum ratio will allow homologous recombination to occur at 
highest frequencies (Miller, 2011). Cells were plated into 96 well plates at desities of 
10, 50, 100, 250, 500, 100 cells per well, each cell desity was infected at an MOI of  
25, 50, and 100, as summarized in Table 4.1. 
 
 
Table 4.1 Range of cell to virus ratio (MOI) and range at which infected cells 
were plated (cell / well). 
 
 
 
 
 
 
 
 
25 MOI 50 MOI 100 MOI 
10 cells / well 10 cells / well 10 cells / well 
50 cells / well 50 cells / well 50 cells / well 
100  cells / well 100  cells / well 100  cells / well 
250  cells / well 250  cells / well 250  cells / well 
500  cells / well 500  cells / well 500  cells / well 
100  cells / well 100  cells / well 100  cells / well 
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4.3.3.2.3 PCR screen: AAV-G4-CT and AAV-LoxP-CT 
 
Once cells were infected and plated at the ranges detailed in Table 4.1 
positive recombination events were identified through PCR. Pools of clones were 
PCR screened using a primer set with the reverse primer nested within the Neomycin 
selection cassette and the forward primed outside the LHA producing an 1810pb 
positive product. In parallel a WT primer set was used as a negative control for 
recombination event and a positive control for the HCT-116 gDNA and PCR reaction 
conditions amplifying a product of 1141bp. 
 
 
Figure 4.15 PCR screen primer design and strategy 
 
Schematic detailing primer set used to identify positive recombination events 
amplifies a PCR product 1810bp (green) along with a primer set to identify negative 
recombination events. This primer set also provides a positive control for gDNA 
extracted from the pools of targeted HCT-116 cells and a positive control for the 
PCR reaction conditions amplifying a product of 1141bp (blue). 
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4.3.3.2.4 rAAV-G4-CT/ rAAV-LoxP-CT control PCR.  
 
HCT-116 gDNA and PCR screen reaction conditions were verified as correct 
by screening the 204 colony containing wells  from rAAV-G4-CT plate out and 526 
colony containing wells from rAAV-LoxP-CT plate out  with the control primer set 
identified in Figure 4.15 amplifying a product of 1141bp, full primer sequence can 
be found in Table 1 of the Appendix. 
 
 
Figure 4.16 rAAV-G4-CT/ rAAV-LoxP-CT control PCR  
 
a. Agarose gel showing a selection of the 204 rAAV-G4-CT wells containing 
colonies post infection b. agarose gel showing a selection of the 526 wells containing 
colonies post infection PCR screened to verify HCT-116 gDNA integrity and suitable 
PCR reaction conditions PCR product 1141. 
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4.3.3.2.5 rAAV-G4-CT PCR screen.  
 
rAAV-G4-CT recombination events were verified by PCR screening gDNA  
extracted from plated HCT-116 cells. Of the 1728 wells plated with infected HCT-
116 cells (96 wells at each range detailed in Section 4.3.3.2); 204 wells grew 
colonies.  Positive primer set identified in table 1 of the appendix was used to 
amplify a PCR product of 1141bp, of the 204 screened two positive clones were 
identified. 
 
 
 
 
 
 
 
 
 
 
Figure 4.17 rAAV-G4-CT PCR screen 
Agarose gel showing two positive recombination events were identified by 
amplification of a 1810bp fragment in gel a; lane 12, and gel b; lane 13.  
 
 
 
 
 
 
 
 
 
 
a. 
b. 
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4.3.3.2.6 rAAV-LoxP-CT PCR screen  
 
rAAV-LoxP-CT recombination events were verified by PCR screening 
gDNA extracted from plated HCT-116 cells. Of the 1728 wells plated with infected 
HCT-116 cells (96 wells at each range detailed in Section 4.3.3.2) 526 wells grew 
colonies.  The positive primer (details of which can be found in table 1 of the 
appendix) was used amplifying a PCR product of 1810b, 8 positive clones were 
identified.  
 
Figure 4.18 rAAV-LoxP-CT PCR screen 
 
Amplification of the 1810bp fragment identified 7 positive recombination events in 
gel a; lane 5, 15, gel b Lane 5,7 gel c lane 11, gel d lane b and gel e lane 6 and 8. 
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4.3.3.2.6 Positive rAAV-LoxP-CT and rAAV-G4-CT PCR re-screen. 
 
Positive pools identified in Section 4.3.3.5 and 4.3.3.6 were expanded up to 
the 24 well stage to ensure robust growth prior to single cell dilution (SCD) to isolate 
clonal populations. At the time of the SCD the pools of positive cells not expanded 
up to 24 well plate were re-PCR screened with the same two primer sets outlined in 
Section 4.3.3.3. Upon rescreening only one of the 6 samples screen was identified as 
positive Figure 4.19.  
 
Figure 4.19 Positive rAAV-LoxP-CT and  rAAV-G4-CT PCR re-screen.   
 
gDNA extracted from targeted HCT-116 cells, previously identified as positive (at 
the 96 well stage) Lane 1-6 –ve control primer set to verify gDNA and reaction 
conditions are suitable Lane 9-14 +ve primer set for inserted Neomycin cassette 
outline in Section 4.3.3.3. 
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4.3.3.2.7 Sequence verification of positive rAAV-LoxP-CT. 
 
All 6 samples re-PCR screened in Section 4.3.3.7 were sent for sequencing 
(Source Bioscience Life Sciences). Only 1 of the 6 were sequence verified as 
positive, this correlated with the 1 positive sample identified in the PCR re-screen 
Section 4.3.3.3, sequencing data was verified using the sequence alignment tool 
clustal omega (EMBL EBI) http://www.ebi.ac.uk/Tools/msa/clustalo. 
 
 
Figure 4.20 Sequencing data from positive pool of cells verified using the 
sequence alignment tool clustal omega (EMBL EBI). 
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4.4 Discussion 
In order to assess directly the capacity of and mechanism through which G-
quadruplex influences gene expression, I designed a set of mutant sequences to 
destabilize G-quadruplex while maintaining Sp1 binding sites. Alongside these I 
designed a set of mutant sequences to destroy Sp1 binding sites while preserving G-
quadruplex in the 6 target regions of selected genes (Figure 4.1). The intended 
approach was to use AAV targeting vectors to reengineer the genome of HCT-116 
cells to incorporate these mutant sequences via homologous recombination. This 
approach is novel, high risk and high cost in both time and resources. I therefore 
proceeded with one preliminary gene target; the well characterised G-quadruplex 
containing CT element of c-MYC in which to optimise and streamline the protocol 
before continuing with the remaining target genes. 
The combination of synthetic gBlock fragments incorporating the mutant 
sequence and Gibson Isothermal Assembly was a quick and efficient methodology to 
engineer the pAAV targeting constructs. This technique was piloted in the Levens 
Lab NIH and brought back to the Quinn Lab where it is now being used routinely. 
The initial attempt to produce infectious recombinant AAV particles was 
based on the methods outlined in (Kim et al., 2008) and proved ineffective in my 
hands. A comprehensive analysis of the protocol revealed a number of steps in that 
could be altered to improve efficiency and are discussed below. 
            The initial strategy relied upon a calcium phosphate co-transfection protocol, 
although this can be an effective method to deliver pAAV constructs into cells, I 
decided to use to the cationic liposome formulation method Lipofectamine LTX 
(Section 2.2.9.1). In addition, I used an alternative helper plasmid system -pDP2rs 
(Plasmid Factory), which is tagged with RFP. This enabled me to assess transfection 
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efficiency which I was unable to do using the previous pHelper system (Stratagene). 
By inserting internal controls throughout the protocol it enabled me to determine the 
success of the individual steps and therefore effectively troubleshoot the approach if 
I failed to get recombinant virus on the second approach. Based on findings in a 
recent review discussing AAV targeting efficiency (Miller, 2011). I also increased 
the incubation period post transfection and post infection from 48hrs to 72hrs. The 
initial protocol used a “crude” virus with limited purification,  which was isolated by 
four cycles of freeze/thaw. The only purification step was centrifugation at 12,000 
r.p.m. for 10 min to remove cell debris however no further viral purification was 
performed. After consulting with colleagues using AAV at the Liverpool CRUK I 
decided to purify the virus using VIRAPUR AAV purification kit. I also treated the 
viral DNA with DNaseI to digest residual and contaminating DNA prior to 
quantification via qPCR as this could lead to a more accurate viral titre. Based on the 
fact that one of the largest determinants of recombination frequency is MOI (Miller, 
2011) I decided to increase the range of both MOI and the density at which the cells 
were plated out at. This was increased from 100µl of virus in a T25 tissue culture 
flask as recommended in (Kim et al., 2008) to the range identified in Section  
4.3.3.2.2 in the hope that the optimum virus to cell ratio would be found. 
 The amended strategy did give improved results, as outlined in Section 
4.3.3.2.3. From the 204 colonies screened 2 positive clones were identified for 
rAAV-G4-CT. From the 526 colonies screened for rAAV-LoxP-CT 8 positive clones 
were identified which is an improvement on no colony growth from strategy 1. 
Despite this improvement the efficiency was low, this was further decreased as 9 of 
the 10 positive pools of cells were lost through SCD leaving only 1 sequence 
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verified positive clone from 3456 wells plated with live virus giving a targeting 
frequency of 0.03%.  
The initial targeting frequency was at 0.1% for rAAV-G4-CT and 0.5% for 
the rAAV-LoxP-CT in the pools of cells, prior to SCD.  The frequency of  G-
quadruplex KO at the CT element was lower than the neutral base pair changes in 
the 5’ UTR (LoxP insertion). This could be due to the fact that a key regulatory 
region in c-MYC which is essential for so many cellular processes as detailed in 
Section 1.3.1.was targeted. It is attractive to postulate that the mutation may have 
functioned to prevent potential G-quadruplex formation and as such has influenced 
c-MYC function. However this can not be confirmed because subsequent down 
stream analysis was prevented by further loss of positive pools through SCD. 
Although low and not sequence verified these initial  targeting frequencies from the 
pools of cells  are in line with estimated targeting efficiencies of AAV of  0.1–1.0% 
(Miller, 2011) and several orders of magnitude higher than those achieved with other 
gene targeting strategies (Thomas and Capecchi, 1987, Vasileva and Jessberger, 
2005). 
It was essential to decipher why the positive colonies in the pools of cells 
were lost through SCD, in order to move forward and improve efficiency of 
targeting. Deciphering the best cause of action at this stage in the protocol was 
difficult it is essential to gain single colonies in order to confirm a truly “isogenic” 
cell line. It is therefore preferable to get the pools of cells to single cell dilution 
rapidly but in contrast, colonies need to reach sufficient confluency to be robust 
enough to be PCR screened (withstanding direct PCR lysis) and SCD. For this 
reason it is beneficial to have single colonies in the initial plate out. This is most 
likely from plateing cells at low density i.e. 10 cells per well plates, however in these 
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experiments very few of the low density (cells/well) plates formed colonies.  The 
500 cells per well and 1000 cells per well plates formed the majority of colonies 
which in turn increases the number of colonies forming within the well, thus creating 
pools of colonies with a mix of correct and incorrect recombinants.  
 In this second attempt I had cultured the positive pools of clones to the 24 
well stage, during which time I believe they were outcompeted by non-recombinant 
or erroneous recombinants and the positive clones were lost. Therefore when 
redesigning the strategy I would SCD directly after the confirmation of positives 
through PCR. Alongside this I would pick colonies using blotting paper from cells 
seeded in 10cm dishes to avoid SCD. 
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Chapter 5   
 
CRISPR & AAV, an efficient approach 
to gene editing 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
180 
 
5.1 Introduction 
AAV targeting of the CT element in HCT-116 cells as detailed in chapter 4 
resulted in a low targeting frequency of 0.03%, with only 1 successful recombination 
event being maintained out of a potential 3,456. This prevented further downstream 
analysis. Here I present a strategy combining the recent technology of the CRISPR-
Cas system with traditional AAV targeting to KO the microRNA Mir137 in SH-
SY5Y cells. 
Alongside AAV targeting of the CT-element in c-MYC; a key gene for the 
Levens Lab, I supervised an MRes student Daniel Grifiths in applying AAV 
targeting vectors to KO the Mir-137; a key gene for the Quinn lab. Despite revised 
AAV protocols, both targeting events failed to produce a functional number of 
recombination events. Owing to funding requirements of my PhD, upon my return to 
the UK I moved my attention from the CT-element to the Mir-137 gene, in order 
develop an efficient gene editing approach combining the CRISPR-Cas system and 
rAAV. to be applied to the CT element and other previously identified G-quadruplex 
targets at a later date. 
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5.1.1 CRISPR-Cas 
RNA-guided Cas9 nucleases derived from clustered regularly interspaced 
short palindromic repeats (CRISPR)-Cas systems have transformed the field of gene 
editing. It is believed that tools and techniques based on Cas9 which is able to 
colocalize RNA, DNA and protein, will grant unprecedented control over cellular 
organization, regulation and behaviour (Mali et al., 2013b). 
Prokaryotes have evolved adaptive immune defences; CRISPR-CRISPR–
associated (Cas) systems that use two short RNAs to direct a single polypeptide 
nuclease; Cas9 to target sites to degrade foreign nucleic acids (Bhaya et al., 2011, 
Wiedenheft et al., 2012, Horvath and Barrangou, 2010) (Figure 5.1). 
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Figure 5.1 Type II CRISPR-Cas systems in bacteria. 
 
Phase1 Immunization: CRISPR  system stores the molecular finger print of previous 
infections by incorporating small fragments of invading phage or plasmid DNA into 
the CRISPR locus termed ‘spacers’.  
Phase 2 Immunity:  The bacterium uses information from phase 1 to produce 
crRNAs, to guide nucleases to locate and cleave invading nucleic acids 
complementary to the spacer. (Adapted from (Mali et al., 2013b)). 
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The Streptococcus pyogenes system has been simplified for use in genome 
engineering. It is comprised of two components; the Cas9 nuclease and a chimeric 
guide RNA (gRNA). The gRNA recognizes a 20-nt target sequence next to the 
protospacer adjacent motif (PAM) trinucleotide; NGG in the genome. This  directs 
Cas9-mediated cleavage of both DNA strands to generate a blunt-ended double-
stranded break, 3 base pairs upstream of the 3′ end of the protospacer (Jinek et al., 
2012) (Figure 5.2). This process has been shown to induce NHEJ and HR in 
eukaryotic systems (Cho et al., 2013, Mali et al., 2013c, Mali et al., 2013a). 
However, the specific details of this process remain poorly understood, as 
demonstrated by the wide range of efficiencies and specificities observed in many 
systems (Mali et al., 2013b). 
 
 
Figure 5.2 Cas9-sgRNA targeting complex. 
 
The S.pyogenes Cas9-sgRNA RNA-guided nuclease complex detailing recognition 
and cleavage. 
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5.1.2 Gene targeting efficiency is increased by double strand breaks 
The introduction of a DSB in target sequences has been shown to increase the 
frequency of gene targeting by 100- to several 1,000- fold in conventional gene 
targeting approaches. As such gene targeting with transfected, linear dsDNA 
constructs is believed to occur by DSB-induced HR (Brenneman et al., 1996, Smih 
et al., 1995, Sargent et al., 1997).  It has since been shown that introducing DSBs 
into the chromosomal target could further improve rAAV targeting efficiencies 
(Miller et al., 2003, Porteus et al., 2003). These studies identify that DSBs result in 
up to 100- fold increased targeting frequencies.  It should be noted that in both 
aforementioned studies, the frequency of random integration was not affected. It is 
therefore plausible to suggest a DSB might shift the ratio of targeted events from 
random-integration events towards targeting. Collectively, these studies indicate that 
the mechanism of rAAV-mediated gene targeting involves the repair of DSBs by 
HR, which is independent of random integration by NHEJ (Vasileva and Jessberger, 
2005). 
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5.2 Aims 
Use emerging technology CRISPR-Cas system to pump prime the AAV gene 
editing system to increase recombination efficiency in order to create a hemizygous 
Mir-137 KO. 
1. Design and engineer CRISPR-Cas gene targeting system to introduce double 
stranded breaks at the Mir137 locus. 
2. Target SH-SY5Y cells with Mir-137 CRISPR-Cas targeting system in 
tandem with rAAV-Mir-137-KO donor. 
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5.3 Results  
5.3.1 A strategy to KO Mir-137 using CRISPR-Cas & AAV. 
The CRISPR-Cas system uses RNA guided Cas9 nucleases to introduce 
double strand breaks at specific sites determined by the guide RNA (Terns and 
Terns, 2011, Mali et al., 2013c). In this case the Mir137 locus was the target site, a 
double strand break at this region should trigger the natural DNA repair pathways 
NHEJ and HR as described in Section 5.1.2.  I have taken advantage of this 
mechanism and combined it with the AAV targeting strategy detailed in Chapter 4, 
which provides an rAAV donor to for integration into the Cas9 cleavage site, 
producing a gene editing system with increased targeting efficiency. The steps of this 
approach are which are outlined in Figure 5.3. 
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Figure 5.3 Modified gene editing strategy; CRISPR & AAV to KO Mir137 
 
Outline of the stages involved in the CRISPR and AAV gene editing strategy, 
targeting SH-SY5Y cells with CRISPR-Cas plasmids prior to AAV infection. 
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5.3.2 Overview of CRISPR-Cas gene editing system to KO Mir137. 
 
In order to effectively target a specific locus using the CRISPR-Cas system a 
number of design, implementation and verification steps are involved as outlined in 
Figure 5.4. 
 
 
Figure 5.4 Stages involved in CRISPR-Cas mediated gene targeting. 
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 5.3.3 Mir-137 gRNA oligonucleotide design. 
 
As detailed in Section 5.1 CRISPR-Cas systems are readily retargeted by 
expressing or delivering appropriate gRNAs (Barrangou et al., 2007, Brouns et al., 
2008, Hale et al., 2012, Jiang et al., 2013). I therefore identified an appropriate 
consensus target sequence G n
20
 GG within the 102 bp Mir-137 sequence (Figure 
5.5).  Once the consensus target sequence was identified I designed the appropriate 
sequence to be inserted into the gRNA vector to enable recognition of the Mir-137 
by the Cas9 nuclease supplied in trans (Figure 5.5).  This recognition sequence was 
constructed by annealing 2 complementary oligonucleotides also identified in Figure 
5.5. 
  
 
Figure 5.5 Identification of CRISPR-Cas gRNA recognition sequence in Mir-
137 
 
Mir-137 sequence chromosome location identified, gRNA recognition sequence 
italic and underlined. gRNA insert design identifying forward and complementary 
reverse oligonucleotides synthesized to be annealed. 
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5.3.4 Inserting gRNA into pGUIDE  
Golden Gate cloning (Section 2.2.3.2) was used as strategy to insert gRNA 
(annealed oligos) into the pGUIDE vector (kind gift from Dr. Patrick Harrison 
University College Cork) rather than gel purifying the backbone. Golden gate 
cloning makes use of  two type II enzyme sites in this case BseRI, treatment of  
pGUIDE plasmid with BseRI liberates a short insert from the pGUIIDE vector 
(Figure 5.6b), which is outcompeted by the Mir-137 gRNA insert (annealed oligos) 
(Figure 5.6c). 
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Figure 5.6 Inserting gRNA into pGUIDE 
 
schematic of the Cas9 WT plasmid plus pGUIDE and the complex they form once 
co-transfected.(adapted from (Mali et al., 2013c) b. pGUIDE plasmid with liberated 
segment (orange), upstream of the U6 promoter(grey) and downstream of the gRNA 
scaffold (blue) post BseRI treatment. c. sequences describing the golden gated 
cloning approach to inserting required RNA (green) into the pGUIDE plasmid 
required for target recognition by pGUIDE colour coded to correlate with b. 
 
 
a. 
c. 
b. 
Cas-9 WT plasmid  
  pGUIDE plasmid 
 
 
CRISPR-Cas9 system 
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5.3.5 CRISPR-Cas transfection optimisation 
CRISPR-Cas targeting relies on successful co-transfection of the guide RNA 
plasmid (pGuide) and Cas9 plasmid (Cas-9 WT). In order to ensure maximum 
efficiency of CRISPR targeting, co-transfection efficiency of SH-SY5Y with 
TurboFect was optimised with a GFP plasmid. 12 well plates were seeded with cells 
and a range of transfection conditions were applied Figure 5.7. GFP transfections 
revealed 3µg DNA and 12µl TurboFect gave the optimum transfection efficiency of 
40%. 
   
 
Figure 5.7 Transfection optimisation 
 
 SH-SY5Y cells transfected with a range of DNA concentrations and transfection 
reagent (TurboFect) amounts to determine the optimum transfection conditions to be 
applied to CRISPR-Cas co-transfcetion. 
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5.3.6 Verification of CRISPR-Cas targeting efficiency. 
SH-SY5Y cells were co-transfected with equimolar Mir-137-pGuide and 
Cas9-WT, at a range of; 1 µg, 2 µg, 3µg (Cas9-WT plasmid).  It was essential to 
determine efficiency of the CRISPR-Cas targeting before proceeding with AAV 
infection as not to waste time or resources. PCR and the T7 endonuclease 1 (T7E1) 
assay were used to determine the efficiency of CRISPR-Cas targeting (Sander and 
Joung, 2014).  
CRISPR-Cas targeting introduces double strand breaks at or around the target 
region (Mir-137), the natural cellular repair process of NHEJ will repair these double 
strand breaks however it is an error prone ligation process that often results in small 
insertions and deletions at cleavage sites. PCR primers were designed to amplify a 
product of 538bp with the target sequence located within the amplicon (Figure 5.8a). 
The target region was amplified through PCR (Figure 5.8b) in each of the co-
tranfection conditions, a % of the amplicons contained mutant sequences due to the 
NHEJ, these are the ampicons have been successfully targeted. To detect the % of 
targeted amplicons, the 538bp PCR amplicons (Figure 5.8b) were gel purified, 
denatured and allowed to re-anneal (Section 2.2.3.1). Due to the % of mutated 
sequences (NHEJ errors) the strands are not all complementary and are thus unable 
to form hydrogen bonds. Those where NHEJ has taken place will form heteroduplex 
DNA. The annealed amplicons are then treated with mismatch-sensitive T7E1 which 
will digest at the sites of flipped out base pairs (hetroduplex DNA). When analysed 
on a 2% agarose gel through electrophoresis the T7E1 treatment of heteroduplex 
DNA; CRISPR-Cas treated group gave rise to 320bp and 208 bp DNA fragments 
which when combined with the % of untargeted amplicons appear as 3 bands on the 
agarose gel (Figure 5.8c). The positive control Promega DNA isolated from a pool of 
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individuals with SNP’s also appeared as 3 bands on the gel while the T7E1 treatment 
of heteroduplex WT SH-SY5Y gDNA gave rise to 1 band acting as the negative 
control. 1ug of DNA failed to show any targeting events , supported by the low GFP 
transfection efficiency (Figure 5.8c), 2µg gave moderate targeting 5% once again 
supported by the increased transfection efficiency, 3µg resulted in optimum targeting 
of 15% supporded by the GFP transfection (Figure 5.8c) 
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Figure 5.8 Verification of CRISPR-Cas targeting efficiency 
 
 PCR and mismatch sensitive enzyme T7E1 used to verify CRISPR-Cas targeting 
efficiency at the Mir-137 locus. a. PCR primers and chromosome location of Mir-
137 along with amplicon sequence amplified via PCR containing Mir-137 target 
sequence (highlighted yellow) required consensus sequence (highlighted red) and 
PCR primers (highlighted blue). b. gDNA extracted from co-transfceted cells and 
PCR amplified with primers outlined in Figure a. verified through gel 
electrophoresis. c. PCR products shown in Figure b, gel purified, denatured, 
annealed, treated with mismatch sensitive T7E1 enzyme and analysed on a 2% 
agarose gel, the increased targeting efficiency identified through PCR reflects the 
increased GFP expression at the range of concentrations observed in Figure 5.7. 
 
 
 
 
b. 
c. 
a. 
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5.3.7 rAAV-Mir-137KO infection. 
Following verification of successful CRISPR-Cas targeting to introduce to 
double strand breaks in turn triggering the natural NHEJ pathway, cells were infected 
with AAV viral particles generated by a former MRes student of the Quinn Lab 
Daniel Grifiths. Infection was carried out at MOI’s of 25, 50 and 100 following the 
protocol outlined in Section 4.3.3.2. 72 hrs following infection cells were plated into 
96 well plates at densities of 250, 500, 100 cells per well, each cell density was 
infected at an MOI of 25, 50, and 100, as summarized in Table 5.1 
 
Table 5.1 Range of cell to virus ratio MOI and range at which infected cells 
were plated (cell / well) 
 
 
 
 
 
 
 
 
 
 
 
MOI 25 MOI 50 MOI 100 
250  cells / well 250  cells / well 250  cells / well 
500  cells / well 500  cells / well 500  cells / well 
1000  cells / well 1000  cells / well 1000  cells / well 
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5.3.8 PCR screen of AAV-Mir137-KO verifying positive recombination events 
   To identify positive recombination events, pools of clones were PCR 
screened using 2 separate primer sets. The first primer set has its forward primer in 
the LHA and its reverse primer in the neomycin resistance cassette amplifying a PCR 
product of 513bp (+ve1, green arrows Figure 5.9). This was a very efficient PCR 
reaction optimised prior to infection using the Mir137-AAV targeting construct as 
DNA template.  It was designed as a 1
st
 round screen to identify recombination 
events amongst the 2592 infected wells allowing us to considerably reduce tissue 
culture work, only maintaining those wells which contained recombinant DNA 
(Figure 5.10). Although this was a fast and efficient PCR the amplicon could have 
been generated from episomal DNA. Therefore positives identified in the 1
st
 round 
were put through a 2
nd
 round of screening using a separate set of primers (+ve2 red 
arrows Figure 5.9) with the  forward primer outside the Left homology arm and the 
reverse  nested in the neomycin cassete giving a PCR product of 2093 bp. 
 
 
 
Figure 5.9 AAV-Mir137-KO PCR screen primer design and strategy.  
 
Primer sets to identify positive recombination events, the 1
st
 round primer set (green) 
amplified PCR products of 513bp and the 2
nd
 round primer set amplified a product 
2093bp (red). 
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5.3.9 rAAV-Mir-137KO PCR screen. 
AAV-Mir-137-KO recombination events were verified by PCR screening 
gDNA extracted from plated SH-SY5Y cells. Of the 2592 wells plated with infected 
SH-SY5Y (96wells at each range detailed in Section 5.3.7) 1867 wells grew colonies 
in total. Positive primer set 1 detailed in Figure 5.9 (primer sequences can be found 
in table 2 of the Appendix) was used to amplify a PCR product of 513bp. The 96 
well plate with an MOI of 100 and cell density of 1000 cells per well had 88 colonies 
form and was the 1
st
 plate to reach a suitable confluency of 50% to withstand direct 
PCR liysis (Section 2.2.13.6.2.1).  It was therefore selected to be screened as 
outlined in Section 2.2.13.6. with 64 clones positive for recombination identified 
from the 96 well plate (Figure 5.10). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
199 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.10 AAV-Mir-137-KO PCR screen 
 
Agarose gel showing 64 positive recombination events by amplification of a 513bp 
fragment from gDNA extracted from targeted SH-SY5Y cells. 
 
 
 
 
 
  
a. 
b. 
c. 
513bp 
513bp 
 
513bp 
 
d. 
d. 
e. 
513bp 
513bp 
 
513bp 
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5.3.10 rAAV-Mir-137KO verification. 
Of the 64 positive pools of clones identified, 9 were selected to be expanded 
into 48 well plates followed by SCD in order to obtain a single colony to ensure a 
truly isogenic cell line. At the time of SCD the 9 selected pools of clones were re 
screened to ensure they were still positive for recombination (Figure 5.11).  
 
 
 
 
 
 
 
Figure5.11 rAAV-Mir-137 KO verification 
 
Agarose gel showing positive clones selected for expansion and SCD were 
rescreened with original positive primer 1 amplifying a product of 513 bp  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
513bp 
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5.3.11 Positive PCR screen of single cell diluted Mir-137 KO clone to verify 
hemizygous KO 
 
             Following verification that all 9 selected pools were still positive for 
recombination after expansion up to the 48 cell stage, they were SCD (Section 
2.2.13.6.5) and incubated for 8 weeks at 37 ˚C. Once single colonies formed and 
reached over 50% confluency in the 96 well plates, 3 colonies were selected to be re-
screened with a new primer set (Figure 5.12a) identifying both alleles of the 
hemizyhgous KO (Figure 5 .12b).  This primer set had a forward primer in the left 
homology arm and a reverse primer in the right homology arm. Therefore both the 
targeted and WT allele were amplified. Amplification of the targeted allele produced 
a 1911bp PCR product including the neomycin selection cassette and amplification 
of the WT allele produced a 545bp PCR product without the neomycin selection 
cassette (Figure 5.15). 
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Figure 5.12 Positive PCR screen of single cell diluted Mir-137 KO clone  
 
 a. Schematic representation of primer set used to screen for hemizygous KO of Mir-
137, 545 pb PCR product for the WT allele and 1911bp PCR product for the targeted 
allele. b Agarose gel showing products from a PCR reaction  in triplicate for each of 
the 3 selected SCD colonies, using primer set identified in a. 
 
 
 
 
 
 
 
 
 
 
a. 
b. 
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5.3.12 Confirmation of positive PCR screen for single cell diluted Mir-137 KO 
clone. 
 
SCD clones were screened with primer set 2 (Figure 5.9) to ensure the Mir-
137 KO recombination event was not episomal. 
 
 
 
 
 
 
 
Figure 5.13 Confirmation of positive PCR screen for single cell diluted Mir-137 
KO clone. 
Agarose gel showing PCR fragments of 2093bp confirming positive targeting events 
in colony F3 and colony F7 following single cell diluition of the Mir-137 KO. 
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5.4 Discussion  
In this chapter I have presented an efficient gene editing strategy, combining 
the CRISPR-Cas system  with traditional AAV targeting to create a hemizygous KO 
of the microRNA Mir137 in SH-SY5Y cells.  
As described in Section 5.1 the CRISPR-Cas systems have gained much 
attention as a transformative gene editing technology, owing to their low cost, high 
efficiency, simplicity and broad range of application (Mali et al., 2013b, Sander and 
Joung, 2014). However there is concern regarding off target effects of CRISPR, 
(reviewed in Cho et al., 2014), although these are currently being addressed (Shen et 
al., 2014).  rAAV gene targeting is a well validated approach to gene editing (Russell 
and Hirata, 1998) and is known to be a high precision technique, stimulating 
homologous recombination directly at 100x higher efficiency than plasmids (Russell 
and Hirata, 1998).  rAAV targeting is however a low throughput technique 
determined by the vast time and resources required to screening and identify 
correctly targeted clones.  
By combining the two technologies in one application it was possible to 
significantly increase targeting efficiency while maintaining the high fidelity of 
AAV (to be confirmed). By co-transfecting with CRISPR-Cas plasmids designed to 
target the Mir-137 locus (Section5.3.3, Figure 5.8a and Figure 5.14b) double strand 
breaks were introduced (Figure 5.14c) which can be repaired by one of two natural 
cellular processes the error prone NHEJ or the high fidelity HR (Figure 5.14d) . 
Following the co-transfection of SH-SY5Y cells with CRISPR-Cas plasmids 
(Mir137-gRNA and Cas9WT) cell were infected with rAAV-Mir-137KO which 
provided the homologous donor DNA (Figure 5.14e), to reengineer the locus to 
delete Mir-137 via homologous directed repair (HDR). 
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Figure 5.14 A strategy to KO Mir-137 using CRISPR-Cas & AAV. 
 
A schematic diagram depicting the series of events occurring inside the 
nucleus during CRISPR-Cas and AAV targeting. a.Mir-137 locus b. CRISPR-Cas 
targeting c. introduction of double strand breaks d. two natural cellular processes 
available to repair the DSB’s the error prone NHEJ or the high fidelity HR. e. rAAV-
Mir-137KO acts as  homologous donor DNA shifting the preference of repair to 
homologous directed repair (HDR)  
 
 
 
 
a 
b 
c 
d e 
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The targeting efficiencies of all approaches used throughout the study are 
outlined in Table 5.2. 
  
Colony 
formation 
 
+ve 
recombination 
prior to SCD 
 
+ve 
recombination 
post SCD 
 
+ve 
Insertion 
into gDNA 
 
rAAV-G4/LoxP-
CT-1
st
  
 
0% 
 
N/A 
 
N/A 
 
N/A 
 
rAAV-G4/LoxP-
CT-2
nd
  
 
21% 
 
0.2% 
 
0.03% 
 
0.03% 
 
rAAV-Mir-137 
 
32% 
 
0% 
 
N/A 
 
N/A 
 
CRISPR & 
rAAV-Mir-137 
 
72% 
 
67% 
 
100% 
 
66% 
 
Table 5.2 Comparison of targeting efficiencies between various 
approaches used. 
 
In addition to the overall increased targeting frequency, it should be noted 
that the combined CRISPR & AAV approach significantly reduces the time and cost 
of targeting. I estimate an initial saving of £1800 in tissue culture and PCR screening 
resources in addition to 3 months salaried time. This is primarily due to the fact that 
as a result of the increased targeting efficiency, the 1
st
 96 well plate to reach 50% 
confluency was screened and contained enough positive recombination events to 
expand and SCD. Therefore preventing the need to wait for and screen colonies 
forming within the remaining 2496 wells. Based on this information, further savings 
could be made as the amount of rAAV virus produced and the range of MOI and cell 
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densities could be further reduced, to creating a further streamlined yet robust gene 
editing system.  
A further consideration which has been highlighted through this combined 
targeting strategy is the potential to further increase targeting frequency through a 
second round of CRISPR-Cas co-transfcetion to make use of the episomal AAV. 
Following infection with rAAV a proportion of the rAAV will remain as a stable 
episome (Duan et al., 1998),  episomal AAV transgene expression has been observed 
for up to one year  (Haidet et al., 2008, Le Hir et al., 2013). During this time cells 
could undergo a second round of CRISPR-Cas cotransfection which would re-target 
the loci, of either those cells which had failed to be targeted in the 1
st
 round or the 
untargeted allele, as only these untargeted cells / alleles would possess the 
complement sequence for recognition by the gRNA. This would introduce ds breaks 
and the episomal rAAV would be the homologous donor sequence thus re-instigating 
HDR to reengineer the region as desired, this also has implications in homozygous 
targeting as it could increase the chance of a homozygous recombination event. At 
this time a study that has not been done. 
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Primers 
 
Applications 
Primers sequence Region amplified 
Expected 
product size 
PCR conditions 
 
5’ LPR VNTR_Fwd 
5’ LPR VNTR_rev 
 
 
 
 
 
 
 
 
 
 
ChIP Screening 
 
5’  ATGCCAGCACCTAACCCCTAATGT 3’ 
5’  GGACCGCAAGGTGGGCGGGA  3’ 
SLC6A4 5’ LPR VNTR 
chr17:28564079-
28564497 
419bp + 
VNTR 
length 
 
Touchdown PCR: 
 
1  cycle:  94°C    3   (min) 
 3  cycles:  94°C    15 (sec) 
                  64°C    30 (sec) 
                  70°C    2   (min) 
  3  cycles: 94°C    15  (sec) 
                  61°C    30  (sec) 
                  70°C    2    (min) 
  3  cycles: 94°C    15  (sec) 
                  58°C    30  (sec) 
                  70°C    2    (min) 
  3  cycles: 94°C    15  (sec) 
                  58°C    30  (sec) 
                  70°C    2    (min) 
  35  cycles: 94°C    15  (sec) 
                  57°C    30  (sec) 
                  70°C    2    (min) 
    1  cycle: 70C     5    (min) 
 
NHE F 
NHE R 
 
ChIP Screening 
& 
Cloning 
 
5’ atggcgcgccggtacctcacaggctgcgagtaga 3’ 
5’ aacggcgcgcctcgagtggcctctcaagagga 3’ 
 
CT element c-MYC 
550bp 
1 cycle: 96°C  (3 min) 
35 cycles: 
95°C  (1 min), 54°C  (1min), 
72°C (1min) 
MAOA proximal F 
MAOA Proximal R 
 
 
 
ChIP screening  
mRNA analysis 
 
5’  ACAGCCTGACCGTGGAGAAG 3’ 
5’  TCCGAATGGAGCGTCCGTTC  3’ 
 
MAOA µVNTR  
chrX:43514243+43514566 
 
 
324 bp 
1 cycle: 96°C  (3 min) 
36 cycles: 
94°C  (1 min), 55°C  (1 min), 
72°C (30 sec) 
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Primers 
 
Applications 
Primers sequence Region amplified 
Expected 
product size 
PCR conditions 
MAOA Distal F 
MAOA Distal R 
 
ChIP screening  
mRNA analysis 
 
5’ GGGTTAAGCGCCTCAGCTTG  3’ 
5’  CTGCTTCCTTAAGTCCACTCTTG 3’ 
 
MAOA Distal VNTR 
chrX:43513612+43513976 
 
 
365 bp 
Touchdown PR as for 5’LPR 
above 
 
CT-AAV-WT-Fwd 
CT-AAV-WT-Fwd 
 
AAV screening  
 
5’  gcgaccttgcttgccctctct 3’ 
5’ tctctgggtgcttggatttgtggat 3’ 
 
CT element LHA+gDNA 
 
1141 bp 
1 cycle: 96°C  (3 min) 
36 cycles: 
94°C  (1 min), 59°C  (30 sec), 
72°C (1min) 
 
CT-AAV-+ve-Fwd 
CT-AAV-+ve-Fwd 
 
AAV screening  
 
5’actgggcactgtcgcaggtc 3’ 
5’ catggccggcgaactgggct 3’ 
 
CT element gDNA + Neo 
 
1810 bp 
1 cycle: 96°C  (3 min) 
35 cycles: 
94°C  (30 sec), 59°C  (30 sec), 
72°C (90 sec) 
 
Mir-137-CRISPR_Fwd 
Mir-137-CRISPR_Rev 
  
 
CRISPR-gRNA 
5’TATTCTTGGGTGGATAATAGT 3’ 
5’ TATTATCCACCCAAGAATACG 3’ 
 
               Mir-137 102 bp 
1 cycle: 95°C  (5 min) 
 
Mir-137 Fwd 
Mir-137 Rev 
 
 
CRISPR-T7E1 5’ CAGAGGAAAGCACTGGGAGA 3’ 
5’ CTTGGCAACCACGGGCGTTTA 3’  
chr1:98511564-98512101 
Mir-137 
538bp 
1 cycle: 96°C  (3 min) 
35 cycles: 
94°C  (30 sec), 62°C  (30 sec), 
72°C (30 sec) 
 
Mir-137-AAV_pos1F 
Mir-137-AAV_pos1R 
 
 
CRISPR & AAV 
screen 
5’ TTGTCACTCCCACTTGTGCC 3’  
5’ GTGGATGTGGAATGTGTGCG 3’  
Mir-137 LHA + Neo 513 bp 
1 cycle: 96°C  (3 min) 
35 cycles: 
94°C  (30 sec), 60°C  (30 sec), 
72°C (30 sec) 
 
Mir-137-AAV pos 1 F2 
Mir-137AAV pos 1 R 
 
 
CRISPR & AAV 
screen 
5’ TGTGCCTCCCTTGACCATC 3’  
5’ GTGGATGTGGAATGTGTGCG 3’  
Mir-137 gDNA + Neo 2093 bp 
Touchdown PR as for 5’LPR 
above 
 
Mir-137-AAV_negF 
Mir-137-AAV_negR 
 
 
CRISPR & AAV 
screen 
5’ TTGTCACTCCCACTTGTGCC 3’ 
 5’GAACCAGTGCGAAAACACCC 3’ 
Mir-137 LHA +/- Neo 
545/  1911 
bp 
1 cycle: 96°C  (3 min) 
35 cycles: 
94°C  (30 sec), 60°C  (30 sec), 
72°C (90 sec) 
Table 6.1: Primer sequences and PCR conditions used during this study. 
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Table 6.2 Vectors cloned during this study. 
 
 
 
 
Vector  
 
Discription  
 
 
pAAV-G4-CT 
 
 
pAAV-TK-accepter with 1.5kb Homology c-MYC 700bp+/-CT element (G4-KO mutated CT element- Figure 4.1b) 
 
pAAV-LoxP-CT 
 
 
pAAV-TK-accepter with 1.5kb Homology c-MYC 700bp+/-CT element  (Figure 4.1b) 
 
pAAV-Sp1-CT 
 
pAAV-TK-accepter with 1.5kb Homology c-MYC 700bp+/-CT element (Sp1-KO mutated CT element- Figure 4.1b) 
 
 
pAAV-G4-VEGFA 
 
 
pAAV-TK-accepter with 1.5kb Homology VEGFA700bp+/-CT element (G4-KO mutated CT element- Figure 4.1d) 
 
pAAV-LoxP-VEGFA 
 
 
pAAV-TK-accepter with 1.5kb Homology VEGFA700bp+/-CT element (Figure 4.1d) 
 
pAAV-Sp1-VEGFA 
 
 
pAAV-TK-accepter with 1.5kb Homology VEGFA700bp+/-CT element (Sp1-KO mutated CT element- Figure 4.1d) 
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Table 6.3 Virus generated during this study 
  
 
Virus  
 
 
Discription  
 
rAAV-G4-CT 
 
 
rAAV-TK-accepter with 1.5kb Homology c-MYC 700bp+/-CT element (G4-KO mutated CT element- Figure 4.1b) 
 
rAAV-LoxP-CT 
 
 
rAAV-TK-accepter with 1.5kb Homology c-MYC 700bp+/-CT element  (Figure 4.1b) 
 
rAAV-Mir-137 KO 
 
 
rAAV-TK-accepter with 1.5kb Homology c-MYC 700bp+/-CT element (Sp1-KO mutated CT element- Figure 4.1b) 
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Table 6.4 Antibodies used in Chromatin Immunoprecipitation (ChIP). 
Clonality, host species, target peptide or protein region, source and catalogue number used in ChIP reactions are shown. 
 
Antibody 
 
Clonality 
 
Host species 
 
Immunogen 
 
Source 
 
Catalogue 
Number 
 
anti-CTCF 
 
 
Monoclonal 
 
Mouse 
 
His-tagged recombinant protein corresponding to human CTCF 
 
Millipore 
 
17-10044 
 
anti-Histone H3 
 
 
Polyclonal 
 
Rabbit 
Synthetic peptide conjugated to KLH derived from within residues 100 to 
the C-terminus of Human Histone H3 
 
abcam 
 
 
 ab1791   
 
anti-Nucleolin  
 
Monoclonal 
 
Mouse  
 
Human nucleolin protein from Raji cell extract. 
 
 
abcam  
 
ab13541 
 
anti-Histone H3 
(tri methyl K9)  
 
Polyclonal 
 
Rabbit 
Synthetic peptide conjugated to KLH derived from within residues 1 - 100 
of Human Histone H3, tri methylated at K9. 
 
abcam 
 
ab8898 
 
anti-hnRNP K 
 
 
Polyclonal 
 
Rabbit 
 
Synthetic peptide corresponding to a sequence from the C-terminus of 
isoform a of human hnRNP K. (NP_002131.2) 
 
abcam 
 
ab70492 
 
Anti-CNBP 
 
Polyclonal 
 
Goat 
Synthetic peptide: 
GESGHLARECTIE 
, corresponding to C terminal amino acids 162-174 of Human CNBP. 
 
abcam 
 
ab48027 
 
anti-RNA pol II 
CTD phospho 
Ser5   
 
Polyclonal 
 
Rabbit 
 
This RNA pol II CTD phospho Ser5 antibody was raised against synthetic 
peptide containing the RNA Pol II heptad repeat consensus sequence 
phosphorylated at serine 5. 
 
 
Active-
Motif 
 
39233 
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